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ABSTRACT
Background: Vitamin D deficiency is highly prevalent in African American and
Hispanic women and there is evidence to show that it can have a deleterious impact in
pregnancy. There is also evidence indicating that vitamin D deficiency is associated with
numerous symptoms such as musculoskeletal pain, poor sleep, and depression but evidence has
been focused on predominantly non-pregnant participants. However, whether low levels of
vitamin D are associated with these and other symptoms during pregnancy is unknown. What is
known is that vitamin D deficiency disproportionately affects pregnant minority women,
therefore, this study was undertaken to understand the impact that vitamin D deficiency has on
pregnancy symptoms and its potential impact on quality of life.
Purpose: The main purpose of the study was to determine the following: (1) if there was
a relationship between vitamin D status, pregnancy symptoms including depressive symptoms
and sleep disruption, health-promoting behaviors, and quality of life, and (2) if differences
existed in vitamin D status, pregnancy symptoms including depressive symptoms and sleep
disruption, health-promoting behaviors, and quality of life between African American and
Hispanic women.
Theoretical/Conceptual Framework: The Wilson & Cleary’s Health-Related Quality of
Life model was used to guide the study. With this framework, the characteristics of the
individual (e.g., age, ethnicity) and the environment (e.g., social support and spirituality) impact
on biological factors (e.g., vitamin D status), symptom status (pregnancy symptoms, depression,
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sleep quality), and functional status (health-promoting behaviors) which all ultimately affect
overall health-related quality of life.
Method: The study used a descriptive, cross-sectional design to examine women at 24 to
32 weeks gestation. A convenience sample of 125 women from underserved, low-income
federally qualified health centers serving predominantly African Americans and Hispanics
participated. The variables assessed included the following: biologic (vitamin D status),
symptoms of pregnancy (Pregnancy Symptom Inventory, PSI), depression (Edinburgh Postnatal
Depression Scale-EPDS), sleep quality (Pittsburgh Sleep Quality Index-PSQI), functional status
(Health-promoting Lifestyles Profile-HPLP), and quality of life (SF-12).
Data Analysis: Statistical analyses were done using SPSS version 22.0. Descriptive
statistics were conducted on all study variables. Independent sample t-tests for continuous
variables and chi-square tests for categorical variables were used to examine differences between
those who were vitamin D deficient (< 20 ng/ml) and vitamin D sufficient ( ≥ 20ng/ml). A
combination of univariate and multivariable logistic regression analyses were conducted to
detect if vitamin D as a binary variable predicted pregnancy symptoms, depressive symptoms,
sleep quality, health-promoting behaviors, and mental and physical quality of life. A series of
independent sample t-tests were used to detect ethnic differences between African American and
Hispanic women on key study variables.
Results: The majority of the pregnant women were either African American (49%) or
Hispanic (42%). They were predominantly either single, living with or not living with their
partner (71.2%), had an income of less than $40,000 (87.2%), had at least a high school
education (86.4%), were predominantly on Medicaid insurance (77.6%), had an unplanned
pregnancy (65.6%), had no history of depression (88%) or anxiety (93.6%), did not have
xiv

gestational diabetes (86.4%), and had planned to breastfeed (80%). The sample was
predominantly multiparous (78.4%). Overall, the vitamin D deficient group had the following
characteristics: they were more likely to be African American, have a lower income, and have
an unplanned pregnancy, and were less likely to breastfeed.
Mean vitamin D level for the entire sample was 19.46 ng/ml, 58.4% (n = 73) with
vitamin D < 20 ng/ml and 41.6% (n = 53) with vitamin D ≥ 20 ng/ml. The most frequently
reported symptoms by pregnant women were tiredness, urinary frequency, food cravings, back
pain, and poor sleep. The mean pregnancy symptom total score for the deficient vitamin group
was 36.2 (SD=18) and for the sufficient vitamin D group was 36.3(SD=18.8); thus no differences
were observed between groups. The sample had a low incidence of depressive symptoms (6.4%,
EPDS score > 12 indicates elevated risk for depression), and there was no significant difference
between deficient and sufficient vitamin D groups [mean = 4.05 (SD = 4.8)] vs mean = 3.62 (SD
= 4.1)].
Overall, the sample had poor sleep quality with a mean PSQI global score of 6.3 where
good sleep quality is defined as ≤ 5. There were significant differences in PSQI global scores
with those being deficient having worse sleep quality (mean = 7.28, SD = 3.6) compared to those
who were sufficient (mean = 5.1, SD = 2.9) scores [t (122) = 3.68, p < .001]. Overall, women
practiced healthy behaviors with a mean HPLP total score of 2.59 (SD = 0.4), where a score of 4
denotes practicing healthy behaviors routinely. Quality of life scores for mental quality of life
were better than average with a mean value of 52.19 (SD = 8.6) where a value >50 denotes good
mental quality of life. Physical quality of life scores were less than average with a mean score of
45.45 (SD = 7.6) where a value >50 denotes good physical quality of life.
Using a binary logistic regression, univariate analyses indicated that only sleep quality
xv

and physical quality of life were significantly predicted by vitamin D status. Patients who were
deficient of vitamin D were 3.1 (95% CI: 1.292–7.47, p = .012) times more likely to have poor
sleep quality compared to those who were sufficient. Despite controlling for other significant
covariates, the predictive value of vitamin D status on sleep quality remained constant.
Similarly, those with deficient vitamin D were 5.78 (95% CI: 2.13–15.7, p = .001) times more
likely to report poor physical quality of life compared to those who were sufficient.
Overall, ethnic differences were found in sleep quality with African Americans having
worse sleep (mean = 7.34, SD = 3.5) compared to Hispanics (mean = 5.33, SD = 3.2) [t(112) =
3.18, p = .002]. Although African Americans were likely to report more depressive symptoms
(mean = 4.63, SD = 5.2) than Hispanics (mean = 2.42, SD = 3.3), these values do not reflect
depressive states. Finally, vitamin D levels were lower in African Americans (mean = 17.02, SD
= 8.3) compared with Hispanics (mean = 21.13, SD = 7.4) [t(113) = -2.77, p = .006].
Conclusions: This study confirmed that vitamin D deficiency is highly prevalent in a
minority pregnant population and provided evidence that deficient vitamin D status could
contribute to worse symptomology in pregnancy. It also provided some evidence that vitamin D
status may impact sleep quality and quality of life which needs to be investigated further.
Although the pregnancy symptoms, depressive symptoms, and health-promoting behaviors were
not significantly predicted by vitamin D status, there were several important findings. It was
evident that sleep quality and physical quality of life were significantly predicted by vitamin D
status. After controlling for significant covariates, being vitamin D deficient significantly
predicted poorer sleep quality and physical quality of life. Furthermore, the ethnic differences
found between African American and Hispanic pregnant women were vitamin D, sleep quality,
and depressive symptoms with a trend toward significance in regards to physical quality of life.
xvi

Implications for Nursing Practice: It is clear that vitamin D deficiency is a significant
problem in pregnant women, especially in at-risk populations. Nursing has an important role in
providing the education and advocacy for screening pregnant women for vitamin D status and
supplementing according to clinical practice guidelines. Based on the current study findings,
sleep disruption and poorer physical quality of life may be problematic in underserved pregnant
women who are vitamin D deficient. The potential for a future study to examine whether
supplementation can improve symptomology, quality of life, and health outcomes is essential.
The beneficial effects of vitamin D supplementation to alleviate symptoms, prevent pregnancy
complications, and enhance overall quality of life need further study with well-designed clinical
trials.
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CHAPTER ONE
PROBLEM STATEMENT
Pregnancy is a period of transition for women which includes not only physical
alterations but psychological and hormonal changes. Women may respond differently to this
transition depending upon their previous life experiences, existing comorbid conditions, and the
support available to them during this time (Kamysheva, Skouteris, Wertheim, Paxton, &
Milgrom, 2010; Kamysheva, Werheim, Skouteris, Paxton, & Milgrom, 2009; Nazik & Eryilmaz,
2013; Wallace, Boyer, & Holm, 1986). Oftentimes, symptoms are manifested during pregnancy
due to the physical and psychological alterations and may include: fatigue, low back pain,
increase urinary frequency, breast pain, nausea, vomiting, and poor sleep (Kamysheva et al.,
2009; Nazik & Erylmaz, 2013; Foxcroft, Callaway, Byrne, & Webster, 2013; Skouteris,
Wertheim, Germano, Paxton, & Milgrom, 2009).
It has been reported that increased physical symptoms in the second trimester of
pregnancy are correlated with higher depressive symptoms (Kamysheva et al., 2010).
Depression in pregnancy has devastating effects not only on maternal outcomes but on fetal
outcomes as well (Bowen, 2006; Gavin, Gaynes, Lohr, Meltzer-Brody, Gartlehner, & Swinson,
2005; Muzik & Borovska, 2010). Recently, low vitamin D has been associated with depression
in pregnant and postpartum women (Huang, Arnold, Qui, Miller, Williams, &Enguobahrie,
2014; Cassidy-Bushrow, Peters, Johnson, Li, & Rao, 2012; Robinson et al., 2014;
Brandenburg,Vrijkotte, Goedhart, & Eijsden, 2012;
1
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Gur, Genc, Eskicioglu, Kurtulmus, & Guclu, 2015; Nielsen et al., 2013). Vitamin D
supplementation has been reported to improve depressive symptomology in non-pregnant
women (Spedding, 2014) and one trial in Iran examined improved depressive symptom scores
with vitamin D supplementation in pregnant women (n=169) at 38-40 weeks gestation, 4 and 8
weeks postpartum (Vaziri et al., 2016). Vitamin D deficiency has also been associated with
fatigue, low back pain (musculoskeletal pain), pelvic floor disorders, poor sleep, and depression
in women (Knutsen, Brekke, Gjelstad, & Lagerlov, 2010; Foxcroft et al., 2013; Lodh et al.,
2015; Cassidy-Bushrow et al., 2012; Huang et al., 2014; Le Goaziou et al., 2014; Badalian &
Rosenbaum, 2010; Parker-Autry, Markland, Ballard, Downs-Gunn, & Richter, 2012). Studies
have suggested that supplementation may be beneficial in alleviating some of these symptoms in
non-pregnant women (Schreuder, Bernsen, & Van der Wouden, 2012; Huang, Shah, Long,
Crankshaw, & Tangpricha, 2013; Arvold et al., 2009; Khoraminya, Tehrani-Doost, Jazayeri,
Hosseini, & Djazayery, 2013). Whether vitamin D level is associated with pregnancy symptoms
has not been studied and is the focus of this proposed study.
The National Health and National Examination Study (NHANES) has reported data
regarding vitamin D levels in non-pregnant childbearing women. For non-Hispanic Black
women, 99% had vitamin D levels <30 ng/ml and of those women, 86% had vitamin D levels <
20 ng/ml. For Hispanic women, 93% had levels <30 ng/ml and of those women, 60% had
vitamin D levels <20ng/ml (Ginde, Sullivan, Mansbach, Carmargo, 2010). Another NHANES
study reported a mean vitamin D of 14.8 ng/ml for non-pregnant African American women and a
mean vitamin D of 19.5 ng/ml for Hispanic women compared with a mean vitamin D of 25.6
ng/ml for White women (Gutierrez, Farwell, Kermah, & Taylor, 2011). Studies have shown that
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vitamin D deficiency is very common in pregnant women, particularly in African American
women with a mean vitamin D of 15.6ng/ml and Hispanic women with a mean vitamin D of 22.4
ng/ml in a NHANES cohort of 928 pregnant women (Ginde et al., 2010). An important
consideration, in regards to the high incidence of vitamin D deficiency in pregnant women, are
the associated adverse obstetric and fetal outcomes (Wagner, Taylor, Dawodu, Johnson, &
Hollis, 2010; Aghajafar et al., 2013; Urrutia & Thorp, 2012).
There is evidence to show there are vitamin D receptors (VDR) on the reproductive
tissues including the placenta, suggesting that vitamin D may play an important part of the
physiologic changes of pregnancy (Urrutia & Thorp, 2012). There is mounting evidence
indicating the consequences of having severely deficient levels of vitamin D during pregnancy
and the impact on the fetus which include: rickets, preeclampsia, preterm birth, increased risk of
cesarean section, low birth weight infants, maternal infections, and gestational diabetes mellitus
(GDM) (Dawodu et al., 2017; Hamilton, et al., 2010; Wagner, McNeil, Johnson, Hulsey,
Ebeling…et al., 2013).
Vitamin D deficiency disproportionately affects minority groups adversely and poorer
health outcomes have been reported in African American and Hispanic women (Weishaar &
Vergili, 2013; Bodnar & Simhan, 2010; Hossein-Nezhad, 2012). Because African American and
Hispanic women are at high risk for having vitamin D deficiency, it is important to investigate if
vitamin D deficiency could contribute to the frequency and type of pregnancy symptoms
experienced by these women. Based on a recent study using electronic medical record data of a
predominantly African American and Hispanic, Medicaid, patient population, 88% of the 302
women studied had vitamin D levels <30 ng/ml (Woo & Penckofer, 2015, April). In addition,
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81% of the African American women studied (n=138) were deficient with a level < 20 ng/ml
while 50% of the Hispanic women (n= 164) were deficient with a level < 20 ng/ml (Woo &
Penckofer, 2015, July).
Purpose
The purpose of this study was to determine if women who are vitamin D deficient have a
greater frequency of pregnancy symptoms including depression and sleep disruption, which may
alter their participation in health-promoting behaviors (e.g., eating a healthy diet, exercise) and
consequently impact their quality of life. Although vitamin D deficiency has been associated
with some of the common pregnancy symptoms such as fatigue, depressed mood,
musculoskeletal pain, urinary incontinence in women who are not pregnant, these associations
have not been reported in pregnant women. Understanding the relationships between vitamin D
status and pregnancy symptoms in a population at risk for vitamin D deficiency could provide
more clinical information and in turn improve the care delivered to these women. Due to the
cross-sectional nature of this study, causative linkages cannot be established but important
relationships between vitamin D status, pregnancy symptoms, depression, sleep quality, healthpromoting behaviors and quality of life were studied.
Theoretical Framework
The theoretical framework chosen for this study was based on Wilson & Cleary’s (1995)
model on health-related quality of life. This theory examined multiple relationships affecting a
person’s quality of life which start at an individual level but also include the environment of the
individual that can have an overarching impact on a person’s biologic factors, symptom status,
functional status, general health perceptions, and overall quality of life (Wilson & Cleary, 1995).
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Wilson & Cleary developed this framework to study clinically relevant variables that impact
quality of life. Their model attempted to combine the established biological and physiological
factors that are known to impact quality of life and integrated the psychosocial factors that play a
significant role as well. Wilson-Cleary’s model is composed of five levels of patient outcomes
which include: biological and physiological variables, symptoms status, functional status,
general health perceptions, and overall quality of life. As shown in Figure 1, the model provided
an excellent framework for the proposed study because it incorporates multiple facets of health
that impact on overall quality of life.
Figure 1. Adaptation of Wilson & Cleary’s (1995) conceptual model for health-related quality of
life

6
The characteristics of the individual included in the proposed study are as follows: the
ethnicity and race of the individual, age, education, and employment status. The main biological
variable in the proposed study is the serum vitamin D status as well as factors that can impact
vitamin D level such as diet (Block’s Vitamin D and Calcium screener), season of the year for
data collection, and level of obesity (measured as body mass index) (Holick, 2007; HosseinNezhad & Holick, 2013). Other biologic factors to be assessed include maternal health
characteristics, anemia status (hemoglobin from complete blood count) (e.g., parity, obstetric
history), as well as comorbid disorders (e.g., depression) and medications including vitamins.
Symptom status will assess type and frequency of pregnancy symptoms (Pregnancy Symptom
Inventory), sleep quality (Pittsburgh Sleep Quality Index), and depressive symptoms (Edinburgh
Postnatal Depression Scale). Functional status will assess health promotion activities (Health
Promotion Lifestyles Profile scale, HPLP v.2). General health perceptions will be assessed by
asking women their perception on overall health in pregnancy and health of the unborn baby
(Standard Form-12 version 2). Lastly, overall quality of life will include measures of functional
mental and physical health and well-being (SF12, v2).
Characteristics of the environment that impact symptom status, functional status, general
health perceptions, and quality of life included in this study are the following: spirituality, social
support, and socioeconomic status (SES) as variables that impact a patient’s quality of life. The
inclusion of the spirituality variable is important to assess in African American and Hispanic
women since evidence shows that spirituality is an important component that influences health in
these ethnic groups (Koenig, 2012). The conceptual model is depicted in Figure 1.
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Specific Aims
The primary aims of this study were: (1) to determine if there was a relationship between
vitamin D status, pregnancy symptoms including depression and sleep disruption, healthpromoting behaviors, and quality of life and birth outcomes and (2) to determine if differences
existed in vitamin D level, pregnancy symptoms, sleep quality, depressive symptoms, healthpromoting behaviors, and quality of life between African American and Hispanic women. The
primary hypothesis was: Women who were vitamin D deficient would have more pregnancy
symptoms including poor sleep quality and more depressive symptoms, fewer health-promoting
behaviors, and poorer quality of life. The secondary hypothesis was: There would be differences
in pregnancy symptoms including depressive symptoms and sleep quality, health-promoting
behaviors, and quality of life between African American and Hispanic women. As an
exploratory aim, if there was a significant relationship between vitamin D status and pregnancy
symptoms, whether depressive symptoms mediated this relationship would be studied.
In conclusion, vitamin D deficiency is common in pregnancy and there are also multiple
physiological discomforts of pregnancy including poor sleep, fatigue, urinary issues, and
musculoskeletal pain which are common in pregnancy. Since there is evidence to show that
many of the symptoms of pregnancy such as musculoskeletal pain and poor sleep are associated
with vitamin D deficiency in the non-pregnant population, it was important to see if this
relationship existed in pregnant women. The theoretical framework that guided the study was
Wilson & Cleary’s Model of health-related quality of life which provided an understanding of
the impact of the biological/physiological variables, its impact on symptom status, and how it
impacted functional status and ultimately quality of life.

CHAPTER TWO
LITERATURE REVIEW
Introduction
As described in Chapter One, the theoretical framework that guided this study was based
on Wilson & Cleary’s quality of life model which describes the key components affecting healthrelated quality of life. The key components reflected in their model include the following:
biological and physiological variables, symptom status, functional status, general health
perception and quality of life. Individual and environment characteristics which impact quality
of life were also integrated components. The main variable of interest in this study was the role
vitamin D status had on symptom and functional status in pregnant women and the impact it had
on quality of life. Each theoretical component of the model is described below based on the
published literature and was synthesized to provide the rationale for the proposed study.
Characteristics of the Individual
Age is an important variable that can influence pregnancy symptoms, maternal health,
vitamin D status, and quality of life (Dotlic et al., 2012; Nazik & Eryilmaz, 2014; Zib, Lim, &
Walters, 1999). As women get older, they may experience an increase in pregnancy symptoms
which may or may not be related to other chronic illnesses due to aging (Bahadoran &
Mohamadirizi, 2015; Nazik & Eryilmaz, 2014). On the other hand, adolescent pregnant women
may be at greater risk for pregnancy symptoms and vitamin D deficiency due to their developing
bones, pubescence, and ever changing bodies (Williams, 2014; King et al., 2015).
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Evidence in the literature indicates that ethnicity is an important individual characteristic
in regards to vitamin D status. African American and Hispanic women are more likely to be
vitamin D deficient when compared to their Caucasian counterparts (Ginde et al., 2010; Castro &
Penckofer, 2014; Taksler, Cutler, Giovannucci, & Keating, 2014; Holick, 2007; Hossein-Nezhad
& Holick, 2013). Hispanic women also have lower vitamin D levels than Caucasians, but higher
levels than African Americans (Ginde et al., 2010; Daly et al., 2012; Giovannucci et al., 2006).
The NHANES data (n=14,319) which included both men and women, compared vitamin D
status based on ultraviolet (UV) radiation and ethnicity, and showed that non-Hispanic Blacks
were likely to be deficient despite being in the highest UV index quartile (Taksler et al., 2014).
Employment and education status is another individual characteristic that can impact
both pregnancy symptoms and vitamin D status. Logically speaking a pregnant woman who
works outside (e.g., mail delivery person) may have a different symptom profile than one who
works inside (e.g., secretary) due to different vitamin D exposures from the sun. However, there
are no studies to date that examine whether types of occupation (indoor or outdoor) impact
pregnancy symptoms. One study reported that employment was a significant predictor of more
pregnancy symptoms in healthy pregnant women (n=909) who resided in Turkey (Nazik &
Eryilmaz, 2014) . They also reported that employment was associated with a greater incidence of
management strategies for pregnancy symptoms.
Employment and education are often related. Less education has been associated with
lower vitamin D levels in epidemiologic studies (Daly et al., 2012; Forrest & Stuhldrere, 2011).
Lower educational levels have also been associated with a decreased likelihood of informing
healthcare providers of symptoms such as urinary incontinence and low back pain (Colapinto,
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Rossiter, Khan, Kirk, & Veugelers, 2014; Giovannucci et al., 2006; Kahyaoglu Sut & Balkanli
Kaplan, 2015; Telleen, 1993; Zib et al., 1999). Thus, it is possible that women who are
employed and/or more educated are likely to report symptoms to their healthcare providers
because they can seek attention for treatment of these symptoms.
Biological Factors
The main biological variable of interest for the proposed study was vitamin D status and
its impact on pregnant women in relation to their symptoms and functional status. There was
significant evidence addressing the biological implications of vitamin D during pregnancy.
Thus, a review of this information is provided.
Vitamin D in Pregnancy
Vitamin D status is essential not only to the mother’s health but also to the health of the
fetus. The need for increased vitamin D intake during pregnancy is due to the increased needs of
the fetus (Hollis & Wagner 2012; Urrutia & Thorp, 2012; Pludowski et al., 2013). The
Endocrine Society defines the standard range of vitamin D as follows: adequate vitamin D level
is > 30 ng/ml, insufficient defined as 20-30 ng/ml, deficient defined as <20 ng/ml and severely
deficient described as <10 ng/ml (Holick, 2007). During pregnancy with development of the
placenta, a megalin transport system is developed that can transport the large vitamin D complex
metabolite across the maternal-fetal surface by expressing genes CYP27B1 which can then
synthesize the vitamin D metabolite to its active biological product of 25(OH)D (HosseinNezhad & Holick, 2013; Wagner, Taylor, Dawodu, Johnson, & Hollis, 2012). Of concern is that
currently the American College of Obstetrics (ACOG), World Health Organization (WHO), and
American College of Nurse Midwives (ACNM) recommend against routine vitamin D screening

11
in all pregnant women, but do recommend screening for those at high risk for vitamin D
deficiency (Dawodu & Wagner, 2012). Thus, pregnant women are not being routinely screened
for vitamin D deficiency and even those at risk for vitamin D deficiency are not being tested by
obstetric providers (Thatcher & Clarke, 2011; Kaludjerovic & Vieth, 2010; Dawodu & Wagner,
2012). Women at risk for vitamin D deficiency include those individuals with darker skin
complexion (different ethnic groups), those living in northern latitudes, and those with obesity,
malabsorptive disorders, hepatic or renal failure, and poor dietary intake (Hossein-Nezhad,
2012). Dawodu & Wagner (2012) described the epidemic of vitamin D deficiency as a global
epidemic that is not being addressed to reduce the burden of disease that vitamin D
supplementation could provide. Therefore, there is a clinical gap in identifying and screening
women at risk for vitamin D deficiency in pregnancy.
The NHANES data showed that almost three quarters of the nation’s African American
childbearing women are vitamin D insufficient/deficient and more than half of childbearing
Hispanic women are deficient (Yetley et al., 2010; Ginde et al., 2010). Other studies have also
shown that vitamin D deficiency is very common in pregnant women (Holick, 2010;
Kaludjerovic & Vieth, 2010; McAree et al., 2013; Johnson et al., 2012).
There are vitamin D receptors (VDR) on all reproductive tissues including the placenta
which supports the hypothesis that vitamin D could play an important role in the physiologic
changes of pregnancy (Urrutia & Thorp, 2012). There are consequences of having severely
deficient levels of vitamin D during pregnancy which may contribute to adverse pregnancy
outcomes such as increased incidence of GDM and preeclampsia. The following section will
summarize research in regards to vitamin D status and adverse pregnancy outcomes.
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Associations of Vitamin D and Pregnancy Outcomes
Preeclampsia. This is a significant adverse outcome in pregnancy because it has high
maternal as well as neonatal morbidity and mortality (Achkar et al., 2014; Tabesh, SalehiAbargouei, Tabesh, & Esmaillzadeh, 2013). Preeclampsia is an important risk factor for having
a preterm birth since the only treatment for preeclampsia is delivery for the safety of the mother
and fetus. There is evidence to indicate that inflammatory cytokines are implicated in the
development of preeclampsia and that vitamin D which has anti-inflammatory effects, may play
a role (Achkar et al., 2014). One mechanism of its anti-inflammatory effect is the
downregulation of uncommitted helper T cells and promotion of the “proliferation of
immunosuppressive regulatory T cells” (Wagner et al., 2012, p. 212). There is also in vivo
evidence to show that vitamin D plays a role in promoting IL-10 production which is antiinflammatory and suppresses the production of inflammatory cytokines like IL-6, TNFα, and
IL1β (Korf, Decallonne, & Mathieu, 2012; Hollis & Wagner, 2013). Therefore, in the presence
of high levels of maternal serum vitamin D, there may be important anti-inflammatory effects
which can potentially protect against the development of preeclampsia.
Tabesh et al. (2013) conducted a meta-analysis of all the studies investigating the
association of vitamin D deficiency and preeclampsia. That meta-analysis found a significant
relationship between vitamin D deficiency and preeclampsia. However, the authors concluded
that more robust and well-powered studies are needed to strengthen this relationship.
A nested case control study published findings after the meta-analysis by Tabesh et al.
(2013) and showed promising results (Achkar et al., 2014). That study used a robust research
design and had a larger sample size of women with preeclampsia (n=169) and without (n=1975).
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Strengths of this study included its method of measuring vitamin D which was
chemiluminescence immunoassay as well as controlling for significant covariates (i.e., BMI,
maternal age, smoking, parity, season, cohort site, and year of collection). Their findings
revealed an odds ratio of 2.48 (95% CI 1.29 -2.83) of preeclampsia in the low vitamin D (<30
nmol/l which is equivalent to 12 ng/ml) group when compared to those with normal vitamin D
levels. Finally, it is also important to note that two randomized control trials evaluating birth
outcomes and vitamin D supplementation corroborated the epidemiological evidence showing
the association between preeclampsia and vitamin D (Wagner et al., 2013; Wagner et al., 2015).
Preterm birth. A consequence of maternal vitamin D deficiency is the increased risk of
preterm birth. The main mechanism associated with vitamin D’s role in preventing preterm birth
is its effect on the innate immune system. Vitamin D is known to activate Toll-like receptors
(TLR) on macrophages, leading to an antimicrobial pathway evidenced in both maternal and
neonatal blood (Walker et al., 2011; Kaludjerovic & Vieth, 2010; Wagner et al., 2012; Korf,
Decallonne, & Mathieu, 2014). The antimicrobial pathway has been instrumental in preventing
perinatal infections associated with preterm delivery especially those in preventing bacterial
vaginosis which is most common in African American women who have a higher incidence of
vitamin D deficiency (Christesen et al., 2012; Thorne-Lyman & Fawzi, 2012; Weinert &
Silveiro, 2014).
A more recently published study reported a significant decrease in preterm birth in
vitamin D deficient pregnant women who were supplemented with vitamin D. Sablok et al.
(2015) conducted a clinical trial where women were randomized to vitamin D supplementation
(n=120) or placebo (n=60). The dosages of vitamin D provided for supplementation were based
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on their vitamin D level (the more deficient they were, the higher the dosage of vitamin D they
received). Doses were as follows: placebo dose vs. one dose of 60,000 IU at 20 weeks gestation,
or two doses of 120,000 IUs at 20 and 24 weeks gestation, or 4 doses of 120,000IUs at 20, 24, 28
and 32 weeks gestation. One hundred percent compliance was reported since administration of
the treatment or placebo was provided at their clinic visits. It should be noted that the study was
conducted in India where vitamin D deficiency is very common due to cultural and religious
practices of wearing head to toe covering; hence, limiting sunlight exposure as well as darker
skin complexion (Sablok et al., 2015). Their study showed that those in the treatment group
(8.3%) had significantly lower rates of preterm labor and birth compared to those in the placebo
(21.1%) group (p = .02), but there were no differences in GDM or hypertensive disorders of
pregnancy (Sablok et al., 2015).
Four randomized controlled trials which were sufficiently powered have demonstrated
that vitamin D supplementation reduces the risk of preterm delivery (Wagner et al., 2015; Sablok
et al., 2015; Dawodu et al., 2013; Wagner et al., 2013). It should be noted that for the patient
populations studied all were pregnant women at greatest risk for vitamin D deficiency (i.e.,
African American women) (Bodnar & Simhan, 2010; Weishaar & Marcley, 2013). Evidence
demonstrates a relationship between vitamin D supplementation and reduced rates of preterm
delivery. Given this information, clinicians should identify women at risk for vitamin D
deficiency to prevent preterm delivery and consider vitamin D supplementation as an adjunct
therapy.
Finally, two recently published meta-analyses analyzed the impact of vitamin D
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deficiency and preterm birth. Both reported positive associations between vitamin D deficiency
as defined as < 20 ng/ml and increased risk of preterm birth (Qin, Lu, Yang, Xu, & Luo, 2017;
Zhou, Two, Huang, Zhu, & Tao, 2017). One meta-analysis included ten studies (n=10,098)
which showed an increased risk of preterm birth with vitamin D deficiency (defined as <20
ng/ml) (OR = 1.29, 95% CI: 1.16–1.45) but included only observational studies. The other metaanalysis included randomized controlled trials and observational studies. An association was
found between increased preterm birth risk and vitamin D deficiency (defined as < 20 ng/ml)
(pooled OR, 1.25; 95% CI: 1.13–1.38) (Zhou et al., 2017). Lastly, an analysis of the randomized
control trials using various doses of vitamin D supplementation (2000 IU to 120,000 IU) but
excluding studies using both vitamin D and calcium supplementation also reported more than a
50% reduction in the risk of preterm births (RR 0.57; 95%CI: 0.36-0.91). However, this metaanalysis did not include the clinical trials conducted by Hollis and colleagues (2013).
Gestational diabetes mellitus. Maternal vitamin D deficiency has been implicated in
increased risk of GDM (Poel et al., 2012; Lu, Xu, Lu, & Zhang, 2016). Vitamin D has been
shown in many epidemiologic studies to influence glucose homeostasis and insulin resistance
(Weinert & Silveiro, 2014; Burris et al., 2012; Thorne-Lyman & Fawzi, 2012). The lower the
vitamin D level, the increased risk of GDM diagnosis based on a meta-analysis of seven
observational studies evaluating the risk of GDM and vitamin D deficiency and was verified in
another meta-analysis that included twenty observational studies (Poel et al., 2012; Lu et al.,
2016). GDM is linked to maternal and neonatal morbidities which include the following:
increased risk of preeclampsia, macrosomia, increased risk of stillbirth, increased risk of preterm
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birth, increased incidence of birth defects with poor control, and type 2 diabetes later in life
(Burris & Camargo, 2014).
Despite the plethora of correlational studies showing that vitamin D has an impact on
glucose tolerance, there is a dearth of randomized controlled trials evaluating vitamin D
supplementation in pregnant women with GDM. A recent study examined vitamin D
supplementation of 5,000 IU daily versus a placebo group receiving 400 IU of vitamin D daily,
which is equivalent to the prenatal vitamin prescribed for women who are <20 weeks gestation
(Yap et al., 2014). Pregnant women were enrolled into the study after confirming their vitamin
D levels were < 32 ng/ml, and randomly assigned to the control or treatment group, while also
allowing pregnant women who had ≥ 32 ng/ml to be in a nonrandomized control group. The
control group (n=80) had twelve pregnant women who tested positive for GDM while the
treatment group (n=78) had only seven test positive for GDM but there was not a statistical
difference (OR 0.56; 95% CI: 0.21-1.50; p = 0.25) (Yap et al., 2014). Although there was not a
statistically significant difference in incidence of GDM in the two groups, the lower the baseline
vitamin D level, the higher the fasting blood glucose on the two hour glucose tolerance test. A
serious limitation of this study was that women who had sufficient vitamin D levels (≥32 ng/ml)
were included in the analysis which could have decreased the effect that vitamin D
supplementation could have had on those who were deficient.
Asemi et al. (2014) evaluated women already diagnosed with GDM who were
randomized into a treatment of one capsule of 50,000 IUs of vitamin D (n=23) or a matching
placebo (n=22). Participants were provided pills at 28 weeks gestation and again at 34 weeks
gestation. Decreased maternal polyhydramnios and infant hyperbilirubinemia, was reported but
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no differences in cesarean section rates, insulin therapy after intervention, newborn birth size and
Apgar score were found. However, the study was only powered for the outcomes of newborn
weight. This study is unique because the effects of high dose supplementation of vitamin D on
women already diagnosed with GDM was examined. However, the small sample size was not
sufficient to detect changes in other outcomes.
There have been many studies with larger sample sizes that have shown an inverse
relationship with vitamin D status and risk of GDM (Burris et al., 2012; Maghbooli, HosseinNezhad, Karimi, Shafaei, & Larijani, 2008; Zuhur, Erol, Kuzu, & Altuntas, 2013; Soheilykhah,
Mojibian, Rashidid, Rahimi-Saghand, & Jafari, 2010). However, there are no randomized
control trials showing a decreased incidence of GDM with adequate vitamin D supplementation
in vitamin D deficient women.
In contrast, another study examined a cohort of pregnant women who were enrolled at 24
to 30 weeks gestation and followed again at 6 to 12 weeks postpartum and screened for vitamin
D levels both in pregnancy and postpartum (Pleskacova et al., 2015). Their study showed no
significant difference in vitamin D status between those who were diagnosed with GDM (n=47)
vs. healthy pregnant women (n=29), as vitamin D status was low in both groups (95.7% < 20
ng/ml in GDM group; 93.1% <20 ng/ml in control group), but the study was limited due to the
small sample size.
Small for gestational age (SGA) babies. Findings of studies conducted to evaluate the
association between SGA and maternal vitamin D deficiency are conflicting simply due to the
variation of when vitamin D status was measured (early or late in the pregnancy) (Weinert &
Silveiro, 2014; Bodnar & Simhan, 2010). Many observational and cross-sectional studies have
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shown correlations with maternal vitamin D deficiency, SGA and low birth weight (Weinert &
Silveiro, 2014; Kaludjerovic & Vieth, 2010). One clinical trial (Sablok et al., 2015) found that
women who received the higher dose of vitamin D supplementation had higher birthweight
babies. However, Wagner et al. (2013) did not see a significant difference in birthweight in their
randomized controlled trial where the control group received 400 IUs daily (n=110) and the
treatment groups received either 2000 IUs (N=201) or 4000 IUs (n=193) of vitamin D daily.
Therefore, there is a need for better quality—more sufficiently powered and well-designed
randomized controlled clinical trials—to establish the association between vitamin D deficiency
and SGA babies.
Maternal health history and characteristics. There are many characteristics of maternal
health that can impact pregnancy symptoms, quality of life and vitamin D status. There has been
some evidence to show that multiparous women who have a history of a forceps or vacuum
delivery, increasing age, or obesity are prone to more pregnancy symptoms (Rodriguez, Bohlin,
& Lindmark, 2001; Wallace, Boyer, Dan, & Holm, 1986). However, one study of 117 pregnant
women (34% primaparas and 64% multiparas) reported no difference in the frequency of
pregnancy symptoms between parity (Zib, Lim, & Walters, 1999). The top five symptoms
reported by these women included micturition, fatigue, pelvic pressure, insomnia, and lower
backache which were greatest during the third trimester. Differences in types of symptoms by
parity were noted with multigravidas having more stress incontinence and skin dryness and
primigravidas having more striae gravidarum (Zib, Lim, & Walters, 1999). Pregnant women
often do not report their discomforts of pregnancy to their healthcare providers (Wang et al.,
2004; Nazik & Eryilmaz, 2014). One study of pregnant women (n=950) reported that only 32%
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of them told their prenatal provider about their low back pain and only 25% of providers
recommended any treatment (Wang et al., 2004). In addition to having low back pain, 58% of
women reported that the low back pain caused sleep disturbances and impaired activities of daily
living (Wang et al., 2004).
A history of depression and/or anxiety prior to pregnancy has been reported to impact
coping with the symptoms of pregnancy. In a cross-sectional study of pregnant women (n=215),
those with severe depressive symptoms and a history of depression had higher frequency and
intensity of pregnancy symptoms/discomforts and poorer sleep quality (Kamysheva et al., 2008).
Another prospective study of pregnant women (n=257) showed that the intensity and frequency
of pregnancy symptoms early in the second trimester were the strongest predictors of depressive
symptoms experienced late in the third trimester (Kamysheva et al., 2009).
There is a vast amount of evidence to support that women with higher body mass index
(BMI), have lower vitamin D levels (Hollis, 2007; Grace, Vincent & Aylwin, 2014; Brock et al.,
2010). Although the exact mechanism as to why obese individuals have lower vitamin D levels
is not completely understood, the proposed rationale is that increased adipose tissue causes
reuptake of the fat-soluble vitamin D which results in less bioavailable vitamin D (Grace,
Vincent, & Aylwin, 2014). Since African American and Hispanic women are at a higher risk for
obesity and poorer maternal health outcomes, the role that vitamin D plays may be confounded
by the obesity (Bryant, Warjoloh, Caughey, & Washington, 2010). However, there is evidence
that pregnant women who are obese are more likely to be depressed, have higher levels of
anxiety, more pregnancy symptoms and have lower quality of life (Li et al., 2012; Amador,
Juarez, Guizar, & Linares, 2008; Doltic et al., 2014). A study of Serbian pregnant women
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(n=604) examining BMI, quality of life, fatigue, depression, social support, and pregnancy
symptoms reported that obese women were more likely to have higher depression scores (using
the Beck Depression Inventory), higher pregnancy symptoms (using Pregnancy Symptom Scale),
and lower mental and physical health as well as decreased health-related quality of life (using the
SF-36) (Doltic et al., 2014).
A meta-analysis of 62 studies examined the association between obesity and mood (i.e.,
perinatal depression and anxiety) in the antepartum and postpartum periods (Molyneaux, Poston,
Ashurst-Williams, & Howard, 2014). The report concluded that obese women had significantly
higher rates of depressive symptoms in pregnancy (OR 1.43, 95% CI 1.27-1.6) and the
postpartum (OR 1.30; 95% CI 1.20-1.42). In addition, higher levels of antenatal anxiety were
also reported (OR 1.41; 95% CI 1.10-1.80) (Molyneaux et al., 2014).
Symptom Status
Physiological and anatomical changes associated with pregnancy symptoms. There
are many physiological changes that occur in normal pregnancy that can cause the
discomforts/symptoms experienced during pregnancy. Changes in hormones (estrogen and
progesterone) that occur during pregnancy often precipitate symptoms such as breast tenderness.
One cross-sectional study compared the symptoms of healthy pregnant (n=117) and age-matched
controls of non-pregnant women (n=119), and reported that symptom frequency was doubled in
pregnant women (Zib et al., 1999).
The major anatomical change during a normal pregnancy includes weight gain from the
fetus, placenta, and amniotic fluid. Other changes due to higher hormone levels of progesterone
and estrogen include a softening of cartilage in joints and relaxation of ligaments (King et al. ,
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2015). Lordosis of pregnancy helps the body accommodate to the increased weight by causing
the pelvis to tilt anteriorly and the sacroiliac joint to widen (King et al., 2015). This can cause
low back pain as well as pelvic pain depending upon the anatomy of the pregnant woman, fetal
weight gain, body mechanics, type of occupation, prior history of low back pain or injury, and
increasing age (Vermani, Mittal, & Weeks, 2011; Wang, et al., 2014).
Evidence suggests that 70% of pregnant women will complain of low back pain in
pregnancy (Chang, Jensen, & Lai, 2014; Facco, Kramer, Ho, & Zee, 2010; Wang et al., 2014).
Some studies have shown that women with low back or pelvic pain have lower quality of life in
pregnancy and that it affects African American pregnant women disproportionately (Chang,
Jensen, & Lai, 2015; Waterfield et al., 2015; Wang et al., 2014; Olsson & Nilssen-Wikmar,
2004).
As the uterus grows, the stomach gets displaced superiorly with intestines moving
laterally resulting in slower gastrointestinal motility (King et al., 2015). As a result, constipation
can be common as the uterus places pressure on the descending colon (King et al., 2015). In
addition, due to pressure the uterus puts on the stomach, indigestion can occur and reflux is
common causing heartburn. Nausea and vomiting also occur in pregnancy which may be due to
the anatomic changes previously addressed. However, these symptoms are not reported by all
women during pregnancy. Because the levels of human chorionic gonadotropin hormone
exponentially increases early in the first trimester, nausea and vomiting may be more frequent at
that time and lessens as this hormone levels off as with progression of the pregnancy
(Cunningham et al., 2010).
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Psychological and emotional changes. Pregnancy is assumed to be a joyous mental state
but the reality is that for many women, it can be a very tumultuous and unnerving mental state.
There are many factors that contribute to the psychological changes that happen in pregnancy
such as whether the pregnancy was planned or not, wanted or not, what the state of the
relationship with the father of the baby is, socioeconomic state, medical history, history of
mental illness prior to pregnancy, age, and social support; all of which can contribute to the
development of depressive symptoms (Lancaster, Gold, Flynn, Yoo, Marcus, & Davis, 2010;
Buneviscius et al., 2009). The adjustment period to finding out about the pregnancy is
compounded with the hormonal changes that occur with increasing estrogen and progesterone
which can have an impact on lability of mood (Lancaster et al., 2010).
Vitamin D and Symptom Complaints
Vitamin D deficiency has been documented in the literature to be associated with many
different symptoms including depressive symptoms, fatigue, sleep disorders, musculoskeletal
pain, and pelvic floor disorders. Many of these symptoms are common in pregnancy and
therefore it is important to review the literature to see what the current evidence is in
understanding the links between these symptoms and vitamin D status.
Vitamin D and depression. Much of the evidence related to vitamin D deficiency and
depression has been published in the general population and many epidemiological and
observational studies have shown the correlation between vitamin D and depression
(Jaaskelainen et al., 2015; Kerr et al., 2015; Hogberg, Bech, Hallstrom, & Petersson, 2014;
Parker, Brotchie & Graham, 2017). In addition, three major meta-analyses evaluating the
randomized controlled trials with vitamin D supplementation for treating depression have shown
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conflicting results (Anglin, Samaan, Walter, McDonald, 2013; Spedding, 2014; Gowda,
Mutowo, Smith, Wluka, & Renzaho, 2015). Anglin et al. (2013) and Spedding (2014) both
showed a significant effect of vitamin D supplementation in reducing depressive symptoms.
However, Gowda et al. (2015) showed no significant reduction in depressive symptoms with
vitamin D supplementation but included individuals with sufficient levels of vitamin D in their
study. This is a significant limitation as vitamin D supplementation may not improve depressive
symptoms in persons who are vitamin D sufficient. A strength of another meta-analysis was that
the studies with biological flaws and those without were examined separately, and the effect size
for the ones without biological flaws showed an effect size of vitamin D supplementation
comparable to that of an anti-depressant medication (Spedding, 2014). Results of the studies are
summarized in Appendix E (Table 1).
The mechanism behind vitamin D and depression has been widely debated. However,
evidence indicates that vitamin D receptors located in the brain could play a role in mental illness
(Patrick & Ames, 2015; Hogberg et al., 2014). Specifically, it has been suggested that serotonin,
the hormone responsible for mood regulation, is potentially modulated by vitamin D. Therefore,
when vitamin D is deficient, serotonin synthesis can be impacted which can lead to depression,
anxiety, and other psychiatric disorders (Hogberg et al., 2014; Patrick & Ames, 2015). In
addition, vitamin D receptors (VDRs) are involved in the regulation of the hypothalamicpituitary axis (HPA) and sympathetic nervous system which is important because dysregulation
of the HPA and sympathetic nervous system is implicated in depression (Hogberg et al., 2014).
Despite most of the evidence showing a correlation with vitamin D deficiency and
depression in adults, one study examined a cohort of 3,251 men and women in the Netherlands
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aged 55 and older (Jovanova et al., 2017). This was a population cohort study that demonstrated
a cross-sectional association with vitamin D status and depression but not a longitudinal
association. Serum vitamin D levels were only drawn at baseline along with a baseline Center
for Epidemiologic Scale–Depression (CES-D) score and follow up CES-D assessments after year
one and year two. Participants were followed up to an average of ten years and assessed for
major depressive disorder diagnosis on their medical record, but serum vitamin D was not taken
again. Therefore the analysis was based on whether baseline vitamin D deficiency (defined as
37.5 nmol/l or 15.2/bg.ml) which was predictive of depressive symptoms and/or major
depressive disorder over time (Jovanova et al., 2017). Their study was limited because it is
unknown if those who were vitamin D deficient at baseline took vitamin D supplements which in
turn could have improved their vitamin D levels, thus reducing depressive symptoms.
In addition to the evidence presented about vitamin D and depression which has focused
on the non-pregnant population, recent literature has been reported on vitamin D and depression
during pregnancy and the postpartum. In the past five years, the evidence has significantly
increased in studies examining vitamin D status and perinatal depression . Appendix E, Table 2,
delineates studies examining vitamin D status and perinatal depression. To date, all the studies
have been observational in nature except for one. Therefore more interventional studies
evaluating whether vitamin D supplementation in pregnant women improves depressive
symptoms are warranted.
The cross-sectional studies have been conducted measuring vitamin D in early pregnancy
with assessment of depressive symptoms in late pregnancy and/or in postpartum period. Because
a variety of tools were used for assessing depressive symptoms comparison across studies is
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difficult. Of the ten studies published, two studies showed no significant association between
vitamin D status and depressive symptoms, but the participants were predominantly Caucasian
(Nielsen et al., 2013; Gould et al., 2015). For example, the study by Gould et al. (2015) had a
sample of Australian women who were mostly Caucasian (n=919) (non-Caucasian, n=121) and
only 8% had vitamin D levels < 25nmol (10 ng/ml). The study conducted by Nielsen et al.
(2013) used evidence of filling anti-depressant medications as its only measure of depression
using a retrospective chart review in a case control study. This study showed no difference risk
of postpartum depression in those women who had a vitamin D level < 15 nmol/L (6 ng/ml)
(Nielsen et al., 2013). A limitation of this methodology is that only individuals prescribed
medication for depression treatment were studied. In addition, women who may have had
counseling as a treatment and those who were not screened at all for postpartum depression were
not captured. Evidence shows that many postpartum women go undiagnosed and untreated
therefore; therefore, using a depressive symptom tool would be beneficial to capture a greater
incidence of these symptoms (Banti et al., 2011; Bernstein et al., 2008; Bonari et al., 2004).
The studies that did show a strong association between vitamin D status and depressive
symptoms in pregnant women or postpartum women were in predominantly African American
and Latino patient populations. Thus, race and/or ethnicity may be an important variable for
consideration in effectiveness. Cassidy-Bushrow, Peters, Johnson, Li, & Sudhaker (2012)
demonstrated a significant association of vitamin D deficiency and depressive symptoms (using
the CES-D) (OR 0.54, 95% CI, 0.29-0.99). That study included only African American pregnant
women in a low socioeconomic community and showed that the odds of higher depressive
symptoms (CESD≥16) decreased by 46% for every one unit increase of log transformed vitamin
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D level (~2.72 ng/ml). Another study with an ethnically diverse sample (43 Caucasians, 30
African Americans, 23 Hispanic, and 1 Asian) showed that postpartum EPDS scores were higher
for those who had lower vitamin D levels using vitamin <32 ng/ml as the cutoff when compared
to those who were sufficient (vitamin D deficiency and > 32 ng/ml) (Murphy, Mueller, Hulsey,
Ebeling, & Wagner, 2010). Another study by Robinson et al. (2014) reported that women who
had the lowest level of vitamin D < 47 nmol (18 ng/ml) were most likely to report postpartum
depressive symptoms (OR 2.19, 95% CI, 1.26-3.78). A unique component of this study was that
depressive symptom screening was done at three days postpartum while participants were still in
the hospital status post-delivery (Robinson et al., 2014). However, one of the limitations of
screening so close to birth is that the volatility of emotions may occur right after childbirth
especially if there were neonatal complications post-delivery (Gjerdingen & Yawn, 2007; Gavin
et al., 2005).
Finally, there was one randomized controlled trial which assessed for an improvement of
depressive symptoms in Iranian pregnant women (n=169) (Vaziri et al., 2016) following vitamin
D supplementation. The sample had a mean vitamin D level of 12.35 ng/ml and pregnant
women received either a placebo or 2000 IU of vitamin D and both groups were permitted to
take their prenatal vitamin which has 200-400 IUs of vitamin D. Their study excluded anyone
who had pregnancy complications, multiple gestation, history of mental illness, or any medical
complications such as thyroid disease, diabetes, heart disease, etc. Despite using such a low
vitamin D supplementation dose for a population so severely deficient, a significant
improvement of depressive symptoms was noted at 38-40 weeks gestation (p = .01) and
postpartum at 4 weeks and 8 weeks (p <.0001) (Vaziri et al., 2016). Of concern, however, is that
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by the end of the study, only 8% of the sample had a vitamin D level > 30 ng/ml. Therefore the
supplementation dose used in the study was not adequate, suggesting that if a higher dose had
been used, perhaps a greater impact on depressive symptoms would have been seen. Therefore,
more robust and well-designed studies need to be done to assess the impact that vitamin D
supplementation could have on depressive symptoms in pregnancy.
Vitamin D and sleep. The link between vitamin D deficiency and sleep disorders has
been shown in some observational studies with non-pregnant individuals (Appendix E, Table 3).
Since vitamin D target sites have been found on the areas of the brain that have to do with sleep,
it is possible that vitamin D may play a role in sleep regulation (Gominiak & Stumpf, 2012).
The brainstem and periventricular areas of the brain are responsible for the retinal projections of
light cues involved in the sleep/wake cycle of the circadian clock. Therefore, if vitamin D plays
a role in the maintenance of this sleep-wake regulation, then deficient levels of vitamin D could
potentially cause sleep disturbance (Gominiak & Stumpf, 2012). In animal studies, vitamin D
target sites have been documented in the neurons in the midbrain and in the basal forebrain and
hypothalamic periventricular region which can influence different parts of the sleep cycle
(Gominiak & Strumpf, 2012).
There is quite a spectrum of sleep disorders but many of the studies have focused on
Restless Leg Syndrome (RLS) which is a sensorimotor neurological disorder which causes
uncontrollable limb movements primarily in the ankles and calves at night leading to sleep
disturbance (Balaban et al., 2012). In one study, individuals with Vitamin D deficiency as
measured by < 20 ng/ml (50 nmol/L) had more severe RLS scores when compared to those with
vitamin D ≥ 20 ng/ml (Cakir et al., 2015). Interestingly enough, most of the participants in the
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study were women, as RLS is more common in women than in men, and women are also more
likely to be vitamin D deficient when compared with men (Cakir et al., 2015; Brock et al., 2010).
Vitamin D deficiency is often associated with concurrent musculoskeletal pain and
muscular myopathy as will be described below, potentially interfering with normal sleep patterns
(McCarty, Chesson, Jain, & Marino, 2014). In a pilot study including patients being evaluated at
a sleep disorder clinic with complaint of nonspecific musculoskeletal pain, 153 patients were
included in the sample and assessed for vitamin D status (McCarty, Reddy, Keigley, Kim,
Cohen, & Marino, 2013). The mean vitamin D for the patient cohort was 19.8 ng/ml with 77
women who had obstructive sleep apnea and RLS as the most common sleep diagnoses. The
study also reported that Black ethnicity, age < 60 years, and obesity predicted vitamin D
deficiency with a 0.73 sensitivity and 0.74 specificity. In contrast, in another study examining
elderly (60-80 years) Korean adults (n=1614), vitamin D deficiency was also associated with
shorter sleep (Kim, Chang, Kim, & Kang, 2014). Study limitations included self-reported sleep
duration. However, another study using actigraphy measurements with elderly U.S. men showed
that vitamin D deficiency was associated with shorter sleep duration and poorer sleep efficiency
function (Massa, et al., 2015).
Ethnicity is an important factor that can have a significant impact on not only vitamin D
deficiency but also the presence of sleep disorders (Andersen & Tufik, 2012). A study of
patients (n=81) who were largely female (95%) being seen at a sleep disorder clinic who had
complaints of musculoskeletal pain reported no association between excessive daytime
sleepiness and vitamin D status when the analysis was run on the total sample. However when
evaluating just the African American patients (35%), there was a significant correlation between
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lower vitamin D status and excessive daytime sleepiness (McCarty Reddy, Keigley, Kom, &
Marino, 2012). Another study (n=1721) found similar results in that those who were vitamin D
deficient (<20 ng/ml) and were more likely to be African American had shorter sleep duration
and poorer sleep efficiency based on actigraphic measurements (Bertisch, Sillau, de Boer, Szklo,
& Redline, 2014). Their study included an older population with a mean age of 68.2 years and
an ethnically diverse sample with 37.2% being White, 27.7% being African American, 11.9%
being Chinese American, and 23.2% being Hispanic.
One of the few intervention studies that evaluated sleep quality and vitamin D deficiency
was a one-armed intervention done on veteran men who had complaints of chronic pain that
showed improvement of pain, sleep latency, sleep duration, and various aspects of quality of life
(Huang, Shah, Long, Crankshaw, & Tangpricha, 2012). The study design incorporated two
groups, a vitamin D deficient group (< 20 ng/ml) and vitamin D insufficient (20 to 29 ng/ml).
Findings indicated that 84% of the deficient group was made up of African American males and
60% of the insufficient group was made up of African American males. Pain was measured on a
0 to 10 analog scale, but also using the bodily pain subscale of the SF-36. In addition, the SF-36
subscales for physical functioning and physical role functioning, and sleep quality using the
PSQI were assessed, and all demonstrated statistical improvements following vitamin D
supplementation.
One study examining vitamin D and sleep quality was conducted with women who were
at 36 weeks gestation of their pregnancy (n=91), which showed no associations between vitamin
D status and sleep quality (using the Pittsburg Sleep Quality Index) (Gunduz et al., 2015). The
mean vitamin D level was 22.9 ng/ml, and no difference in sleep quality was found between
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women classified into deficient (< 20 ng/ml) or non-deficient (>20 ng/ml) groups. However,
sleep quality was reported to be poor for both groups. The study had some limitations in that it
only included women who had delivered babies at term and without complications.
Poor sleep quality is common in pregnancy and can be related to other pregnancy
symptoms. A large study of pregnant women (n=2427) assessing sleep quality using the
Pittsburgh Sleep Quality Index (PSQI), the Epworth Sleepiness Scale (ESS), the vitality scale of
the SF-36, the Insomnia Severity Index (ISI), the International Restless Legs Syndrome
questionnaires, and a short version of the Pregnancy Symptom Inventory (PSI), reported that the
majority reported experiencing poor sleep quality (76%) (Mindell, Cook & Nikolovski, 2015).
An important finding also reported was that a high frequency of pregnancy-related symptoms
was correlated with poorer sleep quality (Mindell et al., 2015). In conclusion, poor sleep quality
and sleep disturbances are common in pregnancy. Since there is evidence to show that vitamin
D deficiency could exacerbate poor sleep, it is important to address these issues since they can
affect the health of both the mother and baby (Mindell, Cook & Nikolovski, 2015).
Vitamin D and musculoskeletal pain. There is a plethora of data published about the
association of vitamin D deficiency and musculoskeletal pain as evidenced below by (Appendix
E, Table 4). The mechanism by which vitamin D plays a role in musculoskeletal pain is in
calcium/ phosphorus homeostasis; however, there are other ways vitamin D affects skeletal
muscle (Girgis, Cliften-Bligh, Hamrick, Holick, & Gunton, 2013). Vitamin D receptors are
found in skeletal muscle and are involved in not only calcium homeostasis but muscle
contraction by calcium influx affecting muscle contractility (Girgis et al., 2013). In addition, in
animal models and some human models vitamin D receptors have been found in skeletal muscle
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providing evidence that vitamin D status is essential in establishing muscle strength and muscle
mass (Girgis et al., 2013). This would explain why those who are vitamin D deficient are more
prone to myalgias, myopathy, and falls or fracture risks (Wacker & Holick, 2013).
In evaluating the evidence of vitamin D deficiency and musculoskeletal pain, most of the
studies include an overwhelming majority of women in their sample sizes (Lodh et al., 2015;
Bergstrom, Palmer, Persson, & Blanck, 2014; Le Goaziou et al., 2014; Al-Jarallah, Shehab,
Abraham, Mojiminiyi & Abdella, 2013; Schreuder, Bernsen, & van der Wouden, 2012; Knutsen
et al., 2010; Lofti, Abdel-Nasser, Hamdy, Omran, & El-Rehany, 2007; Gerdhem, Rinsgberg,
Obrant, & Akesson, 2005; Plotnikoff & Quigley, 2003). There has been evidence to suggest that
there is a differing impact of vitamin D deficiency on musculoskeletal pain based on ethnicities.
Studies that have included immigrant women from Middle Eastern, South Asian, and African
countries and also those that have a significant African American population are noted to have
more severe vitamin D deficiency as well greater musculoskeletal pain (Plotnikoff & Quigley,
2003; Lodh et al., 2015; Bergstrom et al., 2014; Schreuder et al., 2012; Knutsen et al., 2010;
Lofti et al., 2007).
A recent meta-analysis which included nineteen randomized controlled trials (n=3,436)
provided limited confirmation that vitamin D supplementation improved pain scores when
compared to the placebo (mean difference -0.57, 95% CI:-1.00 – -0.15, p = .007) (Wu, Malihi,
Steward, Lawes & Scragg, 2016). However, there was significant heterogeneity of studies
included in the analysis with some studies that recruited patients with chronic pain and some
with localized pain. In addition, the vitamin D supplementation provided in the studies varied
from high dose (100,000) to low dose (as low as 400 IU) (Wu et al., 2016).
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One of the only studies that actually included pregnant women showed that vitamin D
levels were significantly lower in immigrant women (n=68) when compared with a control group
of native Swedish women (n=51) at 12 weeks gestation who also had significantly higher pain
scores for complaints of musculoskeletal pain (Bergstrom et al., 2014). The study was a
prospective study that evaluated a cohort of immigrant women and control group of native
Swedish women who were pregnant and had musculoskeletal pain complaints. Vitamin D levels
were drawn at 12 weeks gestation and again at 6-12 months postpartum. The pain scores in the
immigrant women group had improved by 6 months postpartum which correlated with increased
levels of vitamin D without mention of vitamin D supplementation in either groups (Bergstrom
et al., 2014). When comparing the vitamin D levels to those of native Swedish pregnant women
(N=50), 77.9% of the immigrant women had vitamin D levels of <25 nmol/L (10/ng/ml) whereas
only 3.9% of the controls.
There is evidence that women are at risk for both musculoskeletal pain and vitamin D
deficiency, however there is not sufficient evidence for causality (Straube, Straube, & Moore,
2015). Using the Cochrane Database, only ten studies after rigorous review for quality and
design were included in a meta-analysis demonstrating no statistically significant difference
between placebo and vitamin D supplementation in treating chronic painful conditions (Straube
et al., 2015). The meta-analysis included a vast array of chronic painful conditions such as
fibromyalgia, rheumatoid arthritis, osteoarthritis, and non-specific musculoskeletal pain, and
used a variety of administration methods of vitamin D supplementation from oral to parenteral
administration. Therefore, the eclectic nature of studies could explain the nonsignificant results.
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Vitamin D and pelvic floor disorders. Pelvic floor muscles are challenged and strained
during a normal pregnancy. There is some evidence that vitamin D deficiency could be
associated with greater incidence of pelvic floor disorders. The rationale behind vitamin D and
pelvic floor disorders follows the same rationale as with other musculoskeletal systems. Vitamin
D receptors in the pelvic floor muscles may provide support and strength to the bladder and
urethra. Only one study to date has examined this phenomenon in pregnant women. A crosssectional study of pregnant women (n=148) in their third trimester who were in a university
hospital setting had blood drawn for vitamin D levels at about 36 weeks gestation (Aydogmus et
al., 2015). Women were grouped based on mode of delivery and by vitamin D status (deficiency
defined as <15 ng/ml and sufficiency as>30 ng/ml). Pelvic floor muscle strength was measured
at 8 to 10 weeks postpartum using a perineometer, pelvic floor disorder symptoms were
measured using Urinary Distress Inventory short form (UDI-6), and the Incontinence Impact
Questionnaire short form (IIQ-7) was also administered. Results indicated that women who were
vitamin D deficient had significantly worse pelvic floor muscle strength, both in women who had
vaginal deliveries and cesarean section.
Many epidemiological surveys have been done to test the association of vitamin D
deficiency and pelvic floor disorders for both men and women (Appendix E, Table 5), with a
significant increased odds of vitamin D deficiency in those with pelvic floor disorders. To date,
there have been no randomized control trials evaluating if vitamin D supplementation improves
pelvic floor disorders.
Vitamin D and fatigue. The hallmark symptom of vitamin D deficiency reported in the
general population is that of fatigue (Roy, Sherman, Monari-Sparks, Schweiker, & Hunter,
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2014). In the EViDiF (Effect of correction of Vitamin D in Fatigue) study, patients (n=132) who
had complaints of fatigue, stable chronic medical conditions, and had vitamin D (<30 ng/ml)
were given 3 doses of 50,000 IUs of ergocalciferol (D2) weekly for five weeks. This was a onearmed study with no control group. The sample (n=174) was 71% women and was 21% African
American. Patients completed the Multidimensional Fatigue Symptom Inventory–short form
(MFSI–SF) prior to and following supplementation. Overall, there was a significant
improvement in fatigue symptoms after treatment (Roy et al., 2014). In addition, there has been
another clinical trial evaluating primary care patients (n=138) with mild (20-25 ng/ml), moderate
(10-19ng/ml), and severely deficient (<10 ng/ml) levels of vitamin D (Arvold et al., 2009).
Those who had mild or moderate symptoms (n=50 per group) were randomized to 50,000 IUs
cholcaleciferol or placebo. For those who were severely deficient all (n=38) were given 50,000
IUs of cholecalciferol. Patients took their medications for eight weeks. To measure symptoms,
the Fibromyalgia Impact Questionnaire (FIQ) was used which assessed fatigue, generalized
aching, aching muscles, and muscle weakness (Arvold et al., 2009). Following treatment, there
was a significant improvement in FIQ scores in the treatment groups versus the placebo
(p=0.03).
Another recent double blind placebo-controlled clinical trial to assess impact of vitamin
D supplementation for treatment of fatigue indicated a significant improvement of fatigue
symptoms with vitamin D treatment (Nowak et al., 2016). Their study provided a one-time oral
dose of 100,000 IU of vitamin D (n=58) compared to placebo (n=62) to participants who
complained of fatigue but were otherwise healthy and also vitamin D deficient (<20 ng/ml).
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Fatigue is one of the most common pregnancy symptoms and one of the most debilitating
(Nazik & Eryilmaz, 2013; Zib, Lim, & Walters, 1999). There is a gap in the literature however
as to whether or not fatigue in pregnant women is associated with vitamin D deficiency. Since
fatigue is common during pregnancy, understanding the role of vitamin D is important since
fatigue can cause limitations of activities of daily living which could easily be corrected.
Functional Status
Health behaviors such as increased physical activity and nutrition in pregnant women
have been correlated to better birth outcomes and less depressive symptoms in pregnancy
(Beckham et al., 2015; Ko, Chen, & Lin, 2015; Kowalska, Olszowa, Markowska, Teplik, &
Rymaszewska, 2014; McCullough et al., 2015; Misra, Strobino, Stashinko, Nagey, & Nanda,
1998; Mourtakos et al., 2015). Physical activity has been shown to be associated with higher
vitamin D levels in many epidemiologic studies and found to be a modifiable predictor of higher
vitamin D status (Colapinto et al., 2014; Daly et al., 2012; Gerdhem, Ringsberg, Obrant, &
Akesson, 2005; Moreno, Valtueña, Pérez-López, & González-Gross, 2011). The rationale for
this is that those who engage in physical activity are more likely to be outside in the sun, and
more likely to have healthier diets (Daly et al., 2012; Colapinto et al., 2014).
Another important component of functional status is nutritional intake during pregnancy.
Healthy nutritional intake is very important for maintaining healthy gestational weight gain in
pregnancy. A study done in Spain in Hispanic pregnant women (n=2585), showed that
predictors for increased fruit and vegetable intake based on the Food Frequency Questionnaire
(FFQ) were increasing age, higher educational attainment and increased physical activity (VillarVidal et al., 2015). Compliance with a healthier diet in pregnancy is even more important due to
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the consequences not only to the mother but the fetus as well. One study examined vitamin D
intake and dietary intake in obese and normal weight pregnant women (Karlsson et al., 2014).
They evaluated the vitamin D status in the first trimester of obese (n= 25) and normal weighted
(n=80) pregnant women and found that obese women had 33 % higher dietary intake of vitamin
D in both food and supplement use and yet had significantly lower vitamin D levels when
compared with normal weighted pregnant women. Obtaining sufficient vitamin D from dietary
intake is difficult to achieve, and increased body mass index makes it even more difficult so
supplementation is even more important in these situations (Hollis & Wagner, 2004; Hollis,
2012; Ng et al., 2014).
Quality of Life in Pregnancy
There is a gap in the literature, as there is no evidence evaluating the association of
vitamin D status and quality of life in pregnant women. However there have been some studies
that have evaluated vitamin D status and quality of life in other patient populations. A
systematic review of the literature evaluated vitamin D supplementation and quality of life. This
review included 15 articles and found that most of the studies had methodologic flaws such as no
randomization and blinding (Hoffmann, Senior, & Mager, 2015). In addition, the studies
included a variety of patient populations ranging from healthy to those with chronic diseases, and
ages from adolescence to the elderly (Hoffmann et al., 2015). Many of the studies did not report
mean vitamin D levels prior to and following supplementation. In some of the studies, the
treatment dose included only 400 IUs of vitamin D. This is concerning since a dose of 400 IUs
is often seen as a placebo and will have minimal to no impact on the level. (Baggerly et al.,
2015; Holick, 2007; Hollis & Wagner, 2004; Wagner et al., 2012).
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However, one cross-sectional study that evaluated ninety-seven rheumatoid arthritis (RA)
patients included measures for vitamin D, quality of life (SF-36), depression (Beck Depression
Inventory), pain, fatigue, and physical activity (Health Assessment Questionnaire) (Raczkiewicz,
Kisiel, Kulig, & Tlustochoqicz, 2015). Their study indicated that those RA participants who had
lower vitamin D levels (<20 ng/ml) had higher pain scores and higher depression scores and
lower SF-36 scores for physical quality of life (Raczkiewicz et al., 2015). Although results from
this study cannot be applied to pregnant women, it is interesting to note their study focused on an
at-risk population for pain and their sample also included 86 women and only 11 men.
Characteristics of the Environment
Spirituality. Spirituality is an individual characteristic that may impact a women’s
health during pregnancy. Spirituality has often been cited as a positive resource, as it relates to
health, particularly in the African American and Hispanic communitird (Mann, McKeown,
Bacon, Vesselinov, & Bush, 2012; Jesse, Graham, & Swanson, 2004; Bonelli, & Koenig, 2013).
Spirituality in pregnancy has been shown to be protective against depressive symptoms, prenatal
stress, and anxiety (Mann et al., 2012; Jesse, Graham, & Swanson, 2004; Cheadle et al,. 2015).
One study comprised of largely low-income African American pregnant women (n=130),
reported that psychosocial risk factors and lower spirituality predicted smoking and substance
abuse (Jesse, Graham, & Swanson, 2006). Another study of low socioeconomic African
American women (n=702) reported that those who had lower spirituality and religiosity scores at
baseline ( 6-12 weeks postpartum) had increased depressive symptoms at 6 -10 months as well as
12-15 months postpartum after controlling for significant confounders (e.g., family support,
perceived emotional support, SES) (Cheadle et al,. 2015).
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Social support. Another essential characteristic of the environment is social support.
Social support is a vital psychosocial variable that has a profound impact on the mental and
emotional health of pregnant women. It is not only in pregnancy that social support has been
shown to have protective effect on health outcomes, but in the general population as well
(Salinero-Fort et al., 2011; White et al., 2009). Strong social support in pregnancy has been
linked with decreased adverse birth outcomes, prenatal stress, and depressive symptoms (Collins
et al., 1993; Dominguez et al., 2005; Sumner et al., 2011). One study examined psychosocial
factors like social support, intimate partner violence, trauma exposure, and post-traumatic
distress symptoms in low income pregnant Latina pregnant women (n=203) and followed them
at three months postpartum (Sumner et al., 2011). They reported that positive emotional wellbeing was correlated with increased levels of social support, being foreign-born, and residing in
the United States for less than ten years (Sumner et al., 2011). For low income, pregnant African
American pregnant women (n=1383), it has been reported that positive social support serves as a
mediator between the adverse effects of poor neighborhood quality and perceived stress
(Giurgescu et al., 2015). For high risk pregnant women (n=105), it has been reported that social
support has a direct effect on preparation for motherhood (Giurgescu, Penckofer, Maurer, &
Bryant, 2006). Therefore, social support is a protective resource that can impact maternal wellbeing in vulnerable populations.
Socioeconomic status. Another environmental characteristic affecting quality of life
during pregnancy is socioeconomic status. Lower socioeconomic status has been associated with
poorer health outcomes in pregnancy due to a lack of resources, increased stress, and depressive
symptoms (Giugescu et al., 2013; Berkman, 2009; Curry, Latkin, & Davey-Rothwell, 2008).
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Lower socioeconomic status is associated with living in poorer neighborhoods that have a higher
incidence of violence and crime. The detrimental impact of these poorer neighborhoods on
pregnant women in terms of health outcomes is recently emerging (Giurgescu et al., 2015;
Acevedo-Garcia et al., 2004; Culhane & Elo, 2005; Kim, 2010; Sealy-Jefferson, Giurgescu,
Helmkamp, Misra, & Osypuk, 2015).
Poorer neighborhoods and violence ridden areas may also have an impact on vitamin D
status. It is logical to assume that persons, who live in neighborhoods with violence, will spend
less time outdoors due to fear or the perception of unsafe conditions, thus not reaping the
benefits of the natural absorption of vitamin D. Thus, socioeconomic status should be
considered when examining the quality of life of pregnant women.
In conclusion, there is mounting evidence in regards to the role that vitamin D status has
on symptom status which provided the theoretical basis for the proposed study. Since there is a
gap in the literature in regards to the role that vitamin D status has in pregnancy and its
relationship with symptoms, health-promoting behaviors, and quality of life, the proposed study
was undertaken.

CHAPTER THREE
METHODOLOGY
This chapter will address the study design, the clinical setting including the sample
population and recruitment strategies, and methods of data collection, and all of the measurement
tools used for the study will be described. Vitamin D deficiency is very prevalent in African
American and Hispanic women especially for those living in a northern latitude. The primary
aim of the study was to determine if women who were vitamin D deficient had more symptoms
of pregnancy. In addition, whether women who were vitamin D deficient reported fewer healthpromoting behaviors and poorer quality of life was studied. An exploratory aim of the study was
to test if depressive symptoms mediated the relationship between vitamin D status and pregnancy
symptoms, and also to test any ethnic differences in pregnancy symptoms between African
American and Hispanic women.
Design
A cross-sectional design was used to explore the relationships between variables of
interest (Hulley, 2008). This study examined the relationships between vitamin D and individual
characteristics, biological factors, symptom status, functional status, and their impact on healthrelated quality of life. All of the variables were collected at one time point. Therefore, causal
inferences cannot be made because temporal precedence will not be established. Due to the
nature of the design, it cannot be assumed that the independent variables caused the dependent
variables, but associations will be established. Therefore, the study explored the associations
40
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between vitamin D (independent variable) and symptoms, functional status, and quality of life
(all dependent variables of interest).
Setting
The study was conducted in a federally qualified health center (FQHC) in an urban,
predominantly Medicaid patient population located in a northern latitude. As shown in pilot
data, vitamin D deficiency is highly prevalent in the population to be studied. Woo and
Penckofer (2015, April) showed that 88% of childbearing women had vitamin D levels less than
30 ng/ml at this FQHC. The study site has a medically and economically at-risk patient
population serving predominantly African American and Hispanic women. The FQHC has six
different clinic locations where obstetric patients were being seen. Data collection occurred at
all of these sites in the winter and spring time to capture women when they are most at risk for
vitamin D deficiency.
Sample
An essential step in research design is establishing an adequate sample size to see a
statistically significant effect, which is done through a power analysis. Since there have been
limited studies that have looked at pregnancy symptoms, an estimated fifteen participants per
predictor variable will be used to achieve power (Stevens, 1999). Since there are seven main
variables being studied which include vitamin D status, pregnancy symptom status, depressive
symptom status, health behaviors, quality of life, and social support and spirituality, the
estimated sample size for the study was 105 participants (15 x 7= 105). However, in order to
account for missing data (maximum of 20%), 125 participants were recruited.
The sampling procedure used was convenience. A prior data-mining research study done
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by the researcher showed that among childbearing women, 88% of a sample size of 302 women
had vitamin D levels <30ng/mL; therefore it would be a patient population that was accessible
and was largely vitamin D deficient (Woo & Penckofer, 2015, April). Inclusion criteria were the
following: 1) > 18 years of age; 2) speak and read English or Spanish; 3) confirmed pregnancy at
24 to 32 weeks gestation; and 4) willing to have an extra blood draw for vitamin D level if
necessary (if recruited before or after their GDM screen). Exclusion criteria were the following:
1) significant mental health issues (e.g., treatment for substance abuse, psychosis, bipolar
disorder, or schizophrenic episode; 2) pre-gestational diabetes, HIV infection, and any
autoimmune disorder such as multiple sclerosis or systemic lupus erythematosus.
The rationale for excluding patients with diabetes was that evidence suggests that
depressive symptoms are more prevalent in women with type 1 or type 2 diabetes (Doyle,
Halaris, & Rao, 2014; Penckofer, Doyle, Byrn, & Lustman, 2014; Park, Park, Quinn, & Fritschi,
2015; Fritschi et al., 2012). Since pregnant women with HIV infection and autoimmune
disorders may be more symptomatic and are referred to a collaborating maternal fetal medicine
provider, they were also excluded.
Recruitment of Study Participants
Recruitment of study participants was from all six of the outpatient clinics at the FQHC
that cared for a large obstetric patient population. A letter was sent to all current and future
pregnant patients describing the study along with study contact information (Appendix B).
Addresses of all pregnant patients in their first trimester and early second trimester were
extracted from the electronic medical record and an informational study letter was sent
(Appendix B).
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A meeting was arranged with all obstetric providers to enlist provider support for study
recruitment. Once approval was given, medical assistants were informed about the study and
given flyers to distribute to patients of providers who agreed. Flyers were also posted at all six
clinic locations. The sample flyer (in Appendix C) was approved by the Clinic Quality
Assurance team at the FQHC and the Institutional Review Board (IRB) of Loyola University.
The investigator recruited in the main obstetric clinic at the FQHC where 40% of the
obstetric patients were seen and enrolled as they came for their appointments. Potential
participants were also approached while waiting for their appointment and consented in a private
area. Patients completed the questionnaires while waiting to be seen, and finished after their
provider appointment if needed. Blood was drawn after their appointment in conjunction with
their two-hour glucose tolerance test, when possible. This is the diagnostic screening tool used
at this facility to assess for GDM.
The investigator also viewed the list of scheduled obstetric patients each week to be
strategic about which clinic to recruit at on a daily basis. The investigator also received phone
calls from interested patients that heard about the study through the study flyer, and discussed the
details about the study to these patients. If the patient was interested, the investigator met them
at their next scheduled obstetric appointment.
Some of the clinical sites provided prenatal care in a group setting known as “Centering
Pregnancy”. The investigator also attended group sessions at each of the sites that conducted
“centering groups” to describe the study, determine eligibility to participate, and if agreeable,
enroll participants. The investigator then collected the data at that time if participants were
willing to participate or scheduled another time convenient for them.
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Collection of Data
Informed consent was reviewed and signed (see Appendix D) for each participant.
Patients completed the self-report questionnaires while in the waiting room or in the centering
room. As stated previously, after their clinic visit with the provider, they had their vitamin D
level drawn, along with their two-hour glucose tolerance test for GDM screening when
applicable. One red top tube (3 ml) was drawn, and the blood centrifuged after 30 minutes to
obtain the serum via pipetting. According to Quest laboratory standards, at least 0.5 ml of serum
was placed in a plastic screw top tube, labeled with their study identification number, and placed
in the refrigerator for Quest pickup.
Once all questionnaires were completed and reviewed for missing data and blood was
collected, participants were given a $20 stipend. The results of the serum vitamin D level was
given to the primary care provider by the principal investigator, who then reviewed the test
results with their patient at their future prenatal visit.
Measurements
The study measurements were organized using the Wilson & Cleary Health-Related
Quality of Life Model. The variables were grouped according to the major components of that
model: individual characteristics and environment, biological and physiological variables,
symptom status, functional status, and quality of life. The tools are listed in Table 1 and the
instruments are included in Appendix A in both English and Spanish. The description of each
instrument and its reliability and validity is addressed below.
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Table 1. Variables and Measurements of Study
Variable
Characteristics of the Race/Ethnicity
Individual

Biological and
Physiological Factors

Measurement
Demographic form
(created by researcher)

Data collection
method
Self-report

Age

Demographic form
(created by researcher)

Self-report

Employment status

Demographic form
(created by researcher)

Self-report

Education status

Demographic form
(created by researcher)

Self-report

Type of prenatal care
(centering vs.
traditional)
Intent to breastfeed

Demographic form

Self-report

Demographic form

Self-report

WIC status

Demographic form

Self-report

Vitamin D status

Quest LC-MS

Dietary screener for
vitamin D and
Calcium
Season of collection

Block’s Vitamin D/Ca
short screener

Serum via
venipuncture
Self-report

Demographic form

Self-report

Body Mass Index
Current weight

Height and weight
conducted at visit;

Scale and
stadiometer
measures

Pre-pregnancy weight
Hemoglobin

Results of 2 GTT

Demographic form
Self-report
EMR collection of
EMR
complete blood count per
clinic protocol
EMR collection
EMR
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Table 1 (cont.)
Maternal Health
Factors
(medical and obstetric
history, mental health
history, medications)
Gestational age at
delivery
Birthweight
Complications
Type of delivery
Pregnancy symptoms

Demographic form

Self-report

EMR collection from
mother’s record

EMR

Depressive symptoms

Edinburgh Postnatal
Depression Scale
(EPDS)

Self-report

Sleep symptoms

Pittsburgh Sleep Quality
Index (PSQI)

Self-report

Functional status

Health behaviors

Health-promoting
Lifestyles Profile
(HPLPv2)

Self-report

PSI subscale

Self-report

Overall Quality of life

Limitations of
pregnancy symptoms
on activities of daily
living
Quality of life

SF-12

Self-report

Demographics form

Self-report

Spiritual Perspectives
Scale

Self-report

Social Support

Multidimensional Scale
of Perceived Social
Support (MSPSS)

Self-report

Marital status

Demographics form

Self-report

Symptom status

Characteristics of the Socioeconomic Status
environment
Spirituality

Pregnancy Symptom
Self-report
Inventory (frequency and
limitations on activities
of daily living)
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Characteristics of the Individual
Demographics. Important demographic information about participants such as their age,
race/ethnicity, employment status, and education status were collected on a form created by the
investigator (Appendix A-Instruments). Relevance of each of these demographic variables is
discussed in Chapter Two.
Biological and Physiologic Factors
Vitamin D serum. There has been much controversy over the years as to the best
method for measurement of serum vitamin D. The methods (radioimmunoassay and high liquid
performance chromatography) to measure vitamin D levels in the clinical population have
generated different results in the literature relative to the association of vitamin D and various
health outcomes (Wallace et al., 2010; Hollis, 2010).
The gold standard in vitamin D research has been the liquid chromatography and mass
spectrometry method which is costly, but separates out vitamin D2 and D3 metabolites (Holick,
2007; Phinney et al., 2012; National Institute of Standards and Technology, SRM 972a).
Phinney et al. (2012) provided the basis for the Standards Resource Manual (SRM) that certifies
the adequacy of the measurement of vitamin D metabolites and recommended liquid
chromatography and mass spectrometry as the gold standard for measuring the three different
metabolites of vitamin D: total serum, vitamin D2, and vitamin D3. However since measurement
of the different vitamin D metabolites was not needed, radioimmunoassay was selected for the
study.
Quest diagnostics has been the leading provider for vitamin D measurement using the
radioimmunoassay which is consistent with the NHANES data, Centers for Disease Control
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certified, and meets all internal quality standards for measuring serum vitamin D. For this
reason, the proposed study used Quest Diagnostics to run the serum vitamin D levels. The
clinical site is certified by Occupational Safety and Health Administration (OSHA) and the Joint
Commission on Accreditation of Healthcare Organizations (JCAHO) for use at the FQHC and
follows strict standards for laboratory procedures.
Vitamin D dietary intake. Torin Block’s vitamin D and calcium screener was
developed from their more widely known Food Frequency Questionnaire that is an extensive
self-report evaluation of diet assessment using a law of averages approach (Cummings, Block,
McHenry, & Baron, 1987). It has 19 food items and three questions on supplement use and
questions that adjust for food fortification practices (Cummings et al., 1987). The Block vitamin
D/calcium screener was tested for validity against a seven-day food record on 37 senior citizen
women with a strong correlation (r = 0.76) (Cummings et al., 1987). The Vitamin D/Calcium
screener was also validated against a four-day food record over one year to a sample of 260
women in the age range of 45-70 years of age with a moderate correlation (r = 0.64) (Block,
Woods, Potosky, & Clifford, 1992).
The vitamin D/calcium screener was only available in English and had not been
translated into Spanish. Therefore, in order to include dietary vitamin D intake in the proposed
study that included Spanish language participants, a professional language translation service
was employed to translate the Block’s vitamin D/calcium screener into Spanish. Nutriquest
which is the company that owns the copyright on the vitamin D/calcium screener has given
permission to the investigator for translation of the tool into Spanish (T. Block & K. Kline,
personal communication, May 14, 2015). The translation was performed by VIA Translation
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Incorporated and the instrument is enclosed in Appendix A along with its attestation for
translation.
VIA Translation Incorporated has provided a certified and licensed Spanish translation of
Block’s vitamin D/calcium screener. An outside linguist was employed to review the final
translation and to confirm that translation was adequate. A clear limitation of using this
translated instrument is that it has no psychometric data available for this version, but was being
assessed in this study.
Symptom Status
Pregnancy symptom inventory. The Pregnancy Symptom Inventory (PSI) is a 41-item
questionnaire to assess common symptoms that pregnant women report and their corresponding
limitations on activities of daily living. The instrument was created to be used as a clinical tool
for healthcare providers to refer pregnant women for appropriate consultations if needed in
regards to their symptoms. An initial list of 40 symptoms was generated by asking seven
physicians and midwives working in the Maternity Outpatient Department of their health system
(Foxcroft, Callaway, Byrne, & Webster, 2013). This list of 40 symptoms was then given to a
series of focus groups with women in different trimesters of pregnancy. Many of the symptoms
on the first list were elicited from the focus groups and one item was added to allow participants
to report a symptom not already listed (Foxcroft et al., 2013). The 41-item inventory rates each
of the 41 symptoms on a likert scale: 0 = never experiencing the symptom, 1 = a little of the time
experiencing the symptom, 2 = sometimes experiencing the symptom to 3 = often experiencing
the symptom, with an option of writing in a 42nd symptom if it was not listed. If the participant
marks “1” or greater for a pregnancy symptom, the participant then answers how limiting this
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pregnancy symptom is on their activities of daily living (1 = “not limited at all”, 2 = “limited a
little”, and 3 = “limited a lot”).
Test-retest reliability with several days in between administration has been reported in
pregnant women (n=211). Correlations ranged from 0.51 to 1.0 when examining each item, for
test-retest, and most of the items had correlations ≥ 0.70. For this study, the symptoms most
frequently reported as “often” included urinary frequency, tiredness, poor sleep, and back pain
(Foxcroft et al., 2013).
For the proposed study, a total symptom score was calculated using all items. In
addition, a descriptive analysis of which of these symptoms was most bothersome was done.
Because this tool has only been used for clinical utility and not for research purposes, reliability
and validity is described in Chapter Four.
The PSI was not available in Spanish, so a professional translation service, VIA
Translation Incorporated, was also used to officially translate the document. Two professionals
who spoke Spanish and worked with the intended population translated the document separately
and then compared translations. The verbiage for symptoms and wording was adjusted based on
two independent reviewers. This copy of the tool in Spanish was then given to the VIA
translation services to certify the translation as another means of ensuring validity of the
translation. The certificate for translation is in Appendix A.
Depressive symptoms. The measure chosen for depressive symptoms in pregnancy was
the Edinburgh Postnatal Depression Scale developed by Cox, Holden and Sagovsky (1987). The
EPDS is a 10-item instrument using a likert scale asking the respondent to rate how often they
had a certain thought or feeling ranging from 0 = no, never, 1 = not very often, 2 = yes,

51
sometimes, 3 = yes, most of the time. The responses vary based on the question but have a range
score of 0 to 3, with a minimum score of zero and a maximum score of 30. Respondents rate
their symptoms based on how they have felt in the past seven days. Murray and Cox (1990)
tested the validity of the EPDS for screening of depression in pregnant women (n=100) who
were between 28 and 32 weeks gestation. The EPDS had a sensitivity of 75% and specificity of
90%. Validity of the EPDS was established by its ability to distinguish between minor and
major depression. The positive predictive value was 50% (Murray & Cox, 1990). Reliability of
the EPDS has been established with Cronbach alphas ranging from 0.73 to 0.91 in a systematic
review (Kozinksy & Dudas, 2014).
More recent studies have provided validity and reliability evidence for the EPDS for
depression screening in pregnancy. Bunevicius, Kusminskas, Pop, Pedersen, & Bunevicius
(2008) reported a test-retest reliability for the EPDS of 0.81 and a sensitivity of 92% and
specificity of 95% for women in the first trimester. A sensitivity of 92% and specificity of 92%
was reported for women in the second and third trimesters. The Spanish translation of the EPDS
has reported a sensitivity of 79% and specificity of 95.5% with a positive predictive value of
63.2% (Garcia-Esteve, Ascaso, Ojuel, & Navarro, 2003).
Sleep quality. The Pittsburgh Sleep Quality Index (PSQI) was used to measure sleep
quality symptoms. The PSQI is a 19-item instrument that generates seven component scores
which include: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency,
use of sleeping medication, and daytime function. The majority of items ask the respondent to
rate their sleep symptoms on a Likert scale with responses ranging from 0 = not during the past
month to 3 = three or more times per week, which is calculated into a global score. A global
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PSQI score of >5 indicates a “poor sleeper” and in their original study, a diagnostic sensitivity of
89.6% and a specificity 86.5% was reported (Buysse, Reynolds, Monk, Berman, & Kupfer,
1988).
PSQI was used in prospective study of pregnant women (n=252) who completed the
Beck Depression Inventory (BDI) and the PSQI in their second and third trimesters of pregnancy
(Skouteris, Wertheim, Germano, Paxton, & Milgrom, 2009). The PSQI had a Cronbach alpha of
0.71 at first time-point (15 to 23 weeks gestation) and then Cronbach alpha of 0.76 at the second
time-point (29-39 weeks gestation). However, when removing the sleeping medication
component (since many of the sleeping aids cannot be used in pregnancy), the Cronbach alpha
improved to 0.72 and 0.78 respectively.
The Spanish PSQI has been validated in Peruvian pregnant women (n=652) who were ≤
16 weeks gestation and had low incomes (Zhong, Gelaye, Sanchez, & Williams, 2015). The
Cronbach alpha was 0.57 and although internal consistency was low, it had good construct
validity as evidenced by strong correlations with depressive symptoms (measured by Patient
Health Questionnaire–9) (r = 0.49) and anxiety (Generalized Anxiety Disorder–7) (r = 0.46).
(Zhong et al., 2015). Another study looking at a population of Spanish speaking Hispanics of
Mexican descent (n=792) who completed the PSQI over the phone, reported a Cronbach alpha of
0.77. However, the women in this study were not pregnant (Tomfohr, Schweizer, Dimsdale, &
Loredo, 2013). The Spanish version of the PSQI has been well validated and shown to have a
Cronbach alpha of 0.77 to 0.89 in a variety of populations (Cuellar, Baldwin, Benavente, &
Crowe, 2010).
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Functional Status
Health-promoting behaviors. The instrument selected to measure health-promoting
behaviors was the Health Promotion Lifestyles Profile v. 2 (HPLPv.2). The psychometric
properties of the HPLP were established using literate adult volunteers (n=952) (Walker,
Sechrist, & Pender, 1987). It showed a Cronbach alpha of 0.919 and a test-retest (3-week time
period) reliability of 0.854 (Walker, Sechrist, & Pender, 1987). The HPLP was updated in 1996
to the HPLP version 2 (Walker & Hill-Polerecky, 1996)
The HPLPv.2 is a 52 item self-report questionnaire that assesses six domains which
include the following: health responsibility, physical activity, nutrition, spiritual growth,
interpersonal relations, and stress management. Respondents are asked to rate the frequency of
the reported behavior reflecting each of these domains using a Likert scale ranging from 1 =
never 2 = sometimes, 3 = often, or 4 = routinely. The Cronbach alpha for internal consistency
has been reported as 0.943 for the total score with the range for each of the six domains from
0.793 to 0.873 (Walker & Hill-Polerecky, 1996).
The HPLPv2 was tested in 100 pregnant women and 90 non pregnant women to establish
psychometrics of this population (Telleen, 2003). The Cronbach alpha was reported as 0.93, and
the subscale scores ranged from 0.72 to 0.89.
The HPLPv.2 has been validated in Spanish. Walker, Kerr, Pender and Sechrist (1990)
reported a Cronbach alpha for the total score as 0.93, a two-week test-retest reliability of 0.86,
and the alpha coefficients for the subscales from 0.70 to 0.87. To establish these psychometrics,
Hispanic adult students (n=499) in an adult basic education class for English as a second
language class in a local community college were surveyed (Walker, Kerr, Pender, & Sechrist,

54
1990). It should be noted that the HPLPv.2 Spanish version has not been used with Spanishspeaking Hispanic pregnant women, so the current study assessed reliability and validity of this
measure for the proposed study.
Quality of Life
Standard form–12 (SF-12). Quality of life was measured using the SF-12. It is a 12item questionnaire that is an abbreviated version of the parent instrument of the Medical
Outcomes Survey known as the SF-36 (Ware & Sherbourne, 1992). The SF-36 is an instrument
that measures generic self-report quality of life and has been used in a vast array of populations
including elderly, pregnancy, multiple sclerosis patients, cancer patients, healthy adult, etc.
(Kossakowski et al., 2015). The SF-12 was created as an abbreviated version to decrease
participant burden and increase convenience.
SF-12 measures two different components, physical health and mental health. Each
component is assessed by six items. The scores are standardized using norm-based references
and a score of 50 (out of 100) equates an average quality of life and function whereas scores less
than 30 represents functioning at a level lower than 98% of the population (Ware, TurnerBowker, & Gande, 2005). The SF-12 was used to study health-related quality of life in a
population of predominantly Caucasian pregnant women (n=363) at three time points (36 weeks
gestation, 6 weeks postpartum and 12 weeks postpartum) (Emmanuel & Sun, 2013). The
Cronbach alpha for the total score of the SF-12 at 36 weeks gestation was 0.81, at 6 weeks
postpartum was 0.83, and at 12 weeks postpartum was 0.86. The Cronbach alpha based on the
U.S. population in 2009 for MCS was 0.88 and for PCS was 0.92 (Ware et al., 2010). The
Spanish version of the SF-12 has also shown sound psychometric properties with a Cronbach
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alpha of 0.87 and was used on pregnant primarily foreign born low income Latina women
(n=203) living in the Los Angeles area (Sumner et al., 2011).
Characteristics of the Environment
Characteristics of the environment are included on the demographic and health form
created by the investigator (Appendix A). These variables included the participant’s spirituality,
social support, socioeconomic status (demographic form), and marital status (demographic
form).
Spirituality. Spirituality is an individual characteristic often reported by the African
American and Hispanic communities which may positively impact the well-being of pregnant
women (Mann, 2008). To measure spirituality in a reliable method, the Spiritual Perspectives
Scale was used. This scale is a 10-item instrument created by Pamela Reed, a nurse researcher.
This instrument “measures person’s perspectives on the extent to which spirituality permeates
their lives” and the degree to which “they engage in spiritually-related interactions” (Reed, 1987,
p.337). The instrument uses a 6-point likert scale with the first four questions asking about the
frequency of spiritual activities (e.g., “In talking with your family or friends, how often do you
mention spiritual matters?”), with responses ranging from 1 = not at all to 6 = about once a day).
The next six questions ask about the significance of their spiritual activities or beliefs with likert
responses ranging from 1 = strongly disagree to 6 = strongly agree.
The Spiritual Perspectives Scale has been reported as a valid and reliable instrument for
African American pregnant women (Dailey & Stewart, 2007). The Cronbach alpha was reported
as 0.91, which is comparable to other studies looking at predominantly White pregnant women
which was 0.91 (Jesse & Reed, 2004). The construct validity of the instrument has been
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established, as there are high correlations with other spirituality and religiosity scales and low
correlations with measures of depression using the Center for Epidemiologic Studies–Depression
(CES-D) and the Profile of Mood States (POMS) as well as the measure of stress using the
Perceived Stress Scale (PSS).
The SPS has also been shown to be reliable in a Spanish speaking population. The
Cronbach alpha for one study on HIV-infected women in Columbia showed an internal
consistency of 0.92 (Perez-Giraldo, Veloza-Gomez, & Ortiz-Pinilla, 2012). Another study that
examined cardiovascular risk factors in older Hispanic women in the U.S. showed a Cronbach
alpha of 0.77 (Etnyre et al., 2006). It should be noted that the tool has not been used in Spanishspeaking pregnant women, but due to the acceptable psychometric evidence of its use in
Spanish-speaking Hispanic women, it has been selected to be used for the proposed study.
Social support. The instrument selected to measure social support was the
Multidimensional Scale of Perceived Social Support (MSPSS). This is a 12-item instrument that
measures subjective social support using a Likert scale where 1 = very strongly disagree to 7 =
very strongly agree) (Zimet, Dahlem, Zimet, & Farley, 1988). There are three subscales of
significant other support, family support, and friend support. The psychometrics of the
instrument were tested on pregnant women. Data reported a Cronbach alpha of 0.92 for the total
score, 0.90 for the family subscale, 0.94 for the friend subscale, and 0.90 for the significant other
subscale.
The Spanish version of the MSPSS has demonstrated acceptable psychometric properties
with a Cronbach alpha of 0.85 in elderly men and women (Mantuliz & Castillo, 2002).
Measurement equivalence has been demonstrated between the English version of the MSPSS and
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the Spanish version (Landeta & Calvete, 2002). The instrument has been shown to have a fourth
grade reading level and has been used in low-income and culturally diverse samples (CantyMitchell & Zimet, 2002; Sigler & Rank, 2007; Stephens, Stein, & Landrine, 2010).
Human Subjects Protection
The proposed study was submitted to the Institutional Review Board at Loyola University
and received approval from the proposed recruitment site from the board of directors and IRB at
Loyola (see Appendix D). An informed consent form (Appendix D), was signed by each
participant and was available in English and was translated professionally by VIA translators
into Spanish upon IRB approval of the English version. Attestation of the Spanish translation of
the informed consent is found in Appendix D. The consent form informed the participant that
their healthcare provider at the proposed clinic site would be notified if a positive response was
noted on question number 10 of the EPDS (“The thought of harming myself has occurred to
me”). The participant would then be assessed by the clinician for safety before returning home.
The patient questionnaire booklet was assigned the same identification number as their
blood sample. All data was aggregated and no identifiers were used for the analyses. All the
participants’ information was be coded with an identification number so responses remained
anonymous. The tools completed on paper were kept by the investigator in a locked file cabinet.
The electronic information was also password-protected on the investigator’s computer.
Since participants could potentially experience some discomfort due to the venipuncture,
the proposed study minimized this harm by timing enrollment to the time of GDM screening so
there was only one blood draw. The amount of blood drawn for the vitamin D was one 3 ml red
top tube per Quest protocol. The amount of blood removed for this study is minimal and will not
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put the pregnant woman or the growing fetus at risk for any harm since blood volume in
pregnancy increases by 35-50% (King et al., 2015). Because it was possible that participants
could experience some distress while filling out the EPDS, they were instructed to inform the
principal investigator or healthcare provider if distress was experienced. The EPDS was a tool
used in the clinical practice where recruitment occurred so participants had previous exposure to
these questions.
There were no direct benefits to women for participating in the study. However, since
participants could inquire about the importance of vitamin D status in pregnancy, they were told
to discuss this with their healthcare provider. The results of the vitamin D were given to the
participant’s obstetric provider. The informed consent stated that the participants would be paid
a stipend for their participation in the study, although this was not a benefit of study
participation.
Statistical Analysis
Description of the statistical analyses proposed to answer each research aim will be
described below.
Aim 1
To determine if there was a relationship between vitamin D status (sufficient vs.
deficient), pregnancy symptoms including depression and sleep disruption, health-promoting
behaviors, and quality of life and birth outcomes.
Hypothesis 1. Individuals who have deficient levels of vitamin D are hypothesized to be
more likely to have more pregnancy symptoms, poor sleep quality, more depressive symptoms
and engaged in less health-promoting behaviors and/or have decreased quality of life.

59
Conversely, it is hypothesized that individuals engaging in health-promoting behaviors are less
likely to have deficient levels of vitamin D. With vitamin D measured on a binary scale as
sufficient (vitamin D level >30 ng/ml) versus deficient (vitamin D level <30 ng/ml), both
univariable and multivariable binary logistic regression models were used to assess the
association between these outcomes and vitamin D status. As a measure of effect size,
univariable odds ratios along with their 95% confidence intervals were reported, and based on
univariate analysis, multivariable models were reported with adjusted odds ratios for each factor
after controlling for significant factors impacting the outcome. In order to assess what predictors
were significantly different between vitamin D groups, a series of Chi-square tests and
independent sample t-tests and ANOVA tests were used and reported.
Aim 2
To determine if differences existed in vitamin D level, pregnancy symptoms, sleep
quality, depressive symptoms, health-promoting behaviors, and quality of life between African
American and Hispanic women.
Hypothesis 2. There would be differences in vitamin D levels, pregnancy symptoms,
sleep quality, depressive symptoms, health-promoting behaviors, and quality of life between
African American and Hispanic women. For Aim 2, vitamin D levels as well as all study
outcomes were compared between the African American and Hispanic women samples. For
those measures that are of interval level data, t-tests were used to assess for differences between
these two groups.
Exploratory aim. If a significant relationship between vitamin D levels and total
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pregnancy symptom scores was found, it would allow for a mediational analysis to be conducted
to assess if depressive symptoms mediated the relationship between vitamin D levels and
pregnancy symptom scores.

CHAPTER FOUR
RESULTS

This chapter will describe the results of the study. Basic descriptive statistics on the
study sample will be delineated along with each of the key study variables. In addition, each of
the study aims will be addressed. The primary aim evaluated the relationship between vitamin D
status and pregnancy symptoms including depression and sleep disruption, health behaviors,
quality of life, and birth outcomes. The secondary aims evaluated ethnic differences in vitamin
D status and pregnancy symptoms, sleep quality, depressive symptoms, health behaviors, and
quality of life between African American and Hispanic women. The exploratory aim assessed
whether or not depressive symptoms was a mediator between vitamin D status and pregnancy
symptom profiles.
Enrollment
Three main recruitment strategies were used. First, a letter explaining the study was sent
to all eligible women (babies were 24-32 weeks gestational age) who received prenatal care at
the sites of data collection. The clinic generated the mailing list (approved by the IRB at the site)
for the sole purpose of sending the recruitment letters. The letters (Appendix B) were mailed in
the middle of February, 2016. The second strategy for recruitment was from attendance at
Centering Pregnancy groups which are standard group prenatal visits based on the month of the
patient’s due date. Each Centering Pregnancy group was given a brief presentation of the study,
and women were asked to participate if they met the inclusion criteria. Many
61
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women were amenable to participating and due to the nature of the groups, were all in the
targeted gestational age range. The last strategy was at the time of their obstetric appointment,
where the PI determined women’s interest in the study. Since one of the clinic sites (A) was the
main obstetric clinic, the PI was predominantly at this location where 70.4% (n=88) patients
were recruited. However, there were a total of five other clinic sites where the rest of the
patients were recruited: 13.6% (n=17) at site B, 6.4% (n=8) at site C, 4% (n=5) at site D, 4%
(n=5) at site E, and 1.6% (n=2) at site F. Many clients were open to participating in the study
because they had heard about the study via letter and/or flyers in the clinic. Also, many
providers at the site talked to their patients and referred them for participation.
Figure 2 illustrates the flow of patient enrollment. The Centering groups proved to be the
best recruitment method as 67 women were enrolled by this strategy. Since many women were
waiting at the clinic for their glucose tolerance test for two hours either before or after their
Centering group, they were quite open to participation.
Figure 2. Enrollment flow diagram
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Overall, the combination of mailed letters, seeing flyers about the study in the clinic, and
referral to the study by their prenatal providers was the most successful recruitment strategy.
There were about fifteen patients (12%) who received the letter and called the PI to make
arrangements for study participation at their prenatal appointment.
The final sample of 125 pregnant women was achieved in a little over three months
(March to early June, 2016). Most of the sample was recruited in the spring season aside from
six participants, therefore minimizing seasonal differences on vitamin D levels. The recruitment
site was also in a northern latitude state, therefore exposure to sunlight during winter months was
less.
Data Entry
All self-reported questionnaires were entered manually by the PI and were de-identified
so that participants were only identified by an assigned ID number. Raw data were entered
directly into SPSS software (SPSS Windows version 22.0, Chicago, IL). Data double data entry
was done on the entire sample. Percent error based on double data entry was 5.2%, and
discrepancies were addressed by referencing the patient questionnaire. Therefore, data quality
was ensured with zero percent discrepancy noted upon completion. In addition, scores for all of
the instruments were manually calculated for five random participants in order to compare the
SPSS syntax created to tabulate the scores for each of the instruments. By doing this, it provided
evidence of accuracy of the syntax created for the instruments.
Missing Data
Once data entry was completed, a table was created that listed any missing data from the
self-report questionnaires and EMR data. There were very limited missing data as the researcher
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would examine the booklets upon submission for any missing data. One participant was only
able to complete the main outcome questionnaires (demographic tool, PSI, SF-12, and the EPDS
instruments) as she was sent to the hospital by her provider following her visit to rule out
preterm labor contractions.
There were five symptoms (study ID #004–symptom dizziness; study ID #016–symptom
thrush; study ID # 081–symptom taste changes; study ID #092–symptoms breast pain, and sore
nipples) which were reported by participants (n=4), but they did not complete the limitation of
the symptom to their activities of daily living. Thus, this aspect of the measurement was not
obtainable on these individuals.
Discussion of Key Study Variables
Each of the key study variables were analyzed for normality and outliers. Using SPSS
version 22.0, each variable was tested for normal distribution based on visualization of their
histograms and evaluating skewness and kurtosis using the Shapiro-Wilks test of significance.
The Shapiro-Wilks test was selected because the sample size is relatively small (n=125) (Field,
2009). In the present sample, the only variables normally distributed were the physical
component score (PCS) and mental component score (MCS) of the SF-12 quality of life
instrument. All others were not normally distributed and will be described in the following
sections. The analysis of the variables will be described based on the theoretical model outlined
in chapter one. Characteristics of the individual (demographics, medical/obstetric history,
spirituality), characteristics of the environment (SES and social support), and
biological/physiologic factors (vitamin D status, hemoglobin, hemoglobin A1C), symptom status
(PSI, PSQI, EPDS), functional status (HPLPv.2, PSI subscale), general health perceptions, and
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quality of life (SF-12).
Characteristics of the Individual
In order to assess the characteristics of the individual that could impact quality of life,
demographic, medical history, and obstetric history were collected.
Description of the Sample
As shown in Table 1, almost half the sample was Hispanic (42%) and the rest were nonHispanic (58%). Race was distributed as African American (49%), White (5.6%), mixed (1.6%)
and Asian (0.8%). Women were predominantly either single, living with or not living with their
partner (71.2%), had an income < $40,000 (87.2%), had at least a high school education (86.4%),
were predominantly on Medicaid insurance (77.6%), had an unplanned pregnancy (65.6%), had
no history of depression (88%) or anxiety (93.6%), did not have GDM (86.4%), and planned to
breastfeed (80%). The sample was predominantly multiparous (78.4%). The average selfreported pre-pregnancy BMI was 28.35 (SD=7.8), however BMI was not available on six
participants since they failed to report a pre-pregnancy weight. According to CDC guidelines,
BMI greater than 25 and up to 29.99 is considered overweight, thus many women were
overweight.
Table 2 includes a description of the total sample and a breakdown by vitamin D
deficient (< 20 ng/ml) and sufficient (> 20 ng/ml) groups using Institute of Medicine (IOM)
guidelines (Ross et a., 2012). To see if there were any differences in demographics between
vitamin D groups, statistical testing was done. Findings indicated that there were differences
between groups for income (χ2(4) = 11.2, p = .025), planned pregnancy (χ2(1) = 5.45, p = .020)
and plan to breastfeed (χ2(1) = 3.98, p = .046). There were also significant differences when
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comparing African American and Hispanics ( χ2(1) = 10.02, p = .002). Overall, the deficient
group was more likely to be African American, lower income, had a higher unplanned pregnancy
rate, and had a higher rate of not planning on breastfeeding.
Table 2. Description of Sample
Variable

Total Sample
n= 125 (%)
26.77 (5.7)
18-43

Vitamin D
<20 ng/ml (n=73)
26.10 (5.4)
18-39

Vitamin D
≥ 20 ng/ml (n=52)
27.73(5.7)
18-43

27.7
24-32.6

27.9(2.5)
24.1-32.6

27.5(2.5)
24-32.4

Primipara

27(21.6)

15(20.5)

12 (23.1)

Multipara

98(78.4)

58 (79.5)

40 (76.9%)

62 (49.6)
53 (42.4)
7 (5.6)
1 (0.8)
2 (1.6)

46 (63)
24(33)
1(1.3)
0
2(2.7)

16(30.7)
29(55.8)
6(11.5)
1(2)
0

28.35(7.8)
16.8-53.0

29.0(8.0)
16.8-53.0

27.5(7.7)
18.6-50.40

35 (28)
0 (0)
1 (0.8)
48 (38.4)

15(20.5)
0(0)
1(1.3)
29(39.7)

20(38.4)
0
0
19(36.5)

41 (32.8)

28(39.5)

12(23.1)

39 (31.2)
20 (16.0)
29 (23.2)
21 (16.8)
16(12.8)

27(37)
11(15)
21(29)
7(9.6)
7(9.5)

12(23)
9(17.3)
8(15.4)
14(27)
9(17.3)

Age

Mean (SD)
Range
Gestational age
Mean (SD)
Range

*Race/Ethnicity
Black
Hispanic
White
Asian
Mixed
Pre-pregnancy BMI
Mean (SD)
Range
Marital Status
Married
Divorced
Separated
Single, living with
partner
Single, not living
with partner
*Income
<$5,000
$5,000 to $14,999
$15,000 to $24,999
$25,000 to $39,999
>$40,000
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Table 2 (cont.)
Employment
Full time
Part time
Unemployed
Other________

38 (30.4)
32 (25.6)
50 (40)
5 (4)

22 (30.1)
17(23.3)
31(42.5)
3(4.1)

16(30.7)
15(28.8)
19(36.5)
2(4)

17 (13.6)
50 (40)
8 (6.4)

9(12.4)
32(43.9)
5(6.8)

8(15.4)
18(34.6)
3(5.7)

35 (28.0)
6 (4.8)
9 (7.2)

23(31.5)
2(2.7)
2(2.7)

12(23.1)
4(7.7)
7(13.5)

47 (37.6)
50 (40)
23 (18.4)
2 (1.6)
3 (2.4)

27(37)
31(42.5)
11(15.1)
2(2.7)
2(2.7)

20(38.5)
19(36.5)
12(23.1)
0
1(1.9)

82 (65.6)
43 (34.4)

54(74)
19(26)

28(53.8)
24(46.2)

110 (88)
15 (12)

65(89)
8(11)

42(80.7)
10(19.3)

117 (93.6)
8 (6.4)

70(95.9)
3(4.1)

47(90.4)
5(9.6)

58 (46.4)
67 (53.6)

43(58.9)
30(41.1)

24(46.2)
28(53.8)

53 (42.4)
72 (57.6)

30(41.1)
43(58.9)

23(44.2)
29(55.8)

Education Status
< High School
High school
Associate’s degree/
Technical college
Some college
College degree
Graduate degree
Type of insurance
Medicaid
Medicaid HMO
Private insurance
Obamacare plan
No insurance
*Planned Pregnancy
No
Yes
History of
Depression
No
Yes
History of Anxiety
No
Yes
Enrolled in
Centering
Yes
No
WIC enrolled
No
Yes
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Table 2 (cont.)
GDM
No
Yes
*Plan to Breastfeed
No
Yes
History of type of
delivery
NSVD
Yes
No
Cesarean section
Yes
No
Gestational age at
start of PNC
mean(SD)
(n=120)
Gestational age at
delivery
mean(SD)
(n=115)
Type of delivery
(n=115)
NSVD
Cesarean section
Birthweight (gms)
mean(SD)
(n=115)
Complications

108 (86.4)
17 (13.6)

65(89)
8(11)

43(82.7)
9(17.3)

25 (20)
100 (80)

19(26)
54(74)

6(11.5)
46(88.5)

56
69

41(56.2)
32(43.8)

28(53.8)
24(46.2)

13
112

7(9.6)
66(90.4)

6(11.5)
46(88.5)

8.6(4.4)

9.1(4.4)

8.0(4.3)

38.9(1.8)

38.8(1.8)

39.1(1.8)

89
26

51
16

38
10

3239.6(526.7)

3206.2(529.8)

3283.1(525.1)

41/67(61.1)
10/67(15)
4/67(5.9)
8/67(11.9)
1/67(1.4)

32/46(69.5)
2/46(4.3)
2/46(4.3)
2/46(4.3)
4/46(8.6)

No complications
73
Preeclampsia
12
Preterm-birth
6
Chorioamnionitis
10
Other
5
(n=115)
*p<.05 significant group χ2 group differences
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Biological Factors
Vitamin D Status
This study measured vitamin D levels using radioimmunoassay (RIA) at 24-32 weeks
gestation using Quest Diagnostics. Based on current clinical practice, vitamin D levels are not
routinely obtained in the third trimester in routine prenatal care. However, the professional
organizations for obstetricians and nurse midwifes—American College of Obstetrics and
Gynecology (ACOG) and American College of Nurse Midwife (ACNM)—both recommend
prenatal screening of vitamin D status on those with risk factors for vitamin D deficiency. No
guidelines about rescreening patients to assess if their vitamin D levels are adequate after initial
prenatal screening exist. In the current study, the serum vitamin D levels were not normally
distributed using the Shapiro-Wilks test. There was a positive skew (p<0.05) due to the large
numbers of women who were vitamin D deficient. The level of vitamin D ranged from 5-54
ng/ml, and the mean level for the sample was 19.46ng/ml which is deficient by IOM standards.
The percent in each IOM group as well as the mean per group are provided in Table 3.
Table 3. Vitamin D Status based on Institute of Medicine Guidelines
Vitamin D
<20 ng/ml
n(%)

Mean vitamin D
level deficient
group mean (SD)

Vitamin D
≥ 20 ng/ml
n(%)

73(58.4)

13.56(3.6)

52(41.6)

Mean vitamin D
level sufficient
group
mean (SD)
27.75(5.9)

Table 4 shows the breakdown of vitamin D levels based on the Endocrine Society
guidelines where vitamin D levels were grouped into three categories: sufficiency (>30 ng/ml),
insufficient (20-29 ng/ml), and deficient (<20 ng/ml) (Holick et al., 2011). Using these
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guidelines, 87.2% of women had a vitamin D level < 30 ng/ml while only 12.8% had normal
vitamin D levels.
Table 4. Vitamin D Status based on Endocrine Society Guidelines
Deficient
<20 ng/ml
n (%)
73 (58)

Insufficient
20-29 ng/ml
n (%)
36 (29)

Sufficient
≥ 30 ng/ml
n (%)
16 (13)

Table 5 reveals that African Americans were more likely to be deficient while Hispanics
and other races (Caucasian =7, Mixed= 2, Asian=1) were likely to be sufficient. Using an
analysis of variance (ANOVA), the mean vitamin D level for Hispanic women (21.13 ±7.4) was
significantly higher than African American women (17.02± 8.3). There were significant
differences among the values of race/ethnicity, [F(2, 122) = 7.07, p = .001]. To further examine
the differences among the variables, t-tests were calculated between each pair of measurements.
Tukey pairwise comparisons were conducted with the following noted: (1) the mean of vitamin
D serum levels for African American pregnant women (M = 17.02, SD = 8.33) was significantly
smaller than for Hispanic (M = 21.13, SD = 7.43) [t (113) = 2.774, p = .006]; (2) the mean of
vitamin D serum levels for AA (M = 17.02, SD = 8.33) was significantly smaller than for other
race (M = 25.80, SD = 9.60) [t (70) = -3.030, p = .003]; (3) the mean of vitamin D serum levels
for Hispanic (M = 21.13, SD = 7.43) was not significantly smaller than for other race (M = 25.80,
SD = 9.60) [t (61) = -1.738, p = .087].
Table 5. Vitamin D Status based on Race/Ethnicity
M
AA
17.02
Hispanic
21.13
Other
25.80

SD
8.33
7.43
9.60

n
62
53
10

71
Dietary Vitamin D and Calcium Intake
Dietary vitamin D and calcium intakes were measured using Block’s vitamin D and
calcium screener. The results showed the mean level of dietary vitamin D intake for the sample
was 144.6 IU/day (SD= ±132.8) and average vitamin D supplement use was 482.7 IU/day (SD=
±390.8). Important to note, prenatal vitamins usually have about 400 IUs of vitamin D although
some brands have as high of 800 IUs/prenatal vitamin. In Table 6, only the participants who
reported taking vitamin D supplements were more likely to have sufficient levels of vitamin D [
t(123) = -3.51, p = .001], confirming differences in vitamin D supplement intake between
vitamin D groups. There was no significant difference in dietary vitamin D or calcium intake, or
calcium supplement intake, reported between vitamin D groups.
Table 6. Dietary and Supplement Use of Calcium and Vitamin D

Total sample
(n=125)
Vitamin D
<20 ng/ml
n=73
Vitamin D
≥ 20 ng/ml
n=52

Dietary vitamin
D intake
(IU/day)
mean(SD)
144.6(132.8)

Supplement use
vitamin D
(IU/day)
mean(SD)
482.7(390.8)

Dietary calcium
intake
(mg/day)
mean(SD)
873.9 (617.8)

Supplement
calcium intake
(mg/day)
mean(SD)
171.9(133.6)

141.3(146.0)

387.66(239.1)

830.9(635.7)

153.5(82.9)

149.2(112.7)

616.1(509.5)

934.4(592.5)

197.8(180.4)

Hemoglobin Status
Another biological factor that was measured in this study was hemoglobin and hematocrit
status. Abnormally low hemoglobin, defined as a hemoglobin < 10.5 g/dL (King et al., 2015) is
also known as anemia. Iron-deficiency anemia is one of the most common causes of
fatigue/tiredness and therefore is usually measured in the third trimester since most pregnant
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women will need some supplementation. In the present sample, two people were missing their
hemoglobin and hematocrit values. The mean value of hemoglobin was 11.2(1.02) and for
hematocrit was 34.6(2.9). Table 7 shows the breakdown of hemoglobin values based on vitamin
D group.
Table 7. Hemoglobin and Hematocrit Values of Vitamin D Groups

Total sample
(n=123)
Vitamin D
<20 ng/ml
n=71
Vitamin D
≥ 20 ng/ml
n=52

Hemoglobin
mean(SD)

Hematocrit
mean(SD)

11.2(1.02)

34.6(2.9)

10.9(1.01)

34.0(2.9)

11.5(1.0)

35.2(2.7)

A difference in mean value hemoglobin between vitamin D groups existed [ t(121) = 2.52, p = .013], indicating that the mean hemoglobin in the deficient group was significantly
lower than the mean hemoglobin in the vitamin D sufficient group.
Hemoglobin A1C Status
Another biological marker collected from the electronic medical record was the prenatal
hemoglobin A1C. Hemoglobin A1C is a biological marker of average glucose control over the
past three months (Cunningham et al., 2010). A level 6.0% or greater at the beginning of
pregnancy can indicate undiagnosed type 2 diabetes or pre-gestational diabetes. Due to the
increased risk of GDM in the study population, the clinic has a standard protocol to include
hemoglobin A1C on their initial prenatal panel of labs. Seven participants were missing a
hemoglobin A1C level. Table 8 shows the mean values of hemoglobin A1C based on vitamin D
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groups and there was almost a significant difference between vitamin D groups [ t(116) = 1.953,
p = 0.053] .
Table 8. Hemoglobin A1C based on Vitamin D Groups

Total sample
(n=118)
Vitamin D
<20 ng/ml
n=70
Vitamin D
≥ 20 ng/ml
n=48

Hemoglobin A1C
mean(SD)
5.2(0.4)
5.3(0.36)

5.1(0.34)

Symptom Status
Pregnancy Symptom Inventory
The Pregnancy Symptom Inventory (PSI) is a 42-item questionnaire that measures
different pregnancy symptoms/discomforts found in pregnancy and has an option for writing in
any additional symptom experience. None of the study participants reported additional
symptoms. There was no missing data on the frequency of the symptoms reported. Four
participants were missing the symptom limitations. Since this tool has only been used once,
comprehensive examination of this tool was done to provide evidence for future use. Therefore,
the PSI was examined for frequency of symptoms, limitations of symptoms on activities of daily
living, and functional impact of symptoms as well as whether there were differences in these
aspects between women who were deficient and those who were not.
Pregnancy symptom frequency. As noted in Table 9, the most frequently reported
symptoms showed that tiredness, urinary frequency, food cravings, back pain, headache, and
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poor sleep were the symptoms most often reported.
Table 9. Frequency of Reported PSI Items (n=125)
Symptom

No (%)*

Yes (%)*

Tiredness

20(16)

105(84)

Urinary
frequency

24(19.2)

101(80.8)

Food
cravings

26(20.8)

99(79.2)

Back pain

26(20.8)

99(79.2)

Headache

27(21.6)

98(78.4)

Poor sleep

35(28)

90(72)

Breast pain

40(32)

85(68)

Sore nipples

40(32)

85(68)

Hip/pelvic
pain

43(34.4)

82(65.6)

Nausea

52(41.6)

73(58.4)

Changes in
nipples

52(41.6)

73(58.4)

Shortness of
breath

53(42.4)

72(57.6)

Leg cramps

55(44)

70(56)

Stretch
marks

55(44)

70(56)
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Table 9 (cont.)
Increased
vaginal
discharge

57(45.6)

68(54.4)

Constipation

60(48)

65(52)

Forgetfulness

62(49.6)

63(50.4)

Vomiting

63(50.4)

62(49.6)

Itchy skin

63(50.4)

62(49.6)

Dizziness

66(52.8)

59(47.2)

Dry mouth

68(54.4)

57(45.6)

Snoring

69(55.2)

56(44.8)

Restless leg

74(59.2)

51(40.8)

Reflux

76(60.8)

49(39.2)

Vivid dreams

76(60.8)

49(39.2)

Swollen
hands/feet

77(61.6)

48(38.4)

Incontinence

79(63.2)

46(36.8)

Feeling
depressed

80(64)

45(36)

Acne

80(64)

45(36%)

Changes in
libido

82(65.6)

43(34.4)

Taste/smell
changes

57(45.6)

43(54.4)

Sciatic

89(71.2)

36(28.8)
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Table 9 (cont.)
Anxiety

91(72.8)

34(27.2)

Altered body
image

98(78.4)

27(21.6)

Carpel tunnel

99(79.2)

26(20.8)

Painful veins

104(83.2)

21(16.8)

Hemorrhoids

108(86.4)

17(13.6)

Heart
palpitations

108(86.4)

17(13.6)

Varicose
veins

109(87.2)

16(12.8)

Brownish
marks on
face

110(88)

15(12)

Thrush

117(93.6)

8(6.4)

Fainting

117(93.6)

8(6.4)

*No = never; yes = rarely, sometimes, often

The symptoms that were reported by more than 60% of the sample were compared by
vitamin D groups (Table 10). The symptoms most commonly reported in the vitamin D deficient
group were tiredness, urinary frequency, and back pain. In contrast, the symptoms most
commonly reported in the vitamin D sufficient group were tiredness, urinary frequency, and
headache. There were no symptoms that were significantly different between vitamin D groups.
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Table 10. Most Frequently Reported PSI Items by Vitamin D Groups

Tiredness

Vitamin D < 20 ng/ml
(n=73)
n(%)
60(82)

Vitamin D ≥ 20 ng/ml
(n=52)
n(%)
45(86)

Urinary frequency

59(81)

42(80)

Food cravings

58(79)

40(77)

Back pain

62(85)

37(71)

Headache

57(78)

41(79)

Poor sleep

54(74)

38(73)

Breast pain

50(68)

35(67)

Sore nipples

53(73)

33(63)

Hip/pelvic pain

44(60)

38(73)

Symptom

A sum total PSI score was calculated for each individual by adding all of the symptoms
according to the rating reported for each item (1=never, 2=rarely, 3= sometimes, 4=often). The
possible range for the total PSI scores is 0-126, and for this study the range was 0-78. Table 11
shows the mean PSI total score based on vitamin D categories and no significant difference was
observed. The Cronbach alpha for the PSI total score was 0.895, indicating adequate reliability
(Nunnally & Bernstein, 1994; Devillis, 2012).
Table 11. Total PSI Scores by Vitamin D Groups
Total sample
n=125
mean(SD)
range
36.23(18.0)

Vitamin D
< 20 ng/ml
n = 73
mean(SD)
36.2(17.4)

Vitamin D
≥ 20 ng/ml
n = 52
mean(SD)
36.3(18.8)
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Pregnancy symptom limitation. Of the symptoms that were commonly reported, Table
12 shows the frequency of the limitation that each symptom had on participants (1 = not limited
at all, 2 = limited a little, 3 = limited a lot). Therefore, only participants who selected either
rarely, sometimes, or often for having the symptom would answer the limitation question for that
symptom. For example, if a participant selected “never” for the symptom, then the limitation
section did not apply. The frequency of the limitation for each symptom is presented as well as
the total limitations (sum of a little + a lot) in Table 12. The symptoms most frequently causing
limitations were the following: tiredness (83.8%), poor sleep (77.8%), back pain (76.7%), and
hip/pelvic pain (71.9%). The table only includes symptoms that were reported more than 20% of
the time. Therefore, symptoms such as hemorrhoids, thrush, painful veins, carpel tunnel,
fainting, heart palpitations, varicose veins, and brownish marks on face were not reported.
Table 12. Frequency of PSI Item Limitations
Symptoms

N = valid
responses

Tiredness

105

No
limitations
n(%)
17(16.2)

Limit a
little
n(%)
54(51.4)

Limit a lot
n(%)

Total
Limitation

34(32.4)

83.8

Nausea

73

29(39.7)

37(50.7)

7(9.6)

51.6

Vomiting

62

24(38.7)

31(50.0)

7(11.3)

61.3

Reflux

48

21(42.9)

22(44.9)

5(10.2)

55.1

Constipation

65

36(55.4)

24(36.9)

5(7.7)

44.6

Dry mouth

57

48(84.2)

8(14.0)

1(1.8)

15.8

Food cravings

99

64(64.6)

29(29.3)

6(6.1)

35.4

Poor sleep

90

20(22.2)

37(41.1)

33(36.7)

77.8
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Table 12 (cont.)
Restless leg

51

26(51.0)

16(31.4)

9(17.6)

49

Leg cramps

70

29(41.4)

32(45.7)

9(12.9)

58.6

Snoring

56

37(66.1)

13(23.2)

6(10.7)

33.9

Urinary frequency

101

44(43.6)

47(46.5)

10(9.9)

56.4

Incontinence

46

24(52.2)

20(43.5)

2(4.3)

47.8

Increased vaginal
discharge

68

56(82.4)

10(14.7)

2(2.9)

17.6

Changes in libido

43

31(72.1)

7(16.3)

5(11.6)

27.9

Sciatica

36

15(41.7)

12(33.3)

9(25.0)

58.3

Back pain

99

23(23.2)

33(33.3)

43(43.4)

76.7

Hip/pelvic pain

82

23(28.0)

36(43.9)

23(28.0)

71.9

Breast pain

85

65(76.5)

15(17.6)

5(5.9)

23.5

Headache

98

35(35.7)

44(44.9)

19(19.4)

64.3

Sore nipples

85

68(80.0)

11(12.9)

6(7.1)

20

Dizziness

59

26(44.1)

30(50.8)

3(5.1)

55.9

Shortness of breath

72

27(37.5)

36(50.0)

9(12.5)

62.5

Taste/smell
changes

68

45(66.2)

20(29.4)

3(4.4)

33.8

Forgetfulness

63

30(47.6)

27(42.9)

6(9.5)

52.4

Feeling depressed

45

18(40.0)

23(51.1)

4(8.9)

60.0

Anxiety

34

15(44.1)

15(44.1)

4(11.8)

55.9

Vivid dreams

49

43(87.8)

6(12.2)

0

12.2

80
Table 12 (cont.)
Altered body
image

27

22(81.5)

5(18.5)

0

18.5

Acne

45

38(84.4)

5(11.1)

2(4.4)

15.5

Itchy skin

62

50(80.6)

10(16.1)

2(3.2)

19.3

Changes in nipples

73

63(86.3)

9(12.3)

1(1.4)

13.7

Stretch marks

70

59(84.3)

10(14.3)

1(1.4)

15.7

Swollen hands/feet

48

27(56.3)

16(33.3)

5(10.4)

43.7

It is interesting to note that when comparing the symptoms most frequently reported,
some did not have significant limitations. For example, the symptoms of food cravings and sore
nipples had limitations of 35.4% and 20% respectively, yet their frequency was 79.2% and 68%
respectively. In contrast, only 36% of women reported feeling depressed, but was reported as
having limitations by 60% who reported the symptom. Table 13 compares the symptoms
reported with the most limitation based on vitamin D groups and the number of women who
rated that symptom as limiting a little and/or limiting a lot. Table 14 shows the mean values for
the symptoms causing highest level of limitation. Those who were deficient were compared to
those who were sufficient, using independent samples t-test. The symptoms having greater
limitations in those with vitamin D deficiency were: tiredness [ t(101.54) = 2.20, p = .030], poor
sleep [ t(90) = 2.27, p = .026], back pain [t(97) = 3.13, p = .002], and hip/pelvic pain [t(80) =
2.10, p = .039]. Each of these symptoms were significantly different between vitamin D groups.
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Table 13. Most Limiting PSI Items by Vitamin D Groups
Symptoms
Tiredness
(n=105)
Poor sleep
(n=92)
Back pain
(n=99)
Hip/pelvic pain
(n=82)
Headache
(n=98)
Shortness of
breath (n=71)
Vomiting (n=62)
Feeling depressed
(n=55)

Vitamin D < 20 ng/ml
Vitamin D ≥ 20 ng/mln/total who
n/total who had symptom(%)
had symptom(%)
51/60
37/45
(85)
(82)
45/54
26/38
(83)
(68)
54/62
22/37
(87)
(59)
35/44
24/38
(80)
(63)
36/57
28/41
(63)
(68)
28/41
17/30
(67)
(57)
24/38
14/24
(63)
(67)
16/24
11/21
(67)
(52)

Table 14. Means of Limitation Scores by Vitamin D Groups

Symptoms

Vitamin D < 20 ng/ml
mean(SD)

Vitamin d ≥ 20 ng/ml
mean(SD)

*Tiredness

2.28(0.7)

2.00(0.6)

*Poor sleep

2.28(0.7)

1.92(0.7)

**Back pain

2.39(0.7)

1.89(0.8)

*Hip/pelvic pain

2.16(0.7)

1.82(0.7)

Headache

1.86(0.7)

1.85(0.7)

Shortness of breath

1.83(0.8)

1.60(0.6)

Vomiting

1.74(0.6)

1.71(0.7)

Feeling depressed

1.79(0.7)

1.57(0.6)

*p < 0.05 ** p < .01
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Participants were also asked to list the symptom that in their experience was the worst to
manage. This was not part of the original instrument but added by the PI. Table 15 shows the
top nine symptoms listed as the worst symptom to manage (although 28 were reported) with
back pain as the most frequently reported.
Table 15. PSI Items Reported as Worst to Manage (Top 9)
Symptom

Frequency
n(%)

Back pain

17 (13.8)

Hip/Pelvic Pain

15 (12.2)

Tiredness

15 (12.2)

None

12 (9.8)

Poor sleep

9 (7.3)

Headache

9 (7.3)

Swollen hands/feet

5 (4.1)

Urinary frequency

4 (3.3)

Nausea

4 (3.3)

Table 16 shows the top six symptoms rated as the worst to manage broken down by
vitamin D groups. The frequency of back pain and poor sleep were noted to be much higher in
the vitamin D deficient group than in the vitamin D sufficient group.
Table 16. PSI Items Reported as Worst by Vitamin D Groups

Back pain

Vitamin D < 20 ng/ml
n (%)
13 (17.8)

Vitamin D ≥ 20 ng/ml
n (%)
4 (7.7)

Hip/Pelvic Pain

9 (12.3)

6 (11.5)

Symptom
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Table 16 (cont.)
Tiredness

8 (11.0)

7 (13.5)

Poor sleep

7 (9.6)

2 (3.8)

None

3 (4.1)

9 (17.3)

Headache

5 (6.8)

4 (7.7)

Depressive Symptoms
The EPDS was used to measure depressive symptoms since this measure is used at the
clinical site where data collection took place. The EPDS scores were not normally distributed.
There is a potential range of 0-30 for scores. For this study, the range was 0-19. There was a
significant positive skew since 34.4% of women reported no symptoms of depression reflecting a
score of zero on the EPDS. The mean scores between vitamin D groups was not statistically
significant [ t(123) = 0.530, p = 0.597].
Table 17. Mean EPDS Scores (n=125)

EPDS
score

Total
sample
mean(SD)

Vitamin D
< 20 ng/ml
mean(SD)

Vitamin D
≥ 20 ng/ml
mean(SD)

3.9(4.5)
0-19

4.05(4.8)
0-19

3.62(4.1)
0-17

Evidence indicates that a prior history of depression will increase the risk of depression in
pregnancy. There were eighteen women with a history of depression. Of these, ten were in the
vitamin D sufficient group and eight in the deficient group. The mean EPDS score of those
without a history of depression was M = 3.05, SD = 3.673 and the mean EPDS of those with a
history of depression was M = 8.94, SD = 5.955—significantly different [t(123)=-5.722, p =
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.000]. However, when rerunning the analysis excluding persons with history of depression from
analysis, the EPDS means are still not significantly different between vitamin D groups [ t(105)
= 1.451, p = .150].
Sleep Quality
Sleep quality was measured with the Pittsburgh Sleep Quality Index (PSQI) in order to
have a valid measure for sleep. The PSQI instrument is a validated measure for evaluating sleep
in pregnancy. PSQI is calculated into seven components: subjective sleep quality, sleep latency,
sleep duration, habitual sleep efficiency, step disturbances, use of sleeping medication, and
daytime dysfunction. The items are then summed for a global PSQI score with higher the scores
indicating poorer the sleep quality. The maximum PSQI score is 21 and the minimum score is
zero. A score of five and below is considered to be indicative of good sleep quality (Buysse,
1989). The range of scores for the current study ranged from 0-14. Mean scores for each
component are summarized in Table 18.
It is important to understand the calculation of each of the PSQI sleep components. The
first component of subjective sleep quality used question #6 which asked “During the past
month, how would you rate your sleep quality overall?” with answers ranging from: 0 = very
good, 1 = fairly good, 2 = fairly bad, 3 = very bad. The second component that labeled sleep
latency was computed from question #2 which asked “how long has it usually takes you to fall
asleep each night?” with responses being categorized as 0 = ≤ 15 minutes, 1 = 16-30 minutes, 2
= 31-60 minutes, 3 = > 60 minutes and question #5A which asked “how often have you had
trouble sleeping because you cannot get to sleep within 30 minutes?” with responses categorized
as 0 = not during the past month, 1 = less than once a week, 2 = once or twice a week, 3 = three
or more times a week. The scores for this component are calculated and summed up so that 0 =
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sum of #2 and #5A is 0, 1 = sum of #2 and #5A is 1-2, 2 = sum of #2 and #5A is 3-4, 3 = sum of
#2 and #5A is equal to 5-6, which can be interpreted as that, for people with higher sleep latency
scores, it takes them longer to get to sleep and usually cannot get to sleep within 30 minutes.
Sleep duration is the third component of the PSQI and uses question #4 which asks “how
many hours of actual sleep did you get at night?” with responses categorized as 0 = > 7 hours, 1
= 6-7 hours, 2 = 5-6 hours, 3 = < 5 hours. Therefore, the higher the number on this component,
the less actual sleep they got at night. The fourth component of habitual sleep efficiency is a
calculation using the responses to question #4 (above), question #3 (“when have you usually
gotten up in the morning?”), and question #1 (“when have you usually gone to bed at night?”)
which calculates a habitual sleep efficiency percentage. Therefore the answers are categorized as
0 = > 85%, 1 = 75-84%, 2 = 65-74%, 3 = < 65%. Higher responses to this component show
poorer habitual sleep efficiency.
The fifth component of the PSQI is sleep disturbances and calculates the sum of
questions #5A through J, which list a variety of sleep disturbances such as “have to get up to use
the bathroom” or “feel too cold” which are categorized as 0 = not during the past month, 1 = less
than once a week, 2 = once or twice a week, 3 = three or more times a week for each statement.
The sum of the sleep disturbances are used to determine the sleep disturbance score which is
categorized as 0 = 0 sleep disturbances, 1 = 1-9 sleep disturbances, 2 = 10-18 sleep disturbances,
3 = 19-27. Higher component 5 sleep disturbance score means poorer sleep quality. The sixth
component of the PSQI is use of sleeping medication and uses the responses to question #7
(“how often have you taken medicine (prescribed or “over the counter”) to help you sleep?”)
with responses 0 = not during the past month, 1 = less than once a week, 2 = once or twice a
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week, 3 = three or more times a week.
The seventh component of the PSQI called daytime dysfunction uses the responses to
question #8 (“how often have you had trouble staying awake while driving, eating meals, or
engaging in social activity?”) with responses of 0 = not during the past month, 1 = less than once
a week, 2 = once or twice a week, 3 = three or more times a week) and question #9 (“how much
of a problem has it been for you to keep up enough enthusiasm to get things done?”) with
responses of 0 = no problem at all, 1 = only a very slight problem, 2 = somewhat of a problem, 3
= a very big problem. The sum of the responses to these questions is calculated as their
component 7 score with categories of 0 = sum of #2 and #5A is 0, 1 = sum of #2 and #5A is 1-2,
2 = sum of #2 and #5A is 3-4, 3 = sum of #2 and #5A is equal to 5-6.
Despite non-normal distribution of the vitamin D values, independent sample t-tests were
used to assess any difference in means of PSQI global scores and component scores between
vitamin D groups. Findings indicated that those who were vitamin D deficient had worse sleep
than those who were vitamin D sufficient [ t(122) = 3.68, p < .001] based on the PSQI global
score. Findings also indicated that for those who were vitamin D deficient, they had less sleep
duration [t(121.227) = 3.468, p = .001], more use of sleeping medication [t(93.76) = 2.81, p =
.006], more daytime dysfunction [t(122) = 2.85, p = .005], and worse habitual sleep efficiency
[t(120.80) = 2.68, p = .008], which were statistically significant.
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Table 18. Mean PSQI Total and Subscale Scores (n=124)
PSQI
component
1 Subjective
sleep quality
2 Sleep latency
**3 Sleep
duration
*4 Habitual
sleep efficiency
5 Sleep
disturbances
*6 Use of
sleeping
medication
**7 Daytime
dysfunction
**Total PSQI
Global score

Total
sample
mean(SD)
1.06(0.8)

Vitamin D
< 20 ng/ml
mean(SD)
1.14(0.8)

Vitamin D
≥ 20 ng/ml
mean(SD)
0.94(0.8)

1.16(1.0)

1.22(1.1)

1.1(1.0)

0.73(0.9)

0.94(1.0)

0.42(0.7)

0.87(1.1)

1.07(1.2)

0.60(0.7)

1.52(0.6)

1.58(0.6)

1.44(0.6)

0.27(0.8)

0.42(0.9)

0.08(0.3)

0.73(0.8)

0.90(0.8)

0.50(0.6)

6.3(3.5)

7.28(3.6)

5.1(2.9)

*p < 0.05 ** p < .01 *one participant left without completing the PSQI

Functional Status
Health-Promoting Lifestyle Profile
The Health-Promoting Lifestyles Profile (HPLP)v.2 instrument was created to assess 52
health behaviors and are rated as: never=1, sometimes=2, often=3, and routinely=4. Therefore, a
mean score between 3 and 4, would indicate that an individual was practicing health-promoting
behaviors more often. The HPLP has six subscales including physical activity, nutrition, health
responsibility, interpersonal relations, spiritual growth, and stress management. The Cronbach
alpha for the HPLP for this study was 0.938. The Cronbach alpha for each of the subscales was:
physical activity (0.819), nutrition (0.727), health responsibility (0.62), interpersonal relations
(0.842), spiritual growth (0.820), and stress management (0.745).
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Table 19. Subscale Scores and Average Item Subscale Scores for HPLPv2 (n=124)*

8-32

Range of scores
Actual
Mean total
score (SD)
8-28
15.9(4.7)

9-36

13-35

23.1(4.4)

2.56(0.5)

9-36

14-36

22.6(4.6)

2.51(0.5)

9-36

15-36

26.0(5.3)

2.89(0.6)

9-36

17-36

27.5(4.8)

3.06(0.5)

8-32

12-32

18.8(4.3)

2.48(0.5)

52-208

91-195

134.9(22.3)

2.59(0.4)

Possible
Physical activity
(n=8 items)
Nutrition
(n=9 items)
Health
responsibility
(n=9 items)
Interpersonal
relations
(n= 9 items)
Spiritual growth
(n=9 items)
Stress
management
(n=8 items)
Total scores
(n=52 items)

Mean item
response
1.99(0.6)

*one participant left without completing the HPLPII

As reflected in Table 19, physical activity and stress management subscales were low
when compared to the interpersonal and spiritual growth subscales suggesting that persons were
less likely to be physically active or practicing stress management. The mean HPLP score was
2.6, which would be that the individuals reported healthy behaviors in the “sometimes” to
“often” range. Unfortunately, however, most women did not report their behaviors as being
practiced routinely.
When analyzed based on vitamin D group, there were no significant differences in either
total HPLP scores or any of the subscale scores (Table 20). Although the dietary scores were
higher in the sufficient vitamin D group (suggesting practicing better nutrition more often), they
were not statistically different from those who were deficient.
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Table 20. Mean Subscale Scores of HPLPII between Vitamin D Groups (n = 124)
HPLP subscale

Vitamin D
< 20 ng/ml
mean(SD)
1.96(0.53)

Vitamin D
≥ 20 ng/ml
mean(SD)
2.02(0.65)

Nutrition

2.5(0.44)

2.67(0.54)

Health responsibility

2.49(0.52)

2.52(0.48)

Interpersonal
relations
Spiritual growth

2.83(0.6)

2.96(0.6)

3.04(0.55)

3.07(0.5)

Stress management

2.46(0.49)

2.5(0.59)

Total HPLP score

2.56(0.42)

2.64(0.44)

Physical activity

General Health Perceptions
General health perceptions were measured in this study by asking women to rate the
health of their pregnancy and the health of their unborn baby using the same likert scale items as
the first question of the SF-12 (1 = excellent, 2 = very good, 3 = good, 4 = fair, 5 = poor).
Table 21 shows the responses of the participants to these questions. Overall, the sample
had positive general health perceptions as 86.2% reported their perception of their pregnancy as
“good” or better, and 97.6% of the sample replied “good” or better for their unborn baby. For
the general health perception of the pregnancy, the means were not different between vitamin D
groups [t(104) = .289, p = .773] or the general health perception of the fetus [t(104) = .004, p =
.997].
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Table 21. General Health Perception between Vitamin D Groups*
GHP pregnancy

Total
(%)
n=124

Excellent

20(16)

Vitamin D
< 20 ng/ml
(%)
n=72
15(21)

Vitamin D
≥ 20 ng/ml
(%)
n=52
5(9.6)

Very good

41(33.1)

20(28)

21(40.4)

Good

46(37.1)

23(32)

23(44.2)

Fair

16(13)

13(18.9)

3(5.8)

Poor

1(0.8)

1(0.1)

0
M = 2.43
SD = 0.801
Vitamin D
≥ 20 ng/ml
n=52
15(28.8)

Excellent

42(33.9)

M = 2.48
SD = 1.069
Vitamin D
< 20 ng/ml
n=72
27(37.5)

Very good

47(37.9)

24(33.3)

23(44.2)

Good

32(25.8)

18(25)

14(27)

Fair

3(2.4)

3(4.2)

0

Poor

0

0

0

M = 1.95
SD = .898

M = 1.95
SD = .795

GHP–unborn
baby

Total

*one participant left without completing the General Health Perception questions

Quality of Life
Standard Form–12 (SF-12)
The SF-12v2 was used to measure the health-related quality of life of the study sample.
Quality Metric which is the company that has copyrighted the SF-12, created a software to
calculate norm-based scores for each subscale of the SF-12. The data was collected and
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uploaded into the software per their written protocol. Based on their own data quality check, the
SF-12 scores in the given sample had no missing data, 100% had responses within the tool range,
and had excellent concurrent and discriminant validity. The evidence for concurrent and
discriminant validity on the dataset is provided in Appendix F and was provided by the SF-12
software scoring management system (Maruish, 2012).
Interpretation of the SF-12v2 is based on norm-based scoring which means that the scale
is 1-100, with 50 being the average quality of life for the US population. Scores above 50 reflect
better quality of life and scores below 50 reflect lower quality of life. The scoring software
creates norm-based scores for each of the eight domains and a total score for the physical and
mental component score. The physical component score is composed of four domains: physical
functioning, role functioning (physical), bodily pain, and general health. In addition, the mental
component score is composed of four domains: vitality, social functioning, role functional
(emotional), and mental health. As you can see in Figure 3, the domains of physical functioning,
role functioning, bodily pain, social functioning, and role functional (emotional) were below 50,
and the domains that were above 50 were general health (physical component score domain),
vitality (mental component score), and mental health (mental component score).
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Figure 3: SF-12 scores for the total sample

Table 22 displays the SF-12 subscale scores for both physical component score and the
mental component score based on vitamin D group. The only components significantly different
between vitamin D groups were bodily pain [t(123) = -2.82, p = .006] and physical component
score [t(123) = -3.30, p = .001].
Table 22. SF-12 Scores based on Vitamin D Groups (n=125)
SF-12 domain
Norm-based
scores
Physical
functioning
Role
functioning
(physical)
*Bodily pain
General health
Vitality

Total sample
mean(SD)

Vitamin D
< 20 ng/ml
mean(SD)

Vitamin D
≥ 20 ng/ml
mean(SD)

44.78(9.3)

43.5(9.5)

46.3(8.7)

45.21(9.0)

43.9(9.0)

46.3(9.3)

47.27(10.3)

45.1(10.6)

50.3(9.2)

51.49(9.09)

50.4(10.0)

53..02(7.4)

50.88(9.7)

49.71(9.4)

52.4(9.9)
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Table 22 (cont.)
Social
functioning
Role functional
(emotional)
Mental health
Mental
component
Score (MCS)
*Physical
component
score (PCS)

48.36(9.7)

47.4(10.4)

49.4(9.0)

45.93(11.2)

45.4(11.6)

46.1(10.9)

54.44(8.6)

55.2(8.5)

53.6(8.9)

52.19(8.6)

52.4(8.6)

51.5(8.6)

45.45(7.6)

43.43(7.2)

47.74(7.2)

*p value ≤ 0.001

Characteristics of the Environment
To assess for any environmental factors that could impact on quality of life, spirituality
and social support were assessed in all women.
Spirituality
The Spiritual Perspective Scale (SPS) was used to measure spirituality in the sample to
see if increased spirituality has any impact on health behaviors or quality of life. The range of
possible scores for the SPS tool include 10-60. The instrument is split into four questions
addressing spiritual behaviors (question numbers: 1-4) and six questions addressing spiritual
beliefs (question numbers: 5-10). The mean spirituality score was 47 in the total sample. The
data was negatively skewed with most participants having higher levels of spirituality scores
which is similar to those found in a comparable study with a mean spirituality score of 43.6
(Dailey &Steward, 2007). Table 23 shows that the SPS scores did not differ based on vitamin D
groups.
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Table 23. Mean Total SPS Scores by Vitamin D Groups
Total sample
(n=124)
mean(SD)
range
47 (9.1)
12-60

Vitamin D
< 20 ng/ml
mean(SD)
range
45.9(8.4)
12-60

Vitamin D
≥ 20 ng/ml
mean(SD)
range
48.4(9.7)
12-60

Social Support
Another important variable is social support especially since the study population is a
predominantly low-income patient population and evidence shows poor social support can
adversely impact pregnancy with increased rates of prenatal anxiety and depression, preterm
birth, and low birth weight babies (Rini, Dunkel Schetter, Hobel, Glynn, & Sandman, 2006;
Dunkel Schetter, 2009; Giurgescu et al., 2015; Sealy-Jefferson et al., 2015). Surprisingly, social
support was relatively high as the mean score for the MSPSS was 5.8, with a range of 1-7, with 7
being the highest score of social support. There are three subscales for the MSPSS which
include: significant other, family, and friends. As shown in Table 24, the mean score for
significant other was 6.1 which was the highest subscale score. Family and friends subscale
scores were similar, which shows that the patient population had a significant amount of social
support, which can potentially have positive impacts on health outcomes and healthy behaviors.
In addition, the social support subscale scores based on vitamin D groups showed no significant
differences (Table 25).
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Table 24. Overall Mean Score for MSPSS and Subscales (n=124)
Range of scores
Possible

Actual

Mean (SD)

Significant other

1-7

1-7

6.1(1.4)

Family

1-7

1-7

5.8(1.6)

Friends

1-7

1-7

5.5(1.5)

Total MSPSS score

1-7

1-7

5.8(1.4)

Table 25. Mean MPSS Total and Subscale Scores by Vitamin D Groups (n=124)
Vitamin D
< 20 ng/ml
mean(SD)
Significant other 6.1(1.4)
subscale
Family
5.7(1.7)

Vitamin D
≥ 20 ng/ml
mean(SD)
6.0(1.5)

Friends

5.4(1.6)

5.9(3.0)

Total MSPSS

5.8(1.3)

5.9(1.7)

5.8(1.5)

Data Analysis for Study Aims
The primary aim of the study was to determine if pregnancy symptoms could be
predicted by vitamin D status, health behaviors, quality of life, and outcomes. The secondary
aim was to determine if there were any ethnic differences between African American and
Hispanic women on their pregnancy symptom profile, vitamin D status, health behaviors, quality
of life, and health outcomes. The exploratory aim was contingent on the primary aim—that if a
significant relationship exists between vitamin D status and pregnancy symptoms, see if
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depression scores mediates that relationship. In the following sections, the analysis aims will be
discussed.
Data Analysis for Aim 1
The first aim of the study was to determine if pregnancy symptom functional status could
be predicted by vitamin D status, health behaviors, and quality of life. The proposed hypothesis
is that lower vitamin D status could predict higher pregnancy symptom profiles, poorer healthpromoting behaviors, and poorer quality of life. In order to examine this hypothesis, multiple
Kendall’s tau correlation tests were performed (due to non-normally distributed variables) on all
main variables to see potential associations between variables prior to analysis.
As noted in Table 26, vitamin D status was significantly correlated with PSQI global
score and depressive symptoms (EPDS). The total PSI frequency score was significantly
correlated with PSQI global score, depressive symptoms (EPDS) and both aspects of quality of
life (PCS and MCS). The relationships indicated that the more symptoms experienced by
women, the worse their sleep, depressive symptoms, and their quality of life. Health-promoting
behaviors (HPLP) were not highly correlated with any of the variables other than depression
which indicated that the more the women reported the depressive symptoms, the less likely were
they to engage in health-promoting behaviors. Level of vitamin D was correlated with sleep
score and physical quality of life. For those with higher levels of vitamin D, they reported better
sleep and physical functioning.
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Table 26. Correlation Table of Major Outcomes based on Conceptual Model
Vitamin
D
serum
levels

PSI
total
score

PSQI
global
Score

EPDS
total

HPLP
total

General
health
perception
(1)

PCS
(SF12)

MCS
(SF12)

Vitamin D
1
serum levels
PSI
frequency
total

.014

1

PSQI global
score

-.263**

.228**

1

EPDS total

.021

.370**

.312**

1

HPLP total

.011

-.045

-.089

-.109

1

General
health
perceptions(
1)

-.034

.254**

.083

.156*

-.169*

1

.200**

-.206**

-.190**

-.176*

.028

-.178**

1

-.073

-.215**

-.174**

-.426**

.113

-.153*

.001

Physical
component
score
Mental
component
score

1

* correlation is significant at the 0.05 level (2-tailed)
** correlation is significant at the .01 level (2-tailed)

A binary logistic regression was conducted to examine whether serum vitamin D level
was a significant predictor of pregnancy symptoms, sleep quality, health-promoting behaviors
and physical quality of life and mental quality of life. Therefore, a series of univariate analyses
was initially conducted to assess the impact serum vitamin D had on each of these outcomes.
Vitamin D level was the independent variable and each outcome was dichotomized to examine
the impact.
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One of the major assumptions of binary logistic regression is that the logit of the outcome
variable is linear to the predictor variable when using a continuous variable (Field, 2009). In
order to avoid this assumption, serum vitamin D levels were transformed into a binary variable
based on IOM guidelines with sufficient being  20 ng/ml and deficient being < 20 ng/ml. To
assess the impact of vitamin D status on pregnancy symptoms, a binary variable for pregnancy
symptom total score was created based on the median score of the pregnancy symptom total
score which was 36. Since there is no literature currently using the pregnancy symptom total on
the PSI tool, an approximation based on the sample for more symptoms (>36) and less symptoms
(≤36) was used. The univariate analysis showed that vitamin D status was not a significant
predictor of pregnancy symptom frequency, as noted in Table 27.
Table 27: Univariate Logistic Regression Results with Vitamin D Status Predicting Pregnancy
Symptom Frequency, Sleep Quality, Depressive Symptoms, Health-Promoting Behaviors, and
Quality of Life
Variable

B

SE

p

OR

95% CI

Pregnancy frequency

-.003

0.616 .996

.997

[0.298, 3.334]

Sleep quality

1.066

0.378 .005 2.905

[1.386, 6.091]

Depressive symptoms

.024

0.408 .953 1.024

[0.460, 2.280]

Health-promoting behavior

.031

0.368 .934 1.031

[0.501, 2.121]

Mental component score

-.119

0.388 .758

.887

[0.415, 1.898]

Physical component score

.1.652 0.429 .000 5.219

[2.251, 12.10]

The PSQI global score already has a cutoff score of > 5 indicating poorer sleep quality
with  5 score indicating good sleep quality (Buysse, 1989). In Table 27, vitamin D status was a
significant predictor of good sleep, suggesting that when compared to patients with sufficient
vitamin D, those deficient of vitamin D were 2.9 times more likely to have poor sleep quality.
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Depressive symptoms as measured by EPDS score was categorized based on evidence in
the literature (> 12 for positive depressive symptoms and  12 EPDS score for low depressive
symptoms) and vitamin D status was not predictive of low depressive symptoms. The cutoff
score of EPDS 12 was used to indicate a positive screen as a conservative measure for good
sensitivity and specificity for major depressive symptoms in pregnancy (Cox & Holden, 1991).
Health-promoting behavior was measured by the HPLPv.2 and the binary cutoffs for
health-promoting behaviors was a HPLP mean score of 1 to 2.5 exhibiting poor health-promoting
behaviors and HPLP mean score of 2.51 to 4.00 exhibiting good health-promoting behaviors.
There is no established cutoff for the health-promoting behaviors, but “2” represents exhibiting
the behavior “sometimes”. As shown by Table 27, health-promoting behaviors, vitamin D status
was not predictive of this outcome.
Quality of life is comprised of the physical component score and mental component
score. Both of these measures have national norms with ≥ 50 as better than average quality of
life and a score <50 as lower than average quality of life. As shown in Table 27, vitamin D
status did not significantly predict mental quality of life. However, vitamin D status did predict
physical quality of life. Compared to participants with sufficient vitamin D, those deficient of
vitamin D were almost six times more likely to have poorer physical quality of life.
Based on these univariate analyses, only those significantly predicted by vitamin D status
were included into a binary logistic regression model controlling for significant covariates
related to sleep quality and physical quality of life. Correlation analysis was done with each of
the demographic and outcome variables with sleep quality to detect any significantly correlating
with sleep quality that could be controlled for. The variables that significantly correlated with
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sleep quality included the following: marital status, history of depression, physical component
score, EPDS score, and PSI total frequency score.
Covariates theoretically that should be included in predicting sleep quality are age,
gestational age, history of depression, EPDS score, physical component score, and PSI total
frequency score. Gestational age was not significantly correlated with sleep quality, but was
included in the model anyways since there is evidence that sleep quality is worse with
advancement of gestational age.
Assumptions used for binary logistic regression include ensuring that there is not
multicollinearity amongst variables in the model based on variance inflation factors (VIFs)
(Field, 2009). Variance Inflation Factors (VIFs) were calculated to detect the presence of
multicollinearity between predictors. High VIFs indicate increased effects of multicollinearity in
the model. Variance Inflation Factors greater than 5 are cause for concern, whereas VIFs of 10
should be considered the maximum upper limit (Menard, 2009). All predictors in the regression
model have VIFs less than 10. Table 28 presents the VIF for each predictor in the model.
Since vitamin D status is the main independent variable of interest, binary vitamin D
variable using the IOM guidelines for sufficient and deficient were used. In addition, two items
on the Pregnancy Symptom Inventory tool were removed: “poor sleep” (item number nine) and
“feeling depressed”(item thirty-two). A new total pregnancy symptom total score variable was
calculated without those two items since sleep quality was being measured by the PSQI and
depressive symptoms were being measured by the EPDS.
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Table 28. Variance Inflation Factors for Covariates in Sleep Quality Model
Variable

VIF

Marital status

1.163

Gestational age

1.065

EPDS depression score

1.666

History of depression
Age
Physical component score

1.346
1.168
1.174

Pregnancy symptom total score

1.359

After controlling for marital status, gestational age, EPDS depressive symptom score,
history of depression, age, physical component score, and pregnancy symptom total score, there
remained a significant association between vitamin D status and sleep quality. That is, compared
to patients with sufficient vitamin D, those deficient of vitamin D were 3.1(95% CI: 1.292–7.47)
times more likely to have poor sleep quality. Despite controlling for other significant covariates,
the predictive value of vitamin D status on sleep quality remained constant as seen in Table 29.
Pregnancy symptom total score was also barely statistically significant with an odds ratio less
than one and a 95% confidence interval of 0.93-0.99.
Table 29. Logistic Regression Results Predicting Sleep Quality
Variable
(Intercept)
Marital status (2)
Gestational age

B
4.002
-.175
-.151

SE
3.37
0.13
0.09

p
.236
.186
.091

OR
0.84
0.86

EPDS depression score
History of depression
Age
Physical component score
Pregnancy symptom total score
IOM vitamin D groups

-0.08
-.184
.024
-.009
-.038
1.054

0.06
0.75
0.04
0.03
0.02
3.447

.200
.805
.538
.776
.026
.012

0.92
0.83
1.02
.99
.96[.93-99]
3.1[1.29-7.43]
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Binary logistic regression model to control for potential confounding variables for
physical quality of life included based on correlation analyses of all demographic and the
outcome variable physical quality of life included: EPDS depression score, sleep quality score,
general health perceptions 1 (health of pregnancy), pregnancy symptom total score, and serum
vitamin D. Pre-pregnancy BMI was added though not significantly correlated with physical
quality of life due to the theoretical reason that those who are more obese would have poorer
quality of life. Table 30 shows the VIFs of all of the predictors, and none were greater than ten.
The adjustment of the pregnancy symptom total score made for the prior analysis was also
applied to this analysis since both sleep quality and EPDS depressive symptoms score correlated
with physical quality of life. Therefore, all these predictors were put in a binary logistic
regression model with physical quality of life as the dependent variable.
Table 30. Variance Inflation Factors for Covariates in Physical Quality of Life
Variable
Pre-pregnancy BMI
EPDS depression score
Sleep quality score
General health perceptions 1
Pregnancy symptom total score

VIF
1.486
1.403
1.335
1.470
1.596

Using the IOM categories for vitamin D (sufficient or deficient) and controlling for prepregnancy BMI, EPDS depression score, sleep quality score, and pregnancy symptom total
score, a significant association between vitamin D and physical quality of life remained. The
binary logistic regression indicated that compared to those with sufficient vitamin D, those with
deficient vitamin D were 5.78 (95% CI: 2.13–15.7) times more likely to report poor physical
quality of life (Table 31)
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Table 31.: Logistic Regression Results Predicting Physical Quality of Life
Variable
(Intercept)
Pre pregnancy BMI
EPDS score
Sleep quality
General health perceptions (1)
Pregnancy symptom total score
IOM Vitamin D group

B
-1.19
-0.24
-0.89
-0.01
-0.34
-0.01
1.754

SE
1.39
0.03
0.07
0.08
0.28
0.02
0.51

p
.392
.493
.175
.947
.235
.277
.001

OR
0.97
0.92
0.99
0.72
0.98
5.78 [2.13, 15.7]

Data Analysis for Aim 2
The secondary aim to assess if there were any ethnic differences between African
American and Hispanic women in their vitamin D status, pregnancy symptom profile, sleep
quality, depressive symptoms, health-promoting behaviors, and quality of life. A series of
statistical analyses were used based on the assumptions of independent t-tests and the results are
summarized in Table 32.
Table 32. Summary of Ethnic Differences of Key Variables

*Vitamin D
Mean(SD)
PSI frequency total (pregnancy
symptom total)
Mean(SD)
,
*PSQI (sleep quality)
Mean(SD)

African
American

Hispanic

t-statistic

p value

17.02(8.33)

21.13(7.43)

t(113) = -2.77

p = .006

36.21(17.44)

36.3(18.8)

t(113) = -1.059

p = .292

7.34(3.49)

5.33(3.22)

t(112) = 3.18

p = .002

4.63(5.23)

2.42(3.25)

t(103.83) = 2.77

p = .007

*EPDS (depressive symptoms)
Mean(SD)
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Table 32 (cont.)
HPLPv.2 (health-promoting
behaviors)
Mean(SD)

2.62(0.47)

2.54(0.36)

t(110.72) = 0.97

p = .336

Physical component score (quality
of life)
Mean(SD)

44.21(7.82)

46.84(6.89)

t(113) = 1.905

p = .058

Mental component score
(quality of life)
Mean(SD)

52.12(9.31)

52.27(7.89)

t(112.14) = -0.15

p = .988

*p values <.01

For each analysis comparison, none of the variables were normally distributed based on
Shapiro-Wilk tests (Razali & Wah, 2011). However, the mean of any random variable will be
approximately normally distributed as sample size increases according to the Central Limit
Theorem (CLT) (Field, 2009). Therefore, with a sufficiently large sample size (n > 50),
deviations from normality will have little effect on the results (Stevens, 2009). Thus, a series of
independent t-tests were conducted to compare ethnic differences in vitamin D levels, pregnancy
symptom total scores, sleep quality, health-promoting behaviors, and quality of life.
Comparison between African American and Hispanic women. In Table 31, the
results of the comparisons between these groups are noted. For African Americans, their vitamin
D levels were lower than Hispanics [t(113) = -2.77, p = .006]. There were no differences
between pregnancy symptom total scores between these groups [t(113) = -1.059, p = .292]. For
sleep quality, the mean PSQI global sleep quality score in African American pregnant women
was significantly higher than in the Hispanic pregnant women [t(112) = 3.18, p = .002]
indicating worse sleep quality in African American pregnant women. For depressive symptoms,
the scores were worse for those who were African American as compared to those who were
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Hispanic [t(103.83) = 2.77, p = .007]. However, the mean scores for both groups were still
within normal range. There were no differences between health-promoting behaviors between
these groups [t(110.72) = 0.97, p = .336]. Finally, for both mental and physical quality of life,
there was no significant difference between groups on these outcomes [t(112.14) = -0.15, p =
.988; t(113) = 1.905, p = .058] However, there was a trend for those who were African
American to have lower physical quality of life.
Exploratory Aim
As a result of the null effect of vitamin D status on pregnancy symptoms, the exploratory
aim could not be evaluated. However, since sleep quality was significantly associated with
vitamin D status, a mediational analysis was conducted to evaluate if depressive symptoms
explains the strength of the relationship between vitamin D and sleep quality. In addition, due to
the assumption that in a mediation model, all the variables need to be continuous, the serum
vitamin D was used as a continuous variable (Field, 2009).
A Baron and Kenny mediation analysis was conducted to assess if depressive symptoms
mediated the relationship between serum vitamin D levels and sleep quality. To determine
whether a mediating relationship was supported by the data, three regressions were conducted.
For mediation to be supported, four items must be met: 1) the independent variable must be
related to the dependent variable, 2) the independent variable must be related to the mediator
variable, 3) the mediator must be related to the dependent variable while in the presence of the
independent variable, and 4) the independent variable should no longer be a significant predictor
of the dependent variable in the presence of the mediator variable (Baron & Kenny, 1986). In
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this analysis, the independent variable is serum vitamin D levels, the mediator is depressive
symptoms, and the dependent variable is sleep quality.
First, the regression with serum vitamin D levels predicting sleep quality was conducted.
The regression of sleep quality on serum vitamin D levels was significant, F(2, 122) = 16.05, p <
.001. The results showed that serum vitamin D levels was a significant predictor of sleep
quality, B = -0.14, indicating that the first criterion for mediation was satisfied. Second, the
regression with serum vitamin D levels predicting depressive symptoms was conducted. The
regression of depressive symptoms on serum vitamin D levels was not significant, F(2, 122) =
0.27, p = .605. The results showed that serum vitamin D levels was not a significant predictor of
depressive symptoms, B = 0.03, indicating that the second criterion for mediation was not
satisfied. Next, the regression with serum vitamin D levels and depressive symptoms predicting
sleep quality was conducted. The regression of sleep quality on serum vitamin D levels and
depressive symptoms was significant, F(3, 121) = 26.56, p < .001 suggesting that serum vitamin
D levels and depressive symptoms accounted for a significant amount of variance in sleep
quality.
The individual predictors were examined further. The results showed that serum vitamin
D levels was a significant predictor of sleep quality when depressive symptoms was included in
the model, B = -0.15, indicating that the third criterion for mediation was satisfied. The results
showed that depressive symptoms was a significant predictor of sleep quality when serum
vitamin D levels was included in the model, B = 0.33, indicating that the fourth criterion for
mediation was not satisfied due to the assumption that the serum vitamin D should no longer be a
significant predictor of the sleep quality in the presence of the mediator variable of depressive
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symptoms. As a result, since item 2 and item 4 were not met, mediation cannot be supported.
Therefore, depressive symptoms is not a mediator between serum vitamin D levels and sleep
quality. Results of the mediation analysis are summarized in Table 33.
Table 33. Regression Results with Depressive Symptoms Mediating the Relationship Between
Sleep Quality and Serum Vitamin D Levels
Dependent
Regression 1:
Sleep quality

Serum vitamin D levels

-0.14

0.03

-4.01

< .001

Regression 2:
Depressive symptoms

Serum vitamin D levels

0.03

0.05

0.52

.605

Serum vitamin D levels
Depressive symptoms

-0.15
0.33

0.03
0.06

-4.76
5.73

< .001
< .001

Regression 3:
Sleep quality

Independent

B

SE

t

p

In conclusion, the pregnancy symptom total score was not significantly predicted by
vitamin D status. However, it was evident that sleep quality and physical quality of life was
significantly predicted by vitamin D status. Despite controlling for significant covariates, the
predictive power of vitamin D status for poorer sleep quality and physical quality of life
remained significant. Furthermore, the only ethnic differences found between African American
and Hispanic pregnant women were vitamin D, sleep quality, and depressive symptoms with a
trend toward significance in regards to physical quality of life. Finally, the exploratory aim
proved to be insignificant in regards to depressive symptoms mediating the relationship between
vitamin D and sleep quality. The major implications for the results will be discussed in the
following chapter.

CHAPTER FIVE
DISCUSSION
Vitamin D deficiency is highly prevalent in pregnant women and there is an exacerbated
risk in African American and Hispanic pregnant women (Ginde et al., 2010). Studies have
reported that symptoms such as poor sleep quality, depressive symptoms, musculoskeletal pain,
and urinary complaints have been associated with vitamin D deficiency in women who are not
pregnant as well as men (McCarty et al., 2013; Cassidy-Bushrow et al., 2012; Spedding, 2014;
Huang et al., 2013; Aydogmus et al., 2015). Because these same symptoms are commonly
reported during pregnancy (King et al., 2015; Nazik & Erilmaz, 2014), this study sought to
determine whether these symptoms were due to low vitamin D levels. In addition, since these
symptoms can impact quality of life and health outcomes, this was also examined. Currently
there is a gap in the literature investigating the relationship of low vitamin D levels and
symptoms experienced during pregnancy and its association with health and quality of life.
The Wilson & Cleary (1995) Health-Related Quality of Life framework which addresses
multiple factors and their interrelationships with quality of life was used to guide this study
(Figure 1). Thus, the findings from this study will be discussed relative to this model based on
the following areas: characteristics of the individual, biological factors, symptom status, health
behaviors, health perceptions, quality of life and characteristics of the environment.
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Characteristics of the Individual
Description of the Sample
The convenience sample of 125 pregnant women who participated in the study was
comprised of mostly African American (49.6%) and Hispanics (42.4%) The racial distribution
for the sample compared to data from the National Health and Nutrition Examination Survey
(NHANES) from 2001 to 2006. NHANES had a racial distribution of 16% non-Hispanic Black
and 20% of Hispanic pregnant women with the majority of pregnant women in the non-Hispanic
White category of 56% (Ginde et al., 2010). The discrepancy noted in the current study can be
explained by the fact that the recruitment site was a federally qualified health center (FQHC)
serving a predominantly Medicaid patient population. The average mean age of participants was
26.7 years with a range from 18 to 43 years of age, with a breakdown of 8% (n=10) 18-19 year
olds, 81.6% (n=102) 20-34 year olds, and 10.4% (n=13) 35-44 year olds. The age breakdown of
the sample was similar to that of the NHANES study examining pregnant women: 9% in the age
range of 13-19 years (the inclusion criteria for the current study was a minimum age of 18 years
old), 78% in the age range of 20-34, and 13% in the age range of 35-44. Therefore, the majority
of the participants were in the 20-34 years range which is consistent with the literature. Older
women are more prone to having more discomforts of pregnancy simply due to age and
increased likelihood of pregnancy complication, however women 35-44 years of age in the
current sample actually had lower pregnancy symptom total scores than their younger
counterparts which was not statistically significant (King et al., 2015; Zib et al., 1999;
Cunningham et al., 2014). Women who were aged 35-44 years reported fewer pregnancy
symptoms than the younger cohort and this was also not statistically significant.
In terms of education, 40% of participants had some college education. There was a
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fairly evenly split between those with lower vs higher levels of education level. There is
evidence that the higher the education level of the pregnant woman, the better the management
of pregnancy symptoms (Nazik & Erilmaz, 2014; Telleen, 1993).
In addition to education, 70% of the sample reported an income <$30,000 which reflects
a very low income. However, this level of income is consistent with that reported by FQHCs
and in the state of Illinois, 1,229,655 people were cared for by a FQHC (Kaiser Family
Foundation, 2015). It was also noted that women who were vitamin D deficient (< 20 ng/ml)
had significantly lower income when compared with those who were vitamin D sufficient (20
ng/ml) as reported in Table 1. Evidence exists that low-income women are faced with
significantly more adversity and stress related to their economic status which can negatively
impact health outcomes (Giurgescu et al., 2013; Alhusen, Gross, Hayat, Rose, & Sharps, 2012;
Hirst et al., 2016; Giscombe & Lobel, 2005).
Another important characteristic to recognize is marital status as it can be a reflection of
social support and paternal involvement (Rini et al., 2006; Dunkel-Schetter, Gurung, Lobel, &
Wadhwa; Abdou et al., 2010). Only 28% of the sample was married with no significant
difference between vitamin D groups, but there was a significant difference in marital status
based on ethnicity. In the entire sample of the 125 pregnancy women, only four African
American women were married compared to 26 Hispanic women and five women of other
ethnicities. One review article written by Dunkel-Schetter, Sagrestano, Feldman, and
Killingsworth (1996) noted that impact of spousal involvement or intimate partner involvement
had a greater predictive value on better maternal child health outcomes than family support.
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Another important component that was unique to the current study population was the
fact that almost half (46.4%) of the sample participated in Centering pregnancy group prenatal
group care model. One of the hallmarks of Centering pregnancy model is social interaction and
bonding that occurs between pregnant women who are of similar gestational age (Rising, 1998).
Some investigators have conjectured that the social support inherent in the model is one of the
reasons it has been shown to be effective in improving adverse birth outcomes for at risk
pregnant women specifically in low-income and low resource patient populations (Conde, 2010;
Andersson, Christensson, &Hildingsson, 2013; Rotundo, 2011). However, in the current sample
those who were in centering prenatal care did not have significantly higher social support scores
when compared with those who were in routine prenatal care. The mean MSPSS total score for
those in Centering was 5.84 (SD=1.6) and those in routine prenatal care was 5.81(SD=1.4).
Therefore, interestingly enough social support was not higher in patients in the Centering model,
but social supports were elevated in the sample as a whole.
Biological Factors
Vitamin D Status
Vitamin D deficiency in pregnant women is highly prevalent (Hollis & Wagner, 2013;
Hossein-Nezhad & Holick, 2012; Dawodu et al., 2013). An NHANES study of 928 pregnant
women showed that 80% of Non-Hispanic Black women had a vitamin D level < 20 ng/ml and
45% of Hispanic women had vitamin D levels < 20 ng/ml. In the current study, 74% of African
American women had vitamin D levels < 20 ng and 45% of Hispanic women had vitamin D
levels < 20 ng/ml. Therefore, the current data demonstrated comparable findings to the
NHANES report of vitamin D status in pregnant women. This finding is concerning as there is
epidemiologic evidence that insufficient levels of vitamin D have been associated with vitamin D
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deficiency in newborns which can lead to Rickett’s disease, small for gestational age, increased
asthma symptoms (Aghajafari et al., 2013; Hossain et al., 2014; Litonjua et al., 2014; Weiss &
Litonjua, 2016; ). Thus, the potential policy implications for vitamin D supplementation during
pregnancy are significant if future clinical trials of pregnant women yield positive outcomes
(Litonjua et al., 2016; Jelsma et al., 2013; Hollis & Wagner, 2017).
Dietary Vitamin D and Calcium Intake
Dietary intake of vitamin D and calcium is negligible in terms of raising a person’s serum
vitamin D level to a sufficient level (Hossein-Nezhad & Holick, 2013; Hollis & Wagner, 2013).
In order to raise serum vitamin D levels, an adequate dietary vitamin D supplement needs to be
taken in order to adequately raise serum vitamin D levels (Burris, Thomas, Zera, & McElrath,
2015; Dawodu et al., 2013; Wagner et al., 2013). A prenatal vitamin only has about 400-600 IU
of vitamin D which is not high enough to raise serum vitamin D levels if one is deficient as
evidenced in numerous randomized control trials (Wagner et al., 2013; Hollis et al., 2013;
Dawodu et al., 2013; Asemi et al., 2014). In the current study, 74.4%(n=93) of women were
taking daily prenatal vitamins and 58.4% of these women remained deficient (<20 ng/ml).
Hemoglobin Status
Iron deficiency anemia is common in pregnancy especially in the late second and early
third trimester due to some of the physiological changes of pregnancy (Cunningham et al., 2014;
King et al., 2015). Women in the current study had a mean hemoglobin of 11.2 g/dl which is
consistent with that observed during the late second and early third trimester (> 10.5 g/dl)
(Cunningham et al., 2014; King et al., 2015). Anemia in pregnancy is predominantly caused by
iron deficiency and is related to the increased maternal plasma volume and the increased iron
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needs of the fetus and pregnancy (Cunningham et al., 2014; King et al., 2015; Laflamme, 2011).
Based on the World Health Organization (WHO), the prevalence of iron deficiency diagnosed
(<10.5 g/dl) in developed countries is 18% (De Benois, McLean, Egli, & Cogswell, 2008;
daCosta, Vargas, Clode, & Graca, 2016). In the current sample, about 22.4 % of participants had
a hemoglobin level < 10.5 which is comparable to other studies (DeBenois et al., 2008; daCosta
et al., 2016).
It is important to recognize that women who were vitamin D deficient had lower levels of
hemoglobin (<10.5 g/dl) and hematocrit (< 32%). One potential mechanism that could explain
this difference is possible suppression of iron-regulatory hepcidin by vitamin D which has been
reported (Bacchetta et al., 2014). Hepcidin is an important biomarker for iron homeostasis
because it “suppresses membrane expression of ferroportin, which is the only known exporter of
intracellular iron” (Bacchetta et al., 2014, p.564). Although these researchers studied persons
with chronic kidney disease and not pregnant women, in vitro and in vivo models that showed
that cultured hepatocytes or monocytes when treated with 25-hdyroxyvitamin D (biological
available form of vitamin D), decreased hepcidin levels which in turn had positive effects on
hemoglobin status. Their sample of seven healthy volunteers received a single dose of vitamin
D2(100,000 IU of ergocalciferol) and hepcidin levels were measured twenty-four hours after
supplementation. They reported a 34% decrease in hepcidin levels, but no changes in serum iron
concentration, iron binding capacity or transferrin saturation (Bacchetta et al., 2014). However,
the findings were limited due to the small sample and the fact that they only measured
immediately post supplementation (24 and 72 hours) yet the half-life of hemoglobin is 50-55
days. Thus, since the supplementation results of the study were limited since hemoglobin has a
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half-life of 50-55 days. Thus, future trials are needed to assess if vitamin D supplementation
improves hemoglobin levels over time.
Hemoglobin A1C
Glucose metabolism as measured by hemoglobin A1C is not routinely measured as part
of the initial obstetric panel of pregnant patients but is often done when a woman has risk factors
for GDM (Laptook, Homko, & Biastre, 2013). The mean hemoglobin A1C in the current sample
was 5.2% and did not differ between vitamin D groups which is consistent with the literature
related to type 2 diabetes (Krul-Poel, Wee, Lips, & Simsek, 2017). A meta-analysis and
systematic review which included nineteen studies on the effect of vitamin D supplementation in
patients with type 2 diabetes mellitus, found no significant difference in hemoglobin A1C levels
between those that received vitamin D supplementation and those that did not (Krul-Poel et al.,
2017).
Symptom Status
Pregnancy Symptom Inventory
The Pregnancy symptom inventory (PSI) instrument is a clinical tool developed to assist
clinicians in screening their patients for common discomforts of pregnancy that could be
negatively impacting their activities of daily living (Foxcroft et al., 2013). The initial study used
the PSI on 211 pregnant women having routine midwifery appointments in Australia and
reported that the top four most often symptoms included: urinary frequency (85.2%), tiredness
(87%), poor sleep (62.5%) and back pain (60%) (Foxcroft et al., 2013). These findings were also
found in the current study: tiredness (84%), urinary frequency (81%), back pain (79%), and poor
sleep (72%), but at a much higher frequency for back pain and poor sleep. It is not by
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coincidence that the incidence of poor sleep and back pain was higher in the current study since
these symptoms are associated with vitamin D deficiency and the original study did not report on
the demographics of their study population, thus the ethnicity or race of the sample was
unknown. In addition, the mean gestational age range the women in their study was 12-42 week
which was much larger than the current study.
Therefore, consistent with the literature that vitamin D deficiency is associated with
musculoskeletal pain and poor sleep in the non-pregnant population, it was also found in the
current study with pregnant women (Wu et al., 2016; McCarty et al., 2013). It is plausible that
vitamin D status be an important predictor for the presence of more severe musculoskeletal pain
and poor sleep in pregnancy, however further research and investigations is needed.
At the time of the collection of data for this study, there was no Spanish version of the
PSI. Consequently, as previously reported, this investigator had the tool translated
professionally. Most recently, the psychometrics of the Spanish version of the PSI tool were
reported in a sample of 120 healthy pregnant women in Spain (Oviedo-Caro, Bueno-Antequera,
& Munguia-Izuierdo, 2016). In that sample, the following symptoms were reported to be
problematic: urinary frequency (88.4%), tiredness (73.5%), poor sleep (69%) and increased
vaginal discharge (64%). Although the age of women in that study were older than the current
study population (72.8% were 31 to 44 years of age), the symptoms are comparable to the
current study with a few exceptions (Oviedo-Caro et al., 2016). Vaginal discharge was reported
highly (64.1%) in the Spanish cohort study (Oviedo-Caro et al., 2016), but was not commonly
reported in the current total sample (35%) or even with the Hispanic population (39.6%). The
Hispanic participants in the current study had most commonly reported tiredness (71.6%),
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urinary frequency (69.8%), back pain (54.7%), and poor sleep (52.8%) and at lower frequencies
than the Spanish cohort which could be reflective of the older population that was in the study.
Although no psychometrics were reported for the initial study on the PSI (Foxcraft et al.,
2013), acceptable weighted Kappa coefficients ranged from 0.589 to 0.889 are now reported on
the Spanish version of the PSI tool (McHugh, 2012). According to measurement theory a weight
Kappa coefficient of 0.41 to 0.60 is considered moderate and 0.60 to 0.80 is considered
substantial interrater reliability. For clinical and healthcare studies substantial or above should
be acceptable (McHugh, 2012). Another measure of interrater reliability, the test-retest
reliability (82% to 96%), was also reported by these authors and > 80% test-retest reliability is
generally considered acceptable (Oviedo-Caro et al., 2016; McHugh, 2012). The principal
investigator for the current study spoke with Oviedo-Caro, the PI for the Spanish PSI
psychometric paper and compared translations. These translations were almost identical aside
from one or two symptoms which reflected regional differences (Oviedo-Caro, personal
communication, September 29, 2016). For this study, the English and Spanish instrument
demonstrated reliability that was Cronbach alpha of .893 for the English tool and .921 for the
Spanish tool, both of which are acceptable (DeVillis, 2011).
The PSI provided valuable information about the frequency and type of the symptoms
pregnant women reported. Total scores on the PSI were not significantly different between
vitamin D status, however, the limitations imposed by some symptoms were significantly
different with women who were vitamin D deficient reporting more limitations imposed by the
following symptoms: tiredness, poor sleep, back pain, and pelvic and hip pain when compared to
those who were sufficient. Since there has been no literature to examine the limitations impacted
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by pregnancy symptoms this study was able to add this unique information to the symptoms
reported by diverse women who are pregnant.
Depressive Symptoms
Depression is a highly prevalent, both in the antenatal period (9 to 20%) and postpartum
period (19.2%) which has devastating consequences to the mother as well as to the family
(Garfield, Matthews, & Janusek, 2015; Byrn & Penckofer, 2015; Melville et al., 2010; Gavin,
Gaynes, Lohr, Meltzer-Brody, Gartlehner, & Swinson, 2005). More recently, depression is
being studied during the antenatal period in order to prevent pregnancy complications such as
preterm delivery and poor maternal attachment with negative sequelae on infants as well as
depression development in the postpartum period (Davalos, Yadon, & Tregellas, 2012;
Giurgescu et al., 2015; Plant et al., 2013). Although depressive symptoms have been associated
with lower vitamin D in numerous studies in nonpregnant populations (Spedding, 2014, Anglin
et al., 2013), its study in women during the antenatal and postnatal period is limited. The
evidence of vitamin D deficiency and perinatal depression has been strong with multiple
observational studies and epidemiologic studies showing an inverse relationship between vitamin
D and depressive symptoms (Cassidy-Bushrow et al., 2012; Huang et al., 2014, Brandenburg et
al., 2012; Robinson et al., 2014; Bobbitt et al., 2015).
For this study, depressive symptoms was measured by the EPDS. Results showed that
the scores for this sample were unexpectedly low for an underserved, low socioeconomic status
patient population. The mean EPDS score was 3.9 (range of scores = 0 to 19). The total
potential range for this tool is 0 to 30. This finding is somewhat consistent with another study in
the same region that examined pregnant women. Byrn and Penckofer (2015) studied depression

118
in pregnant women with 48% of the sample who had GDM and 52% who did not have GDM.
The mean EPSD for the women in that study was 6.26 with no differences between groups,
however, a history of depression was associated with higher EPDS scores for women who had
GDM. In the current study, the EPDS scores were lower but presence of GDM was less
(13.6%). In addition, in the Byrn and Penckofer (2015) study, 15% of the sample had a history
of depression whereas only 12% had a history of depression in this study sample. Thus, the
current study has some comparable findings to previous patients from the same geographic
region.
Another study used a convenience sample of African American pregnant women (n=166)
at 24-28 weeks gestation and assessed for depressive symptoms with EPDS as well as social
support (Alheusen et al., 2012). That study reported clinically significant depressive symptoms
(EPDS> 12) in more than half of their women (59%; n=98). A significantly higher incidence of
depressive symptoms accompanied by lower social support scores (Alheusen et al., 2012) were
reported as compared to the current study. Potential reasons for differences may have included
the following: women in the current study reported good social support and spirituality and only
12.8% of the sample of the current study had an income > $40,000. Both of these previous
studies although important, did not address vitamin D status and its potential role in depression
during pregnancy.
In terms of studies that have examined depression during pregnancy and vitamin D status,
one such study used the Center for Epidemiologic studies (CES-D) to measure depressive
symptoms (Cassidy-Bushrow et al., 2012). In this study, African American pregnant women
(n=178) of low socioeconomic status and had a mean Center for Epidemiologic Studies
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Depression (CES-D) score of 15.2 (score of ≥ 16 is considered depression). This study also
included pregnant women with comorbidities such as pre-gestational diabetes and hypertension
which may have contributed to their depressive symptoms. In addition, the mean vitamin D was
13.4 ng/ml for this sample which may have been contributory, yet the vitamin D level for the
current study was comparable at 17.02 ng/ml in African American pregnant women. Another
study has shown that vitamin D was not associated with postpartum depressive symptoms in 605
women with postpartum depression when compared with 875 postpartum women without
postpartum depression (Nielsen et al., 2013).
Another recently published study from Iran, conducted a randomized control trial that
had 78 pregnant women in the treatment group of 2000 IU daily of vitamin D supplementation
starting at 26-28 weeks gestation and 75 pregnant women in the placebo group (Vaziri et al.,
2016). The baseline EPDS scores for both groups was not significantly different nor were their
vitamin D levels, with a mean vitamin D level of 12.35 ng/ml at baseline for the entire sample.
The results of the study reflected a significant decrease of depressive symptoms at 38–40 weeks
gestation (p=.01) and at 4 and 8 weeks after birth (p<.001) in the vitamin D supplementation
group (Vaziri et al., 2016). To date, this is the only vitamin D supplementation trial in regards to
perinatal depression.
Overall in the current study, depression did not differ between women who were
sufficient and those who were insufficient. However, given that the women in the study were
primarily not depressed, it would be challenging to find statistical significance. In addition, in
the current study, the EPDS is used routinely as part of their pregnancy care (screened once
every trimester by registered nurse and again by health support workers at home visits) and it is

120
possible that the women are sensitized to the measure perhaps contributing to the lack of
depression reported. Finally, although the EPDS was higher for those with a history of
depression (M=8.94) compared to those who did not (M=3.05) in the current study, there were
no differences in vitamin D levels between these groups probably due to the lack depression
severity even in those with a history of depression.
Sleep Quality
Sleep is a significant problem during pregnancy with reports insomnia rates in the third
trimester of pregnancy as high as 60% (Sivertsen, Hysin, Dorheim, & Eberhard-Gran, 2015).
Sleep issues have been reported to get worse as the pregnancy progresses due to normal
physiological changes of pregnancy including an increasing size of the uterus, decreased
respiratory capacity in a supine position, and increased incidence of nocturia and urinary
frequency (King et al., 2015; Schuiling & Likis, 2015). A recent study of 2,427 pregnant women
examined sleep quality across all months of pregnancy and reported that 100% of them had sleep
disturbances (Mindell, Cook, & Nikolovski, 2014). Sleep disturbances during pregnancy have
been reported to significantly impact the health and quality of life of the mother and contribute to
poor birth outcomes (Volkovich, Tikotzky, & Manber, 2015; Okun et al., 2010; Chang, Pien,
Duntley, & Macones, 2009; Skouteris et al., 2009; Tomfohr et al., 2015). For the current study,
the Pittsburgh Sleep Quality Index (PSQI) was used to measure sleep quality. The mean global
score for the sample was 6.3 with a score of ≤ 5 denoting good sleep quality. Therefore, sleep
quality was poor in this study sample. Notably, there was a statistically significantly difference
in sleep quality between vitamin D groups (t(122) = 3.68, p < .001). Those who were vitamin D
deficient had significantly worse sleep quality (PSQI global score, mean = 7.28) compared to
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those who had sufficient vitamin D levels (PSQI global score, mean = 5.1).
Several studies have reported that vitamin D may impact sleep quality in those who are
not pregnant. A cross-sectional study in Turkey that evaluated a cohort of men and women but
predominantly women in their sample (n=102) assessed vitamin D status and its association with
sleep quality (PSQI) and restless leg syndrome (International Restless Leg Syndrome Study
Group (IRLSSG) symptom scale), which is commonly considered a sleep disordered condition
(Cakir et al., 2015). Their study resulted in a significant difference in PSQI global scores and
restless leg syndrome scores between vitamin D groups based on IOM guidelines (20 ng/ml
being sufficient, <20 ng/ml being deficient) (Cakir et al., 2015). Therefore those that were in the
vitamin D deficient group had higher PSQI and restless leg syndrome symptoms when compared
with those in the vitamin D sufficient group.
In addition, McCarty et al.(2013) indicated that those individuals being evaluated for a
sleep disorder who had a deficient vitamin D levels (n=153) were more likely to be diagnosed
with a sleep disorder and also had greater complaints of nonspecific musculoskeletal pain. Their
study also showed that African American participants were 50 times higher than White/Hispanic
participants to be vitamin D deficient (McCarty et al., 2013).
The PSQI has several components (sleep duration, habitual sleep efficiency, use of
sleeping medication, and daytime dysfunction). Differences were found according to vitamin D
status. In the current study, those who were vitamin D deficient reported a mean 6.7 hours of
sleep at night as compared to those with vitamin D sufficiency who reported 7.6 hours of
nighttime sleep. This finding is consistent with a study of vitamin D deficient elderly Korean
people who reported shorter sleep duration ( 4 hours of sleep duration) than those who were
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vitamin D sufficient despite controlling for significant covariates (Kim et al., 2014). Another
study that corroborated the relationship between vitamin D deficiency and shorter sleep duration
was conducted on a predominantly Caucasian population (n=3048) assessing wrist actigraphy
and total sleep time, sleep efficiency, and wake time after sleep onset based on vitamin D status
(Massa et al., 2015). Their results indicated that vitamin D deficient group had higher odds of
short sleep duration (< 5 hours) (OR 2.15; 95% CI 1.21–3.79) (Massa et al., 2015).
In contrast, a study of pregnant women at 36 weeks gestation (n= 92) resulted in no
difference in PSQI global scores between vitamin D groups with sufficient being  20 ng/ml and
deficient being < 20 ng/ml (Gunduz et al., 2015). The mean PSQI global scores were similar to
the current study (vitamin D deficient group mean PSQI score = 6.5 and the sufficient group
mean PSQI score = 5.8) (Gunduz et al., 2015). The difference in component 1 (subjective sleep
quality) and component 3 (sleep duration) approached significance (p =.08 and p = .09
respectively) between vitamin D groups (Gunduz et al., 2015).
There were items on the PSQI that validated the PSI symptoms, primarily in those related
to urinary issues. Sleep disturbances which are common in pregnancy especially with increasing
gestational age and nocturia due to physiological nature of the uterus growing and less room for
the bladder to expand. This leads to “getting up in the middle of the night” (item 5 b of PSQI)
and “have to get up to use the bathroom” (item5c of PSQI) (King et al., 2015). Another common
sleep disturbance universal to pregnant women is “feeling hot” (item 5g of PSQI) and that is
related to the changes in pregnancy hormones and increased body mass in pregnancy (King et
al., 2015).
In terms of sleeping medication use, the current study found that vitamin D deficient
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pregnant women were more likely to need to use some sort of sleep medication on average once
a week whereas those who were vitamin D sufficient had a mean < 1, which on average meant
they did not need sleeping medication in the past month. One randomized placebo controlled
clinical trial examined Persian women (n=54) at 26 to 30 weeks gestation, seeking treatment for
sleep disturbance at a psychiatric outpatient clinic (Khazaie, Ghadami, Knight, Emamian, &
Tahmasian, 2013). Pregnant women in the treatment group received Diphenhydramine HCl or
Trazadone for insomnia versus the placebo group. Objective sleep measures using wrist
actigraphy and depressive symptom scores using the EPDS were measured. The treatment group
for insomnia had significantly lower depressive scores after 2 weeks (p= .037) and 6 weeks of
treatment (p <.0001) (Khazaie et al., 2013). This study was significant in that it showed that
improvement of sleep in third trimester resulted in improved depressive symptoms which further
supports the connection between poor sleep quality and depression.
Overall, sleep is a major health issue for pregnant women and poor sleep quality can have
deleterious effects on the pregnancy and postpartum (Siverstsen et al., 2015; Tham et al., 2016).
In this study, women had overall poor sleep quality which could be reflective of the third
trimester of pregnancy but there was a significant difference in impact of poor sleep quality
based on vitamin D groups. Those who were vitamin D deficient had significantly poorer sleep
quality scores which provides further evidence that vitamin D status may indeed exacerbate poor
sleep quality already prevalent in third trimester of pregnancy.

124
Functional Status
Health-Promoting Lifestyle
Practicing healthy behaviors during pregnancy enhances the pregnancy experience (King
et al., 2015) and also improves health outcomes related to weight gain throughout and after
pregnancy (Faucher & Barger, 2015). For the current study, health-promoting behaviors were
measured by the Health-promoting Lifestyle Profile v.2 which has six subscales including:
physical activity, nutrition, health responsibility, interpersonal relations, spiritual growth, stress
management. The mean score of the global HPLP score for the entire sample was 2.59 (SD=0.4)
which equates to practicing healthy behaviors “sometimes to often”. Another study utilized the
HPLP tool in assessing healthy behaviors of Mexican American (n=56) and African American
(n=52) pregnant women. They reported a mean score of 2.7(SD=0.4) for African American
women and 2.3(SD=0.3) for Mexican American women (Esperat et al., 2007) which were similar
to the current study. One distinct difference was that some of the Hispanic women were US
immigrants and not all were English speaking in the current study in contrast to the Esperat et al.
(2007) sample. In the current study, the mean for patients who completed the Spanish version
of the HPLP was 2.32 (SD=.26) as compared to 2.64 (SD=.44) for those who completed the
English version. This difference was statistically significant based on an independent samples ttest (p = .002). Overall, the current study sample practiced healthy behaviors sometimes to often
in their pregnancy which could provide some insight into why the sample had such low
depressive symptom scores and good birth outcomes.
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General Health Perceptions
Health of Pregnancy and Fetus
These were items that were created by the investigator and have not been used in the
literature. Thus, there may be limitations in these measures since validity and reliability were
not previously established. However, for women who were vitamin D deficient, 21% had rated
their health perception of their pregnancy as “excellent” and 28% rated it as “very good” when
compared with only 9.1% of vitamin D sufficient women who rated their pregnancy health as
“excellent” and 40.4% rated the health of their pregnancy as “very good”. Overall, there could
be an inherent optimism in pregnancy and perceptions of health influenced by their spirituality or
by their social support or receiving quality prenatal care resulting in a positive pregnancy
experience. Research indicates that those who have a poor health perception have poorer health
outcomes, therefore since these participants had such positive health perceptions of their
pregnancy, it is reflected in lower depressive scores and overall good birth outcomes (Maruish,
2012).
Quality of Life
Promoting good quality of life during pregnancy is important to ensure the health of the
mother and the unborn child. For this study, quality of life was assessed using the SF-12. In the
current study the mean physical quality of life score was 45.2 (SD= 7.5). Previous scores
reported scores in the range of 40.51 to 52.7 in pregnant women (Lau, 2012; Ramirez-Velez,
2011; Couto et al., 2009; Nicholson, Setse, Hill-Briggs, Cooper, Strobino, & Powe, 2006). The
most significant factors negatively impacting quality of life were physical back pain (76.7% of
the sample reported this symptom) and hip/pelvic pain (71.9% of the sample reported this

126
symptom). Differences in limitation on activities of daily living between vitamin D groups were
significant. Those who were vitamin D deficient had more limitation with back pain [t(97) =
3.13, p = .002], and hip/pelvic pain [t(80) = 2.10, p = .039]. Consistent with literature in nonpregnant women in regards to increased bodily pain, vitamin D deficient pregnant women had a
mean 45.1 score for bodily pain and 50.3 score for women in the vitamin D sufficient group
(Maruish, 2012). However, in a sample of white pregnant women (n=125), quality of life was
measured every three weeks throughout the pregnancy starting at 4-6 weeks gestation and
physical quality of life subscales plateaued in the third trimester with significantly higher
subscale scores at 29 weeks gestation of physical limitation (60), role limitation for physical
(65), and bodily pain (52) (Hueston & Kasik-Miller, 1998). The previous study is not
comparable to the current study since it examined a predominantly White patient population,
80% of sample was married or in stable relationship, and 61% of sample was employed outside
of the home, however it does provide insight that physical quality of life could be impacted by
race, social support and income.
In direct contrast to the current study, another study examined an Australian pregnant
patient population (n=363) using the SF-12 at 36 weeks gestation, 6 weeks postpartum and 12
weeks postpartum (Emmanuel & Sun, 2014). The sample was predominantly Caucasian
pregnant women (n=292; 80.4%) and 88.2% of the sample was with their partner during
pregnancy. The mean physical health score was 55.13(SD=22.45), bodily pain was
68.53(SD=23.63), role physical was 55.8(SD=22.67), therefore these scores are significantly
better than those found in the current study (Emmanuel & Sun, 2014). In addition, the mental
health subscale scores were also significantly higher ranging from 70.25 to 79.28. This is
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significant, because despite not measuring vitamin D status in the study, it can be assumed that
since a majority of the sample was Caucasian, that their vitamin D levels probably were not as
deficient as those found in African American pregnant women.
Supporting these findings in the significant in the current sample, was the correlation
between physical component scores and pregnancy symptom total score (r = -0.31, p < .001)
indicating that higher PSI total scores were associated with poorer physical health. A metaanalysis recently published investigating the impact that vitamin D supplementation had on
generalized pain showed a significantly greater mean decrease in pain in those who were
supplemented than those who were in the placebo group (Wu et al., 2016). Wu et al. (2016)
examined 19 randomized controlled trials and patient populations varied from healthy
individuals with complaints of pain to those with rheumatoid arthritis, fibromyalgia, etc.
Therefore the studies included were fairly heterogeneous with use of varying doses of vitamin D
supplementation also. Thus, the potential for vitamin D supplementation to alleviate back and/or
hip pain are worthy of future study considering the impact on their physical quality of life.
In terms of mental well-being, the women in the current study reported a mean score of
52.0 (SD= 8.6) with previous scores reported as 40.51 to 52.7 in pregnant women (Lau, 2012;
Ramirez-Velez, 2011; Couto et al., 2009; Nicholson, Setse, Hill-Briggs, Cooper, Strobino, &
Powe, 2006). There was a significant correlation between mental component score and
pregnancy symptom total score (r=0.32, p <.001) indicating that more symptoms were also
associated with worse mental health. The mental health scores were better than physical health
scores in the current study and in other reported studies (Lau, 2012; Ramirez-Velez, 2011; Couto
et al., 2009; Nicholson, Setse, Hill-Briggs, Cooper, Strobino, & Powe, 2006; Hueston & Kasik-
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Miller, 1998). The reason for these findings may be due to the unusually high social support and
spirituality scores of the current study population. Research has shown that increased social
support and higher levels of spirituality have a protective effect on psychological distress in
pregnancy (Mann et al., 2010; Giurgescu et al., 2015; Feldman et al., 2010; Rini et al., 2006).
Characteristics of the Environment
Spirituality
Spirituality and religiosity has been shown in the literature to have a positive effect on
health outcomes both in pregnant and non-pregnant women (Koenig, 2012; Mann et al., 2010;
Mann et al., 2008; Cheadle et al., 2015). The current study population had elevated levels of
spirituality as measured by the Spiritual Perspectives Scale. The mean score of the SPS in this
sample was 4.7, with a max score of 6.0. The scores for the study sample were similar to other
studies (3.64 for those without religious affiliation and 4.57 for those with a religious affiliation)
that utilized a similar patient population and used the same measurement tool (Dailey & Stewart,
2006).
The current study was limited in that participants were not asked if they had a religious
affiliation but due to the higher SPS scores, the assumption can be made that many of the
participants did have a religious affiliation especially since the recruitment site was a faith based
clinic. Therefore, higher levels of spirituality among the study participants could be one of the
explanations for lower depressive symptom scores. This explanation is supported by a recent
study of low income African American new mothers (n=702) that found that higher levels of
spirituality and religiosity predicted lower levels of depressive symptoms (Cheadle et al., 2015).
It is important to recognize that spirituality and religiosity is potentially an important social
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support system for pregnant women which can contribute to better health outcomes and lower
depressive and anxiety symptoms (Mann et al., 2010).
Social Support
Poor social support has been widely recognized as a risk factor for perinatal mood
disorders, adverse birth outcomes and potentially influential factor with coping in pregnant
women who have minimal amount of resources (Giurgescu et al., 2015; Rini et al., 2006;
McKee, Cunningham, Jankowski, & Zayas, 2001; Collins, Dunkel-Schetter, Lobel, &
Scrimshaw, 1993). In the current study, social support was relatively high with a mean MSPSS
score of 5.8, with 7 being the highest score of social support. More importantly, significant other
subscale for the study population was even higher with a mean score of 6.1. The increased
perceived social support in the current population could potentially account for the unusually low
depressive symptom scores observed in this study. There has been evidence to support these
findings. Feldman et al. (2000) studied low income African American and Latina women with
singleton pregnancy in the first trimester (n=247), which showed that that prenatal social support
significantly predicted higher birth weight infants adjusted for gestational age.
Discussion of Study Aims
Aim 1
To determine if there was a relationship between vitamin D status, pregnancy symptoms
including depression and sleep disruption, health-promoting behaviors, and quality of life.
The primary aim for the current study was to examine whether vitamin D status was a
significant predictor for pregnancy total score, sleep quality, health-promoting behaviors and
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quality of life. In using a logistic regression model, the univariate analysis with vitamin D as a
binary variable, only sleep quality and physical quality of life was predicted by vitamin D status.
Therefore, pregnancy symptom total score, depressive symptoms, health-promoting behaviors
and mental quality of life were not significantly predicted by vitamin D status.
In regards to the current literature, there is no evidence of other studies that have
examined pregnancy symptom total score and vitamin D status. Therefore, the current study is
the first to use the PSI tool as a total score and as described earlier in the chapter, it is not
surprising that it was not significantly predicted by vitamin D. The tool identifies many
symptoms that currently do not have evidence regarding their association with vitamin D status.
Specific measures of the symptoms previously discussed in chapter 2 such as depression,
musculoskeletal pain, fatigue, and pelvic floor disorders have confirmed that it is predicted by
vitamin D status. Thus, a global tool like the PSI may not have been the best measure to capture
pregnancy symptoms.
The insignificant findings for vitamin D status predicting depressive symptom score was
also not surprising considering the low EPDS scores (i.e. 32% of the sample scoring a zero).
Most likely there were not enough people who had depressive symptoms to be able to see any
effect of vitamin D status. In other studies, almost a third of the participants had elevated
depressive symptom scores which showed a positive predictive factor for vitamin D in pregnant
women. For example, Cassidy-Bushrow et al. (2012) had 41.6%, Brandenbarg et al. (2012) had
28% whereas in the current study, only 6.4% (n=8) had elevated EPDS scores as measured by a
score > 12. Even one study that included predominantly Non-Hispanic white, married women
with college or graduate degree pregnant women, had a 12.6% incidence of elevated depressive
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symptom scores demonstrated a very modest association with lower vitamin D levels and
depressive symptoms (Huang et al., 2014). The variation in results could also be due to different
instruments being used for assessment of depressive symptoms with Cassidy-Bushrow et al.
(2012) using CES-D, Brandenbarg et al. (2012) using CES-D, and Huang et al. (2014) using the
Patient Health Questionnaire-9 (PHQ-9).
There is no evidence in the literature about healthy behaviors and vitamin D status in
pregnant women, but there are some studies examining other patient populations. In a study
examining determinants for vitamin D status among children, a representative sample of 2686
children from 10-11 years of age were surveyed (Munasinghe, Willows, Yuan, & Veugelers,
2015). Healthy behaviors were measured by a physical activity instrument and nutrition by food
frequency questionnaire. It was found that adolescents who participated in higher levels of
physical activity and whose parents completed college were more likely to take vitamin D
supplements, which is interesting to note though the current study did not include pregnant
women < 18 years of age (Munasinghe et al., 2015). Other studies have examined physical
activity alone as a healthy behavior and have shown an association of low vitamin D among
those who practice low levels of physical activity (Brock et al., 2010; Man et al., 2015).
However, healthy behaviors were not predicted by vitamin D status in the current study
and more specifically physical activity was not different between vitamin D groups. There is an
assumption that if someone at risk for vitamin D deficiency is taking a vitamin D supplement,
they are also practicing other healthy behaviors related to nutrition, health responsibility and
stress management. However that was not evident in the current study.
Lastly, it is not surprising that mental quality of life was not predicted by vitamin D
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status because both vitamin D groups had above average mental quality of life scores with
vitamin D sufficient group with a mean of 51.5 and the vitamin D deficient group with a mean of
52.4. However, in contrast, physical quality of life was significantly predicted by vitamin D
status. Based on the logistic regression that controlled for pre-pregnancy BMI, EPDS depression
score, sleep quality score, general health perceptions on pregnancy, and pregnancy symptom
total score, vitamin D status was still a significant predictor. There are no other studies that have
examined quality of life with vitamin D status as the predictor in pregnant women. This will
provide further evidence to explore this association and whether vitamin D supplementation can
improve physical quality of life in pregnant women particularly those at risk for vitamin D
deficiency.
The evidence between vitamin D status and sleep quality has been inconsistent with a
majority of articles indicating an association between vitamin D deficiency and poor sleep
quality but several lacking an association. One study reported no association between vitamin D
groups using  20 ng/ml as sufficient and < 20 ng/ml as deficient and sleep (PSQI) in pregnant
women (n= 92) who were about 36 weeks gestation (Gunduz et al., 2015). As noted in Appendix
E, many studies have indicated a positive association with vitamin D deficiency and poor sleep
quality but did not study pregnant women. Since poor sleep quality is associated with increased
incidence of depression (antenatal and postpartum) and anxiety and adverse birth outcomes, it is
essential that research continue to explore these important relationships.
One study examined a group of pregnant women with a history of adverse pregnancy
outcomes (n=120) compared to a control group of pregnant women with no history of adverse
pregnancy outcomes (n=120). They were screened for depression and anxiety (with Hospital
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Anxiety and Depression Scale (HADS) and quality of life (SF-36) (Couto et al., 2010). Their
study indicated that women with a history of adverse pregnancy outcomes had significantly
higher depression and anxiety scores and poorer physical and mental quality of life (Couto et al.,
2010). Their sample included a predominantly White patient population (70% control group to
73% previous adverse pregnancy outcome group) and married (75 control group to 88% previous
adverse pregnancy outcome group). Therefore, the previous population is different from the
current study population. However, it is important to note because if these depressive and
anxiety symptoms and poor quality of life are being seen in a White, upper socioeconomic,
married patient population, then it is possible to see these trends in exacerbated in an African
American, low socioeconomic patient population that already has a higher incidence of adverse
pregnancy outcomes (Bodnar et al., 2010).
Aim 2
To determine if differences existed in pregnancy symptoms, sleep quality, depressive
symptoms, health-promoting behaviors and quality of life between African American and
Hispanic women.
The ethnic differences in vitamin D status and sleep quality found between African
American and Hispanic pregnant women was expected since there is already great deal of
literature showing African American women are more likely to be vitamin D deficient (Ginde et
al., 2011; Hossein-Nezhad, & Holick, 2013). However, no studies have investigated ethnic
differences in sleep quality specifically between African American and Hispanic pregnant
women. However, the current study showed there was an ethnic difference in sleep quality
between African American and Hispanic pregnant women, in that African American women has
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significantly worse sleep quality (mean PSQI global score = 7.34) when compared to Hispanic
pregnant women (mean PSQI global score = 5.33). Consequently, since vitamin D deficiency
has been correlated with poor sleep quality, it is not surprising that there was an ethnic difference
in sleep quality as well since African American women had significantly lower vitamin D levels
(mean = 17.02 ng/ml) when compared with Hispanic women (mean 21.13 ng/ml).
The ethnic difference in depressive symptoms found in the current study is inconsistent
with the literature. Blackmore, Groth, Chen, Gilchrist, O’Connor, & Moynihan, (2014)
examined the differences in depressive symptoms and proinflammatory cytokines in African
American pregnant women compared to non-African American pregnant women. Their study
indicated that African American pregnant women were not significantly more likely to have
higher EPDS scores than non-African American pregnant women, but they were more likely to
have higher levels of interleukin-6 (IL-6) across all four time points of 18 weeks gestation, 32
weeks gestation, 6 weeks postpartum and 6 months postpartum. However, this previous study
did not compare African American pregnant women specifically with Hispanic women, as the
comparison group, was classified as “non-African American”. There is increasing evidence that
increased inflammatory profiles can be correlated with increased depressive symptoms (Almond,
2013), however interestingly in the Blackmore et al. (2014) study, this was not found to be the
case. Another study found African American pregnant women (n= 152) to have more depressive
symptoms (mean CES-D = 16.9) with higher incidence of preterm birth and low birth weight
babies as compared to White pregnant women (n= 200) with less depressive symptoms (mean
CES-D = 9.9) (Mustillo, Krieger, Gunderson, Signey, McCreath, & Kiefe, 2004).
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Contrary to the current study, health-promoting behaviors have been reported to be
significantly different between African American (n=50) and Mexican American pregnant
women (n=56) (Esperat et al., 2007). Mexican American pregnant women had lower HPLP total
scores with a mean 2.3 (SD=0.3). However, the current study grouped Hispanic women together
with immigrant women and did not distinguish those who were Hispanic but American born.
Therefore, results from the current study and Esperat et al. (2007) were not be comparable since
immigrant Hispanic women may have different health-promoting behaviors than Mexian
American pregnant women.
Ethnic differences in quality of life between African American and Hispanic women was
not found in the current study. However, one study showed that African American pregnant
women (n=66) had poorer physical and mental quality of when compared with White women
(n=66) and those of other ethnicities (n=21) (Nicholson et al., 2006). Their study also showed
that women who had depressive symptoms as measured by CES-D  16 had significantly poorer
physical quality of life scores with subscale of role functioning physical dropping to 32 when
compared to pregnant women without depressive symptomology who had a role functioning
physical score of 62 (Nicholson et al., 2006).
Exploratory Aim
Do depressive symptoms mediate the relationship between vitamin D levels and sleep
quality? It was expected that depressive symptoms would not be a successful mediator of the
relationship between vitamin D levels and sleep quality since there was a low incidence of high
depressive symptom scores. The second criterion for mediation is that the independent variable,
in the current study was vitamin D levels would significantly predict the mediator, which was
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depressive symptoms. Based on univariate analyses as part of aim 1, it was already known that
vitamin D status was not a significant predictor of depressive symptoms. However, it would be
interesting to examine if sleep quality mediates the relationship between vitamin D levels and
physical quality of life which can be examined further in a future study.
Study Strengths and Limitations
There were many strengths to the current study which included a large sample size,
collection of self-report questionnaires with minimal missing data, reliable vitamin D serum
levels on all participants, and strong reliability on instruments. Due to the consistency of data
collection performed by the same person, the protocol was accurately followed and
questionnaires were reviewed with patients prior to providing the stipend in order to get
clarifications if items were missing. In addition, participants were very willing to enroll and
were invested in the study which could be due to their provider encouraging them to participate,
the investigator’s explanation of the importance of the study, and/or recruitment site staff being
invested in recruitment. However, interested participants could potentially introduce bias
(Trochim & Donnelly, 2007).
There were some limitations to the current study. First, this was a cross-sectional study
with only one time point of measurement. Therefore only correlations could be conducted.
Thus, if the study had multiple time points throughout the pregnancy to show trends and verify
relationships of vitamin D status with sleep quality and physical quality of life, it would have
been a stronger design. However, due to the exploratory nature of the research question and
limitations related to funding and time, only a cross-sectional study could be accomplished. The
results of the study do provide significant evidence for further investigation. A pilot study to
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examine if vitamin D supplementation improves sleep quality and physical quality of life would
be a next logical step.
In addition, as mentioned above, only symptoms reflected in the literature to be
correlated with vitamin D deficiency should have been assessed. Because the PSI tool had a
large variation of symptoms that do not relate to vitamin D status in any meaningful way, it
potentially diminished the strength of the symptoms that were significantly related to vitamin D
status. Therefore, in a future study, symptoms common in pregnancy based on the current
evidence that are correlated to vitamin D deficiency should be included.
Another important variable in the characteristics of environment related to depressive
symptoms and adverse pregnancy outcomes is exposure to racism and neighborhood disorder
(Giurgescu, McFarlin, Loma, Craddock, & Albrecht, 2011; Giurgescu et al., 2015; SealyJefferson et al., 2015; Dominguez, Dunkel-Schetter, Glynn, Hobel, & Sandman, 2008) was not
assessed in this study. The role of exposure to racism is still not well understood, but in one
study, 72 African American postpartum women (24-72 hours after birth) were evaluated for
psychological distress, neighborhood quality/environment, and perceived racial discrimination
(Giurgescu et al., 2012). This study found that pregnant women who had higher levels of
perceived racial discrimination had higher psychological distress and those with objective
physical disorder had higher risk for preterm birth (Giurgescu et al., 2012). These characteristics
of the environment were not measured in the current study and could have provided significant
insight into understanding relationships found between vitamin D status and sleep quality and
quality of life.
It has been reported that racism has the potential to cause on a systemic inflammatory
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response (Giurgescu et al., 2016). One study found that among 96 African American pregnant
women measured during their second trimester of pregnancy, racial discrimination was
associated with higher cytokine levels (interleukin-4 and interleukin-6) even after controlling for
covariates. Vitamin D does play a role in inflammation as it has anti-inflammatory effects
(Wagner et al., 2012). Therefore, another limitation of the current study is that other physiologic
markers other than vitamin D and hemoglobin were not measured in the study due to cost.
Collection of the inflammatory markers could provide an interesting biological link between
vitamin D and symptoms as other studies have reported these findings (Accortt et al., 2017;
Garfield, Matthews, & Janusek, 2016).
Another important factor as it relates to neighborhood disorder, is the fact that if women
are living in a neighborhood with high crimes rates and violence, they will most likely not be
spending significant amounts of time outside being exposed to sunshine. However, exposure to
sunlight for African American women has not typically been a significant predictor of vitamin D
status (Freedman et al., 2013; Hossein-Nezhad & Holick, 2013) and therefore seasonality is
usually not an important predictor in African Americans but it is in other ethnicities (Freedman
et al., 2013).
Lastly, the current study included a group of participants with high social support which
is not reflective in other studies with similar demographics. Thus, self-selection into the study
with bias could contribute to these positive findings. Therefore, those who did have severe
depressive symptoms could have chosen not to participate in the study. Therefore, this limits the
generalizability of the results and highlights the need to explore those groups who do not have
social support and may be depressed.
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Nursing Implications
Advanced Nurse Practitioners (APNs) provide prenatal care for a significant amount of
pregnant women in the U.S., which include Family Nurse Practitioners (FNPs), Women’s Health
Nurse Practitioners (WHNP), and Certified Nurse Midwives (CNMs) (Brooten et al., 2007).
Therefore, APNs have an important role in providing education to pregnant women about
vitamin D deficiency and its detrimental effects in pregnancy. Pregnant women at risk need to
be screened at their initial obstetric visit which is recommended by both American College of
Obstetricians and Gynecologists (ACOG) and American College of Nurse Midwives (ACNM),
the professional bodies that accredit obstetric physicians and nurse midwives (Committee
opinion #495; King et al., 2015). APNs have a central role in screening and educating women
about their vitamin D levels and the potential role it may play in improved pregnancy
complication and improve vitamin D status of their child. Registered nurses who are caring for
pregnant women have a role in education, and incorporating the evidence about vitamin D needs
in pregnancy is also very important, especially in the outpatient setting.
Secondly, another important nursing implication from the current study is recognizing
that physical symptoms in pregnancy can impact quality of life. Discussing proactive
suggestions for management or minimization of physical symptoms in pregnant women could
alleviate some of these discomforts. Physical activity during pregnancy has been shown to
decrease musculoskeletal pain found in pregnant women (Mogren, 2005). Another study
reported that in 380 pregnant women, poor physical activity correlated with worse quality of life
as measured by SF-36 which was the parent tool (Bahadoran & Mohamadirizi, 2015). There has
also been evidence that practicing physical activity can be protective against depressive
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symptoms (Demissie, 2010; Battle, Abrantes, Schofield, & Kraines, 2015). Notable criteria for
physical activity for pregnant women should include low-to-moderate intensity, with gentle,
gradual increases in activity, clear safety guidelines, and tips for preventing injury or
overexertion (Battle et al., 2015).
Another important nursing implication for the current study is the application of social
support in caring for pregnant women. Since there is some evidence that social support
can positively impact quality of life, nurses have been on the forefront about promoting
programs like Centering pregnancy that can increase the social support of pregnant women.
Despite not seeing a difference in social support scores between routine care and centering
pregnancy care, there is still a role for centering pregnancy care in improving the social networks
of pregnant women.
Another crucial component based on the results of this study is the impact of spirituality
on depressive symptoms and mental quality of life. This study did not find a significant
relationship between vitamin D and each of the following: spirituality, depressive symptoms, and
mental quality of life. However, there is evidence that indicates vitamin D is associated with
perinatal depression and it is important to assess spirituality as a potential protective factor
(Cassidy-Bushrow et al., 2012; Brandenburg et al., 2012). Nurses should continue to encourage
communities of faith to be involved in healthcare and engage nurses to speak at churches and
faith communities about health screening and disease management in vulnerable
communities. Engaging pregnant women who have little to no support in groups for education
and/or encouragement and recognizing the importance of socialization during pregnancy can
have a profound impact on pregnancy outcomes. Increasing mental health resources for
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pregnant women is another role for nursing to better care for at risk pregnant women. Since
vitamin D deficiency has been associated with depressive symptoms, it is essential that nurses
and APNs screen for vitamin D status as evidence suggests its link to mental health.
Nursing has the responsibility to be a fierce advocate for vulnerable patient populations
and addressing the health disparity that exists and with the social justice charge given to nurses
by the American Nurses Association code of ethics (ANA, 2001). Nursing has a unique role to
recognize and address the needs of pregnant women and to educate them about self-care and the
importance of nutrients like vitamin D in pregnancy.
Future Research
Based on the results of this descriptive study, future research needs to focus on validating
the impact that vitamin D may have on sleep quality and quality of life in pregnant women.
There seems to be some discrepancy in the literature about vitamin D status and sleep quality,
therefore confirmatory studies to assess a correlation between vitamin D deficiency in pregnant
women and poor sleep quality need to be conducted.
Ongoing clinical trials assessing vitamin D supplementation on depressive symptoms will
provide clarity and confirmation that improvement of vitamin D status can positively impact
mental health. One example of a randomized control trial in type 2 diabetic women entitled
“Sunshine 2 Study” funded by NINR (R01NR013906) is enrolling depressed women (CES-D
score of > 16) in either a placebo (5,000 IU/week) dose or 50,000 IU/week) dose to determine
the efficacy of vitamin D supplementation on mood symptoms, self-management of diabetes, and
quality of life found on clinical trials.gov website (Penckofer, 2013, July 17). This study is still
recruiting participants but will provide evidence for the impact of vitamin D supplementation at
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multiple time points (baseline, 3 months and 6 months) on treatment of depression. Even though
the study is not examining pregnant women, the study will provide much needed evidence about
type 2 diabetic women who are more prone to depressive symptoms (Penckofer, Doyle, Byrn, &
Lustman, 2014). Although the current study only had 13.6% (n=17) of the sample diagnosed
with GDM, there is a lot of evidence to indicate that women who are gestational diabetics double
their risk for type 2 diabetes later in life (Laptook, Homko, & Biastre, 2013). In addition,
women with GDM have been reported to have more depressive symptoms (Byrn & Penckofer,
2015), thus evaluating vitamin D would be especially important in this group.
Since type 2 diabetes is on the rise especially in Hispanic women and they are also at risk
for vitamin D deficiency, it important to understand the impact that vitamin D supplementation
can have in diabetic women (Castro & Penckofer, 2014). In Europe, the DALI (vitamin D and
Lifestyle Intervention) study is ongoing which will enroll pregnant women at risk of GDM from
nine different European countries who will be randomized to different lifestyle interventions
including vitamin D supplementation (Jelsma et al., 2013). This study will provide important
evidence for preventive measures that impact GDM development in at risk pregnant women and
also provide much needed evidence for the role that vitamin D supplementation will have in
potentially preventing GDM.
Medical University of South Carolina is also undergoing a major initiative for screening
and treating all pregnant women who are vitamin D deficient in their university clinics.
Therefore they will provide further evidence to the impact that vitamin D supplementation has in
pregnancy (Hollis & Wagner, 2017). In addition to evaluating the impact of vitamin D
supplementation on birth outcomes and pregnancy complications, they will also be assessing the
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impact that vitamin D supplementation can have on genomic mutations at an epigenetic level
(Hollis & Wagner, 2017).
Another important area of research is understanding the role of inflammatory processes
and its relationships between vitamin D status, depressive symptoms, poor sleep quality and
quality of life. Future studies should include these components to determine mechanics of action
which may translate to ways to prevent adverse perinatal outcomes. Vitamin D does seem to
play a central role, but high quality supplementation trials need to be done to confirm these
biologic relationships and demonstrate benefit on these outcomes.
The findings of this study provided exploratory evidence that vitamin D has a role in
influencing symptoms such as poor sleep. This study also contributed to the evidence in regards
to the association of vitamin D status in pregnant women and its relationship to sleep quality
burden and poorer physical quality of life. In a sample of 125 pregnant women at risk for
vitamin D deficiency, vitamin D status was predictive of poor sleep quality and poor physical
quality of life. It is important that populations who are at the greatest risk for vitamin D
deficiency be studied. The potential for a future study to examine whether supplementation can
improve symptomology, quality of life and health outcomes is novel. The beneficial effects of
vitamin D supplementation to prevent pregnancy complications such as preterm birth and
preeclampsia only further emphasizes the need to conduct well designed clinical trials. In
addition, the inclusion of diverse women who are at greatest risk for vitamin D deficiency cannot
be ignored so future studies must target these at risk groups. Finally the low cost for such an
intervention could provide exponential benefit to many who suffer from health disparities
emphasizing the need for further investigation.

APPENDIX A
INSTRUMENTS (ENGLISH AND SPANISH)
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Demographic and Health History Information
ID #____________ MRN#__________________ Date_________________

Pre-pregnancy weight: _____________________
Today’s weight: ____________
Today’s height: ____________
Estimated Due Date: __________________
Gestational age today: ______________
LCHC clinic site:

o
o
o
o
o
o

3750 W. Ogden avenue
3860 W. Ogden Avenue
Homan Square
Farragut
Archer
Breakthrough

Please fill out the information below.
1. Age: _______________
2. Ethnicity: (please circle one)
o Hispanic
o Non-Hispanic
3. Race: (please circle one)
o African American (Black)
o Mixed please specify: ____________
o Other
4. If Hispanic, which best describes you: (please check one box)
o Born in the U.S.
o From Mexico
o From Latin America
o From Spain
o From the Carribean
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o From Puerto Rico
o From South America
o Other ____________________
5. Language preference: (Please check one box)
o English
o Spanish
6. Marital Status: (please circle one)
o Married
o Divorced
o Separated
o Single, and living with partner
o Single, and not living with partner
7. Education status: (please check highest level of education)
o Grammar school
o Middle school
o High school
o Associate’s degree/Technical college
o Some college
o College degree
o Graduate degree
8. Household income: (please check one box)
o <$5,000
o $5,000 to $14,999
o $15,000 to $24,999
o $25,000 to $39,999
o $40,000 to $54,999
o $55,000 to $64,999
o >$65,000
9. Employment status: (please check one box)
o Full time
o Part time
o Unemployed
o Laid off
o Disability
o Other________
10. What type of insurance?
o Medicaid
o Medicaid HMO (Family Health Network, Harmony)
o Private insurance (BCBS, United, Aetna)
146

o Obamacare plan
o No insurance
11. Are you currently enrolled in the WIC (Women, Infants, Children) program?
YES

NO

12. If you are enrolled, how many months pregnant did you enroll? ______________
13. Are you planning on breastfeeding?
14. Was your current pregnancy planned?

YES
YES

NO
NO

15. Please list any prescribed medications you are currently taking:
______________________
______________________
______________________
______________________

____________________
____________________
____________________
____________________

Over the counter medications:
______________________
______________________

___________________
___________________

16. Have you ever been diagnosed with depression?

YES

NO

YES

NO

IF YES when? ________________
diagnosed with anxiety?
IF YES when? ________________
diagnosed with any other MH illness __________________
17. Please circle any of the following conditions you have been diagnosed with either in the past
or in this pregnancy:
o Asthma
o Diabetes
o Hypertension
o Depression
o Bipolar Disorder
o Schizophrenia
o Thyroid disorder
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o Anemia
o Other__________________
18. How many times have you been pregnant? _______________
19. How many of those pregnancies did you deliver a full term (after 37 weeks)
baby? ___________
20. How many of those pregnancies did you deliver a preterm (between 20 and 37
weeks) baby? ____________
21. How many miscarriages/abortions have you had? ___________________
22. How many living children do you have? ____________________
23. How many vaginal deliveries have you had? ________
Complications: (check all that apply)
o Vacuum delivery
o Forceps delivery
o 3rd or 4th degree laceration
o Other ________________
24. How many cesarean sections have you had? _______
25. Are you currently getting prenatal care through Centering Pregnancy? YES
CONTACT INFORMATION
1. What is your current address?
Number and Street
City
State
Zip
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or

NO

2. Contact information:
Home phone number
(please enter in format:
###-###-####)
Cell phone number
(please enter in format:
###-###-####)
Email address
(please enter in format:
###-###-####)
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Demografía y Salud Información Historia

ID #____________ MRN#__________________ La fecha _________________
Season ______________
Código postal ____________
Peso antes del embarazo_____________________
Peso hoy: ____________
Altura de hoy: ____________
La fecha de nacimiento del bebé : __________________
Cuántas semanas estás hoy: ______________
Clinica lugares:

o
o
o
o
o
o

3750 W. Ogden avenue
3860 W. Ogden Avenue
Homan Square
Farragut
Archer
Breakthrough

Por favor complete la información de abajo.
1. Cuántos años tienes _________
2. Etnicidad: (por favor marque uno)

o Hispanos
o No Hispanos
3. Race: (please circle one)
o Afroamericano
o Mezclado Por favor especifica: ____________
o Otros
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4. Si Hispanos, Lo que te describe mejor: (por favor marque uno)
o nacido en los Estados Unidos From Mexico
o de américa latina
o de Mexico
o de España
o del caribe
o de Puerto Rico
o Otro _______________
5. Preferencia: (por favor marque uno)
o Ingles
o Español
6. Estado civil:
o Casado
o Divorciado
o Separado
o Sola, viviendo con pareja
o Sola, no viviendo con pareja
7. Estado de la educación: (por favor marque más alto nivel de la educación)
o Escuela primaria
o Escuela secundaria
o Grado asociado
o Alguno colegio
o Grado de la universidad
o Título de posgrado
8. los ingresos del hogar
o <$5,000
o $5,000 to $14,999
o $15,000 to $24,999
o $25,000 to $39,999
o $40,000 to $54,999
o $55,000 to $64,999
o >$65,000
9. Estado de Empleo: (por favor marque uno)
o tiempo completo
o medio tiempo
o desempleados
o Otro ___________________
10. Qué tipo de seguro de salud?
o Seguro de enfermedad
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o
o
o
o

Seguro de enfermedad HMO (Family Health Network, Harmony)
Seguro private (BCBC, United, Aetna)
Obamacare plan
No seguro

11. Estás inscrito en el programa WIC?

Sí

NO

12. Si está inscrito, ¿cuántos meses de embarazo ha inscrito? __________
13. ¿Está pensando en amamantar?

Sí

NO

14. Por favor, indique todos los medicamentos recetados que está tomando actualmente:
______________________
______________________
______________________
______________________

____________________
____________________
____________________
____________________

La medicina sin receta:
______________________
______________________

___________________
___________________

15. Alguna vez ha sido diagnosticado con depresión? Sí

NO

Con ansiedad? Sí

NO

otras enfermedades de salud mental? _________________
16. Por favor marque cualquiera de las siguientes condiciones se le ha diagnosticado:
o Asma
o Diabetes
o Hipertensión
o Problema con su tiroides
o Anemia
o Otro _______________
17. Cuantas veces has estado embarazada? ______________
18. Cuántos bebés nacidos a término (después de las 37 semanas)? ___________
19. Cuántos bebés nacidos a término prematuro (entre 20 y 36 semanas) __________
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20. ¿Cuántos abortos involuntarios / abortos han tenido? _____________
21. El número de hijos vivos tiene? ______________
22. ¿Cuántos nacimiento bebé vaginales? _____________
Complicaciones durante parto:
o
o
o
o

Parto vaginal ventosa
Parto con fórceps
Tercero o cuarto grado de laceración
Otro ____________________

23. Cuántas cesáreas ha tenido? ________________
24. ¿Está recibiendo atención prenatal en grupo?

Información del contacto
1. ¿Cual es tu dirección?
Nombre y calle
Ciudad
Estado
Código postal

2. Número de teléfono
Número de teléfono de
casa
(escribir como este:
###-###-####)
Número Celular
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Sí

NO

(escribir como este:
###-###-####)
Dirección de correo
electrónico
(escribir como este:
____@___.com
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Pregnancy Symptom Inventory in Spanish, email author for copy of translation.
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General Health Perceptions

For each of the following questions, please mark an
describes your answer.

in the one box that best

1. In general, would you say your health in pregnancy is:

    

Excellent

1

Very good

2

Good

Fair

3

Poor

4

5

2. In general, would you say the health of your unborn baby is:

    

Excellent

1

Very good

2

Good

3
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Fair

Poor

4

5

Percepciones generales de salud
Para cada una de las siguientes preguntas, por favor marque con una
casilla que mejor describa su respuesta.

la

1. En general, ¿diría que su salud durante el embarazo es:

  

Excelente

1

Muy buena

Buena

2

3

 

Pasable

4

Mala

5

2. En general, ¿diría usted que la salud de su bebé por nacer es:

  

Excelente

1

Muy buena

Buena

2

3
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Pasable

4

Mala

5
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SAMPLE RECRUITMENT LETTER
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Dear Ms. ________________
Greetings. My name is Jennifer Woo and I am a certified nurse midwife who
previously worked at Lawndale Christian Health Center. I am enrolled in the doctoral
nursing program at Loyola University and studying pregnant women to determine
whether the level of vitamin D in your blood is related to how you feel. You will be
asked to complete a questionnaire booklet that asks about pregnancy symptoms, mood,
sleep, health behaviors, and quality of life. You will also need to take a blood test so that
we can know the level of vitamin D in your blood.
Research suggests that women who have low levels of vitamin D may be at
greater risk for poor pregnancy and birth outcomes such as early delivery and diabetes in
pregnancy. There is also evidence to suggest that women who have lower levels of
vitamin D are also at increased risk for common discomforts like musculoskeletal pain,
sleep issues, depressive symptoms, and fatigue, but most the studies have not included
pregnant women.
Therefore, we would like to study whether vitamin D levels are related to how
you feel. Pregnant women who are 24 to 32 weeks into gestation may participate. If you
are interested in participating in this study, please call me at XXX-XXX-XXXX. I will
ask questions to see if you meet the study inclusion criteria. If you do, then I will
schedule a time to meet you in the clinic at your next appointment. At that time, we will
review a document to make sure you understand the study.

You will be paid a small

amount for your time with a $20 Target or Walmart gift card. I thank you in advance for
your willingness to review this letter and look forward to hearing from you!
Sincerely,
Jennifer Woo, CNM, WHNP
Doctoral Nursing Student, Loyola University Chicago
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APPENDIX D
INFORMED CONSENT, LOYOLA IRB APPROVAL LETTER,
ATTESTATION OF SPANISH INFORMED CONSENT
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LOYOLA UNIVERSITY CHICAGO
HEALTH SCIENCES DIVISION
MAYWOOD, ILLINOIS
DEPARTMENT OF
MARCELLA NIEHOFF SCHOOL OF NURSING
INFORMED CONSENT

Participant’s Name __________________________________________________________
Medical Record number: ______________________________________________________
PROJECT TITLE: Vitamin D and pregnancy symptoms

THE APPROVAL FOR THIS PROJECT EXPIRES ON XX/XX/XXXX

Participant Information
PRINICIPLES CONCERNING RESEARCH: You are being asked to take part in a
research project. It is important that you read and understand the principles that apply to all
individuals who agree to participate in the research project described below:
1. Taking part in the research is entirely voluntary
2. We do not know if you will benefit from taking part in the research but the
knowledge obtained may help others.
3. You may withdraw from the study at any time without anyone objecting and without
penalty or loss of any benefits to which you are otherwise entitled.
The purpose of the research, how it is to be done, and what your part in the research will be is
described below. Also described are the risks, inconveniences, discomforts and other important
information which you need to make a decision about whether or not you wish to participate.
You are urged to discuss any questions you have about this research with the staff member.
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PURPOSE OF RESEARCH: You are being asked to participate in this study because you are
pregnancy and are at risk for vitamin D deficiency. There is evidence that shows that women
who are African American and Hispanic are at greatest risk for having vitamin D deficiency.
In addition, there are physiological changes that happen in pregnancy that can cause, some
discomforts. These are commonly called symptoms of pregnancy which may include increased
urinary frequency, low back pain, and sleep problems. These symptoms can cause significant
discomfort to normal pregnancy and interfere with quality of life.
Some observational studies have shown that many of the common discomforts of pregnancy like
low back pain, sleep discomforts, urinary issues, are also associated with vitamin D deficiency
but no one has looked at this association in pregnant women. Therefore, it is important to see if
there is a connection between vitamin D deficiency and pregnancy symptoms and how it impacts
your quality of life.
This purpose of this study is to see if y our vitamin D status is correlated with higher frequency
of symptoms of pregnancy and what its impact is on your quality of life.
This research is sponsored by Loyola University. Approximately 125 people will participate in
this research.
DESCRIPTION AND EXPLANATION OF PROCEDURES: If you agree to participate in
this study, you will be required to provide a one time blood sample to measure your vitamin D
level. In addition, you will be required to fill out a packet of self-report questionnaires that
describe your pregnancy symptoms, sleep quality, depressive symptoms, in addition to other
demographical information. Your healthcare provider at Lawndale Christian Health Center will
be notified if you report having thoughts of harming yourself as reflected in question number 10
on the Edinburgh Postnatal Depression Scale (EPDS).
RISKS/DISCOMFORTS: Enrollment in the study, you will need to get your blood drawn and
may experience some discomfort with this procedures. You may also feel uncomfortable
answering some of the survey questions or think more about your pregnancy symptoms.
BENEFITS: You will not benefit from participating in this study.
FINANCIAL INFORMATION: You or your insurance company will not be charged for the
laboratory blood draw that you will have done in this study. Insurance information will not even
be collected, as the bill for the laboratory blood draw will be paid for by the investigator,
Jennifer Woo. You will receive $20 for participating in this study.
RESEARCH RELATED INJURY: In the event that you are injured or have side effects as a
result of participating in this research project, your doctor will take the necessary steps to treat
the problem. There are no funds available from Loyola University Medical Center, Loyola
University Health System or Loyola University Chicago to pay for the cost of care of the
problem. You will be financially responsible for the cost of care of any problems. By signing
this form, you are not giving up any legal rights to seek to obtain compensation of injury.
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INFORMATION COLLECTED AND WHAT WILL HAPPEN TO IT: In order to meet the
goals of the research study (see Purpose of Research section of this consent), we will collect
information on you, your tests results, and how you do from you and your Lawndale Christian
Health Center medical records. The information will be collected by Jennifer Woo who is a
doctoral student at Loyola University Chicago.
In this way, we will learn about the impact your vitamin D status may have on the frequency of
pregnancy symptoms.
The information we will collect and send includes:
X DEMOGRAPHIC INFORMATION (e.g., name, address, phone number)
X MEDICAL RECORD(including, but not limited to laboratory values, patient medical history)
X SELF-REPORTED QUESTIONNAIRES
X BLOOD SAMPLE
We will collect and provide this information about you for the duration of the study.
WITHDRAWAL OF CONSENT: Your consent to use and disclose your medical information
for the purpose of this research study is completely voluntary. You can withdraw your consent
for LUMC to use and disclose your information and your consent to participate in this study at
any time without affecting your ability to receive care and treatment at LCHC unrelated to the
research study. Withdrawal means that all study procedures and follow-up will stop and we will
not send any more information about you to the sponsor of this research or its designees.
However, information already used and disclosed to the research sponsor prior to the time of
your withdrawal from this study may continue to be used and disclosed by LUMC and the
sponsor.
If you withdraw from the study, we will ask that you sign the form attached to this consent and
send it to Jennifer Woo. Your withdrawal from the study will not have any affect on any actions
by LCHC taken before the attached form is received by LUMC.
Your study doctor, the Institutional Review Board, the regulatory authorities, or the sponsor,
may terminate the study at any time with or without your consent.
CONSENT
I have fully explained to _____________________________ the nature and purpose of the
above-described procedure and the risks that are involved in its performance. I have answered
and will answer all questions to the best of my ability. I may be reached at 312-513-2214.
______________________________________________ Date:___/ ___/ _____

197
Jennifer Woo and Susan Penckofer, the principal investigator for this study, will be available to
answer any questions you may have3. Jennifer Woo can be reached at: 312-513-2214
Although you have the right to revoke this authorization, you accept that such revocation will not
apply to any uses and disclosures of your information that are described in the Loyola University
Health System Notice of Privacy Practices or otherwise allowable under any Federal or State
laws.
You will receive a signed copy of this informed consent document.
You have been fully informed of the above-described research program with its possible benefits
and risks. Your signature below indicates that you are willing to participate in this research
study and agree to the use and disclosure of information about you as described above. You do
not give up any of your legal rights by signing this consent document.
______________________________________________ Date:___/ ___/ _____
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Table 1

Vitamin D and depression
Authors/Title

Year

Jaaskelainen et al. 2015
Higher serum 25hydroxyvitamin
D concentrations
are related to a
reduced risk of
depression

Design

Crosssectional
study men
and women
30-79 based
on Health
2000 survey
which used
self-report
questionnair
es and
comprehensive
health
examination

Sample
characteristics
Finnish sample
cohort
N=5371
Men–47%
Women–53%
Measures:
Beck Depression
Inventory (BDI)
DSM-IV diagnosis
code for major
depressive disorder,
dysthymic disorder,
and anxiety disorder
Lifestyle factors
(BMI, physical
activity, and tobacco
and alcohol use)
Metabolic healthrelated factors
Dietary index
VD method:
Diasorin RIA

Results

Logistic
regression showed
increased odds
ratio of 0.65 (95%
CI 0.46. 0.93)
from highest to
lowest quartiles of
vitamin D and
depression.
Therefore,
reduced risk of
25% in those who
had higher vitamin
D levels even after
adjustment for
significant
demographic,
lifestyle and
metabolic factors.
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Kerr et al.

2015

Associations
between vitamin
D levels and
depressive
symptoms in
healthy young
adult women

Crosssectional
study with
sample for
depressive
symptoms
weekly for 4
weeks and
vitamin D
level at
week 1 and
week 5.

U.S. college
undergraduate
women
N=185
Measures:
CES-D, Season,
BMI,
Ethnicity,
Physical activity,
Time outside in
daylight hours,
Dietary intake of
vitamin D, Antidepressant and
multivitamin use

Multivariate
prediction model
which showed that
lower Week 1
vitamin D3
predicted clinical
significant
depressive
symptoms across
Week 1–week 5 (β
= -0.20, p < 0.05),
controlling for
season, BMI,
race/ethnicity,
diet, exercise, and
time outside.

VD method: LC-MS
Gowda et al.
Vitamin D
supplementation
to reduce
depression in
adults: Metaanalysis of
randomized
controlled trials

2015

Metaanalysis of
randomized
controlled
trials which
used vitamin
D
supplementa
tion to
reduce
depression
or
depressive
symptoms

RCTs that compared
vitamin D only or
vitamin D and
vitamin D combined
with other vitamins
or antidepressants
with a placebo
included;
Participants ≥ 18
years of age
Total of 9 studies
included
Final N=4923

No significant
reduction in
depression was
seen after vitamin
D
supplementation
(standardized
mean difference =
0.2895% CI, -0.14
to 0.69; P = 0.19);
limitations–most
of the studies
included
individuals with
low levels of
depression and
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Vitamin D
methodology varied
with each study

Spedding, S./
Vitamin D and
Depression: A
Systematic
Review and
Meta-Analysis
Comparing
Studies with and
without
Biological Flaws

2014

Metaanalysis of
randomized
controlled
trials using
vitamin D
supplementa
tion for
depression.

15 RCTs included in
analysis; 7 studies
did not have
biological flaws and
8 studies had
biological flaws;

Vitamin D
methodology varied
with each study

sufficient serum
vitamin D at
baseline. The
studies included
used different
vitamin D doses
with variations in
intervals of
treatment
7 studies with no
biological flaws
showed
standardized mean
difference (SMD)
of 0.78 (CI 0.24,
1.27); Cohen’s
rule of thumb,
SMD of 0.8 is
considered a large
effect so
significant effect
of vitamin D in
improvement of
depression;
8 studies with
biological flaws
showed SMD of
-1.1 (CI -0.7, -1.5)
which showed a
negative effect of
vitamin D on
depression
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Anglin et al.
Vitamin D
deficiency and
depression in
adults:
systematic review
and meta-analysis

2013

Metaanalysis of
published
observationa
l and RCTs
studying
vitamin D
and
depression

One case-control
study, 10 crosssectional studies, 3
cohort studies

Vitamin D
methodology varied
with each study

Lower vitamin D
levels found in
people with
depression with
SMD =0.60, 95%
CI 0.23-0.97);
Increased odds
ratio of depression
for the lowest to
highest vitamin D
groups with OR
=1.31. 95% CI
1.0-1.71; Cohort
studies showed
significant hazard
ratio of depression
for the lowest to
highest vitamin D
groups (HR =
2.21, 95% CI
1.40-3.49)
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Table 2

Vitamin D and perinatal depression
Authors/Title

Miyake et al.

Year

Design

2015

Cross-sectional
study to evaluate
the relationship
between dietary
vitamin D intake
and depressive
symptoms in
pregnancy.

Intake of dairy
products and
calcium and
prevalence of
depressive
symptoms during
pregnancy in
japan: A crosssectional study

Sample
characteristics
Japan
N=1745
Measures:
Dietary History
Questionnaire
(DHQ)
CES-D for
depressive sx

Results

Using logistic
regression vitamin D
intake in the highest
quartile was
significantly
associated with lower
prevalence of
depressive symptoms
with OR 0.52, 95%
CI 0.30-0.89).

VD method: not
drawn, only
based on dietary
vitamin D intake
Gould et al.
Association of
cord blood
vitamin D at
delivery with
postpartum
depression in
Australian
women

2015

Cross-sectional
study as part of a
larger RCT grant
looking at
vitamin D status
at delivery and
subsequent risk
of Postpartum
depression (PPD)
at 6 weeks and 6
months
postpartum

Australia
N=1040
Caucasian
N=919
Non-Caucasian
N=121
Measures:
EPDS
VD method:
LC/MS

Adjusted Relative
risk for VD status and
PPD at 6 weeks PP
was not significant
(RR 0.92; 95% CI
0.84-1.02, p=0.11) or
at 6 months PP with
RR 0.96 ; 95% CI
0.88-1.05, p=0.41)
However, only 8% of
sample had VD level
< 25 nmol/L;

207
Bobbitt et al.

2015

Early pregnancy
vitamin D and
patterns of
antenatal
inflammation in
AfricanAmerican
women

Cross-sectional
study evaluating
if vitamin D
status and
inflammatory
markers are
associated with
antenatal
depression in a
cohort of AA
pregnant women

U.S.
N=147
VD measured in
1st trimester
Inflammatory
markers
measured in 2nd
trimester along
with CES-D

After adjusting for
covariates, only IL1β was significantly
associated with
vitamin D status and
depressive symptoms
(p=0.032)

Measures:
CES-D, IL-6,
IL-10, IL-1β,
and TNF-α
VD method:
Chemiluminesce
nce
immunoassay
Gur et al.
Mid-pregnancy
vitamin D levels
and postpartum
depression.

2014

To examine if
mid pregnancy
vitamin D status
had an impact on
postpartum
depressive
symptoms at 1
week, 6 weeks
and 6 month
postpartum

Turkey
N=189 after 1
week PP
N= 184 after 6
week PP
N=179 after 6
mo PP
Measures:
EPDS
VD method:

Univariate ANOVA
used to evaluate
maternal depression
(EPDS≥12) and
vitamin D level and
those with severe VD
(<10ng/ml) had a
P=0.002 in 1st week
PP, in 6th week PP
P=0.004 and in 6th
month PP P=<0.001
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Robinson et al.

2014

Low maternal
serum vitamin D
during
pregnancy and
the risk for
postpartum
depression
symptoms

Huang et al.
Association of
serum vitamin D
with symptoms
of depression
and anxiety in
early pregnancy

Prospective study
examining if
vitamin D status
at 18 weeks is
associated with
postpartum
depressive
symptoms at 3
days after birth

Australia
N = 796
All Caucasian
women
Measures:
EPDS
VD Method:
LCMS

2014

Cross-sectional
study to evaluate
associations
between early
pregnancy VD
and antepartum
depression and
anxiety
symptoms at 20
weeks gestation

U.S.
N=498
Non-Hispanic
white
429/498(87%)
Other 13%
Mean vitamin D
34.4 ng/ml
Measures:
Depression,
Anxiety, and
Stress Scales
(DASS-21)
Patient Health
Questionnaire
(PHQ-9)
VD method:
LC/MS

Logistic regression
model showed
women in the lowest
quartile of VD levels
(<47 nmol/L) were
significantly more
likely to report six or
more depressive
symptoms in the first
days after birth (OR
2.19, 95% CI, 1.263.78)
Multivariate linear
regression analysis
showed a 1 ng/ml
lower VD level was
associated with 0.043
and 0.40 higher
DASS-21 and PHQ 9
scores(P values
=0.052 and p=0.029);
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Nielsen et al.

2013

Vitamin D status
during
pregnancy and
the risk of
subsequent
postpartum
depression: A
case-control
study

Case-control
study nested in
the Danish
National Birth
Cohort to
evaluate if low
vitamin D in
pregnancy
increased the risk
of postpartum
depression

Denmark
N = 605 with
PPD
N = 875 control
group

Noted no association
between low vitamin
D status and risk of
PPD. With VD<15
nmol/L(6 ng/ml) and
risk of PPD, OR 1.35,
95% CI (0.64, 2.85)

Measures:
Diagnosis of
PPD (measured
by women
filling
prescriptions for
antidepressive
medications)

** Noted an
increased risk of PPD
with VD >50 nmol/L
(20 ng/ml)

VD method:
LC-MS

CassidyBushrow et al.
Vitamin D
nutritional status
and antenatal
depressive
symptoms in
African
American
women

2012

Cross-sectional
study to examine
if there is a
relationship
between early
pregnancy (1st
trimester)
vitamin D status
and depressive
symptoms in 2nd
trimester.

U.S.
AA pregnant
women
N=178
Measures:
CES-D
VD method:
Chemiluminesce
nce
immunoassay
platform

Logistic regression
analysis with adjustment for significant
covariates showed an
inverse relationship
between VD and
CES-D≥16 with OR
0.54, 95% CI, 0.290.99)

210
Brandenbarg et
al.

2012

Maternal earlypregnancy
vitamin D status
is associated
with maternal
depressive
symptoms in the
Amsterdam born
children and
their
development
cohort

Epidemiologic
study to evaluate
if vitamin D
status impacted
perinatal
depressive
symptom scores
in a pregnant
population.

Netherlands
N=4236
VD measured in
early pregnancy
(median time 13
weeks) and
depressive
symptoms
measured at 16
week gestation

Logistic regression
with adjustment with
significant covariates,
vitamin D deficiency
(VD < 29.9 nmol/l)
had an OR 1.48, 95%
CI, 1.13-1.95.
Vitamin insufficiency
as defined by 30 to
49.9 nmol/l had an
OR 1.44; 95% CI,
1.12-1.85;

Measures:
Center for
Epidemiological
Studies for
Depression
(CES-D)
VD method:
Enzyme
immunoassay
method

Murphy et al.
An exploratory
study of
postpartum
depression and
vitamin D

2010

Cross-sectional
study to
determine if
vitamin D status
can predict
presence of
depressive
symptoms in
postpartum
women.

U.S.
N=97
White–43
AA–30
Hispanic–23
Asian–1
Measures:
Demographic

Using mixed model
approach, used
pooled t tests of
unadjusted mean
EPDS sum scores
compared at each
time point for
insufficient (VD<32
ng/ml) versus
sufficient (VD>32
ng/ml). Adjusting for
significant covariates,
mothers with lower
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Edinburgh
Postnatal
Depression
Scale
VD method:
RIA

levels of vitamin D
had higher EPDS
scores during first 7
months postpartum
(P=0.02).

Table 3
Vitamin D and sleep
Authors/Title

Cakir et al.
An evaluation of
sleep quality and
prevalence of
restless leg
syndrome in
vitamin D
deficiency

Year

Design

2015

Cross-sectional
design with 2
cohorts: group 1:
VDD cohort
(VD<20ng/ml)
and group 2:
vitamin D
≥20ng/ml)

Sample
characteristics
Turkey
N=102
Group 1 = 57 (49
women: 8men)
Group 2 = 45 (41
women: 4 men)
Measures:
PSQI
IRLSSG
symptom severity
scale
Ferritin
Hemoglobin
Iron

Results

Restless Leg syndrome is
higher in group 1 (p=.03)
than in group 2;
PSQI scores worse in
group 1 (p=0.046) than in
group 2

212
Magnesium
VD method: not
stated

**Gunduz et al.

2015

Sleep deprivation
in the last
trimester of
pregnancy and
inadequate
vitamin D: is
there a
relationship?

Massa et al.
Vitamin D and
actigraphic sleep
outcomes in older
communitydwelling men: the
MrOS sleep study

Cross-sectional
study with
pregnant women
recruited at 36
weeks gestation

Turkey
N=92
Measures:

No association between
vitamin D status and
sleep quality based on
PSQI global score or any
of the subcomponents.

PSQI
VD method:
High performance
liquid
chromatography
(LC)
2015

Cross-sectional
study with a
large cohort of
community
dwelling men to
evaluate the
association
between vitamin
D status and
sleep outcomes

U.S.
N = 3048
84.1% Caucasian
Measures:
Wrist actigraphy
worn for an
average of 5
consecutive days
for 24 hours to
assesse:
Total sleep time,
sleep efficiency,
wake time after
sleep onset
(WASO)

Logistic regression
analysis adjusted for
significant covariates
showed that lower
vitamin D levels had
higher odds of short (< 5
hours) sleep duration
(OR 2.15 95% CI 1.213.79)
In addition, lower
vitamin D levels had
increased odds of sleep
efficiency < 70%
function (OR 1.45; 95%
CI 0.97-2.18); No
difference in WASO
scores with vitamin D
status.
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VD Method:
LC-MS
Kim et al.

2014

Association
between selfreported sleep
duration and
serum vitamin D
level in elderly
Korean adults

Cross-sectional
study examining
association
between selfreported sleep
duration and
serum vitamin D
levels in elderly
Korean adults

Korea
N=1614
M:F–748:866
Measures:
Self-reported
sleep duration
VD method:

Multiple linear
regression, even after
adjustment for
confounders, vitamin D
deficiency correlated
with shorter sleep
duration. Women had
significantly lower serum
vitamin D levels than
men.

RIA
Huang et al.
Improvement of
pain, sleep, and
quality of life in
chronic pain
patients with
vitamin D
supplementation

2013

One arm
intervention
study

U.S. veterans
with chronic pain
N=28 (all male)

Group 1: vitamin
D insufficient 20 Group 1 = 11
ng/ml to 29
Group 2 = 7
ng/ml)
Group 1 = 9 AA
Supplemented
males
1200 IU/daily
Group 2 = 11 AA
for 3 months
males
Group 2: vitamin
D deficient ≤ 20 Measures:
ng/ml
PSQI
Supplemented
VR-36 (QOL
with 50,000
measure)
IU/weekly for 3
months
Pain score (0 to
10)

Noted improvements in
pain score (p<0.0001),
sleep latency (p=0.019),
sleep duration (p=0.012),
bodily pain (p=0.014),
general health (p=0.006),
vitality (p=0.048) and
social functioning
(p=0.017) from baseline
to 3 month
** vitamin D
supplementation
improved pain scores,
sleep quality and various
aspects of quality of life
in patients with severe
chronic pain.
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VD method:
LC/MS

McCarty et al.

2013

Nonspecific pain
is a marker for
hypovitaminosis
D in patients
undergoing
evaluation for
sleep disorders: a
pilot study

Cross-sectional
study of patients
being evaluated
at a sleep
disorder clinic
who had
concomitant
complaints of
nonspecific MS
pain

US
N=153
(76.5% women;
23.5% men)
(35% AA; 65%
White)
Complaints of
nonspecific MS
pain

Noted: VDD more
prevalent in patients
diagnosed with sleep
disorder
Risk factors noted for
VDD:
Race, age < 60 yrs of
age, and BMI

Mean vit D level:
19.8 ng/ml
Measures:
Sleep dx:
obstructive sleep
apnea, hyperinsomnia, restless
leg syndrome,
insomnia, other;
VD method:
immunoassay by
Diasorin
McCarty et al.
Vitamin D, Race,
and Excessive

2012

Cross-sectional
study with
patients being
seen at a sleep

U.S. sample
N=81(77 women;
24 men)

When examining entire
cohort, there was no
significant correlations
between vitamin D levels
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Daytime
Sleepiness

medicine clinic
who had
complaints of
MS pain

(28 AA; 53
White)
Measures:
Epworth
Sleepiness Scale
(ESS)

and ESS; However, in
the AA population (35%)
who had significantly
lower vitamin D levels
also had significantly
higher ESS scores.

VD method:
Diasorin (RIA)
Balaban et
2012
al./Serum 25hydroxyvitamin
D levels in
restless legs
syndrome patients

Prospective casecontrol study to
evaluate if
people with
Restless Leg
Syndrome (RLS)
have lower
vitamin D levels
compared to
healthy control
subjects without
Restless Leg
syndrome.

Turkey
N = 36 (patients
with RLS)
M:F–8:28
N = 38 (control)
M:F–11:27
Measures:
Idiopathic RLS
Rating scale
VD method:
chemiluminescen
ce immunoasssay

Significant inverse
correlation between
vitamin D levels and
disease severity in
females (p=0.01, r = 0.47); therefore the lower
the vitamin D level, the
higher the RLS score.
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Table 4
Vitamin D and musculoskeletal pain/health
Authors/Title

Straube et al.
Vitamin D for the
treatment of
chronic pain
conditions in adults

Yea
r

Design

Sample
characteristics

Results

2015

Metaanalysis
using the
Cochrane
Central
register of
controlled
trials,
MEDLINE,
and
EMBASE to
February
2015

10 studies included

No consistent
pattern that vitamin
D treatment was
associated with
greater efficacy
than placebo in any
chronic painful
condition (low
quality of
evidence).

Adults > 15 years
of age with all
types of chronic
pain conditions;
vitamin D
supplementation
was given either
PO or IV with a
placebo or active
comparator, with
no restriction to
type, dose or
frequency of
vitamin D
treatment
VD method:
variable
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Gendelman et al.
A randomized
double-blind
placebo-controlled
study adding high
dose vitamin D to
analgesic regimens
in patients with
musculoskeletal
pain

2015

Randomized,
doubleblinded and
placebocontrolled
study to test
the effect of
PO given
4000 IU of
vitamin D vs.
placebo on
different
parameters of
pain for 3
months (time
0, 6 weeks
and at 12
weeks)

Israel pain clinic
Male: 14
Female: 60
≥ 18 yrs of age
Measures:
Pain syndromes
(eg. spinal pain,
osteoarthritis, etc)
Previous
medications
Visual Analogue
Scale (VAS)
McGill Pain
Questionnaire
(MPQ)
Patient Global
Perceived Effect
(PGPE)
Panel
Inflammatory
cytokines
VD methodology:
Diasorin RIA

Using student ttest, the group
receiving vitamin
D supplementation
achieved
statistically
significant decline
in their VAS scores
from week 0 to
week 12 (p<
0.001), while the
placebo group did
not.
The significant
inflammatory
cytokines that
improved with
vitamin D group
include TNF-α ,
LTB4 and PGE.

218
Lodh et al.

2015

Assessment of
Vitamin D status In
Patients of Chronic
Low Back
Pain of Unknown
Etiology

Crosssectional
prospective
study of
patients at an
orthopedic
clinic with
low back
pain of
unknown
etiology

India

Student t-tests
showed women
M:F ratio (54:146)
with lower vitamin
200 control samples D levels with
chronic back pain
Measures:
compared to
controls p valuen <
BMI
0.0001;
Serum glucose,
calcium,
phosphorus, uric
acid, rheumatoid
factor, CRP,
alkaline
phosphatase, total
protein and albumin
VD method:
ELISA

**Bergstrom et al.
Observational study
of vitamin D levels
and pain in
immigrant pregnant
women living in
Sweden

2014

Prospective
longitudinal
study crosssectional of
pregnant
women with
MS pain at
12 weeks
gestation in
pregnant and
again at 6-12
mos
postpartum

Sweden
Immigrant women
N=68
Control group
native Swedish
pregnant women
N=51
Measures:
Pain using VAS
Parathyroid
hormone (PTH)

Maximum number
of low back pain
patients were in the
age group of 31-50
yrs; Calcium and
alkaline
phosphatase was
positively
correlated with
vitamin D and
glucose showed
negative correlation
with vitamin D
Significantly higher
proportion (77.9%)
of immigrant
women had level of
vit D < 25 nmol/l
(10 ng/ml)
compared with
3.9% of controls;
Pain via VAS
significantly higher
in immigrant
women when
compared with
controls at 12th
gestational week
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Alkaline
phosphatase (ALP)
VD method:
Competitive
chemiluminiscence
assay

Von Kanel et al.

2014

Vitamin D and
Central Hypersensitivity in
Patients with
Chronic Pain

Crosssectional
study to
examine the
relation
between
VDD and
mechanical
pain
sensitivity

Switzerland
M:F (82:92)
N = 174
Measures of central
hypersensitivity:
Mechanical
pressure pain
sensitivity,
Widespread Pain
Index (WPI),
Symptom Severity
Score (SSS),
fibromyalgia
VD methodology:
Chemiluminescent
immunoassay

Le Goaziou et al.
Vitamin D
supplementation for

2014

Prospective
on armed
study of

Switzerland
18-50 yrs of age

(p<0.001); An
increase in vitamin
D levels from 12
weeks gestation to
postpartum time
point correlated to a
decrease in pain
(p<.01) using a ttest.
Linear regression
analysis to test for
significant
relationship
between vitamin D
and measures of
central sensitivity
including
accounting for
significant
covariates; Results
showed Lower
vitamin D levels
were related to
greater symptom
severity (r= -0.21.
P= 0.008); mean ±
standard error of
the mean increase
in pain intensity of
0.61±0.25 for each
25 nmol/L decrease
in vitamin
D(p=0.011)
Before treatment,
mean vitamin D
level of 23.7
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diffuse
musculoskeletal

patients with
complaints of
diffuse MS
(DMS) and
vitamin D
deficiency.
Supplementa
tion provided
based on
vitamin D
level of
200,000 IU
in either one,
two or three
doses; with
measures
taken before
treatment and
45-60 days
after
treatment

pain: Results of a
before-and-after
study

M:F - 14:35
N = 49
Patients received
different doses of
vitamin D
supplementation
based on their
vitamin D level
Measures:
Demographics
Mean pain
evaluation score
Quality of life
(COOP-WONCA
chart)

nmol/L, mean pain
evaluation score
5.07 and a mean
quality of life score
3.55. Using
ANOVA, after
vitamin D
supplementation,
adjusted mean
vitamin D increased
to 118.8 nmol/l
(p<0.001), mean
quality of life score
increased to 2.8
(p<0.001), and
mean pain
evaluation score
decreased to 2.8
(p<0.001).

VD method:
Not stated

Al-Jarallah et al.
Musculoskeletal
pain: should
physicians test for
vitamin D level?

2013

Prospective
case control
study
recruiting
patients from
rheumatolog
y clinic with
complaints of
MS pain.

Kuwait
N = 124 with MS
pain
M:F–77:118
N= 82 age & sex
matched controls
Measures:
Demographics

Vitamin D levels
were deficient in all
patients (<50
nmol/l); There was
no statistical
different (p=0.368)
observed between
the mean vitamin D
values of patients
and controls,
27.6±13.06 nmol/L
versus 25.82±15.06
nmol/L.
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Muscle and gait
evaluation
Symptoms related
to MS pain
Sun exposure
Dietary habits
Parity
PTH
Calcium
Alkaline
Phosphatase
Albumin
VD method:
radioimmuno-assay
Sinha et al.

2013

Improving the
Vitamin D Status of
Vitamin D
Deficient Adults Is
Associated With
Improved
Mitochondrial
Oxidative Function
in Skeletal Muscle

Schreuder et al.

2012

Longitudinal
study
evaluating
the
mitochondria
l phoxidative
function in
skeletal
muscles in
symptomatic
VDD
patients with
VD supplementation

United Kingdom

Semicrossover

Netherlands

N=12
M:F–7:5
VDD patients with
complaints of
fatigue or muscle
cramps (with
exclusionary
criteria for
comorbid
conditions)

Linear regression
model showed that
decreasing vitamin
D levels was
associated with
increasing
mitochondrial
oxidative function
(r = -0.41,
p=0.009). All
patients report
decrease in fatigue
after treatment

Patients in vitamin
D group were
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Vitamin D
Supplementation
for Nonspecific
Musculoskeletal
Pain in NonWestern
Immigrants:
A Randomized
Controlled Trial

randomized
controlled
trial in nonWestern
immigrants
who are
VDD with
VD supp-

N=84

lementation
for 3 months
for MS pain

Group 2 - VD for 6
weeks; placebo 6
weeks

M:F–20:64
Vitamin D < 50
nmol/l
Group 1–VD for
entire 12 weeks

significantly more
likely than placebo
group to experience
pain relief after 6
weeks of treatment
(34/9% vs 19.5%,
p=0.04); Significant
difference in pain in
VD-VD group
when compared
with placebo-VD
group (p=0.005)

Group 3 - VD
method: placebo for
6 weeks; VD for 6
weeks
Measures:
VAS for pain
VD method: radioimmunoassay

Knutsen et al.
Vitamin D status in
patients with
musculoskeletal
pain, fatigue and
headache: A crosssectional
descriptive study in
a multi-ethnic
general practice in
Norway

2010

Crosssectional
descriptive
study to
evaluate if
patients with
non-specific
MS pain,
headache and
fatigue are
more likely
to be vitamin
D deficient

Norway
Multi-ethnic
population
Norway
N=249
M:F–61:188
Europe, America,
SE Asia
N=83

85% of patients
from Middle East,
Africa, and South
Asia had deficient
vitamin D level
with minimal
seasonal variation;
Logistic regression
analysis showed
headache was
significantly
associated with VD
(OR 2.6; p=0.008)
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M:F - 27:56
Middle East, Arica,
South Asia

after adjustment for
gender, season,
geographic region
of origin and age

N = 240
M:F–78:162
Measures:
Demographics
International
Classification of
Primary Care codes
(ICPC-2)
VD method:
HPLC-MS

Heidari et al.
Association
between
nonspecific skeletal
pain and vitamin D
deficiency

2010

Crosssectional
matchedcontrol
design with
patients with
nonspecific
skeletal pain
compared
with patients
without pain
with matched
mean vitamin
D levels

Iran
N = 276 in skeletal
pain group
M:F not provided
N = matched
controls
M:F not provided

Using logistic
regression and
adjusting for
significant
covariates, positive
association between
VDD and skeletal
pain (OR 2.94; 95%
CI = 1.1-4.3.
p=0.0001); Greater
positive
associations in
women compared
with men (OR =
2.1, 95% CI -=1.14.3, p=0.001)
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Houston et al.

2007

Secondary
analysis of a
population
based study
in a crosssectional
design
evaluating
the
association
of vitamin D
status and
physical
performance

Italy

2007

Crosssectional
study to
evaluate the
association
of VDD and
low back
pain in
childbearing
women
compare to
healthy age
matched
controls

Egypt

Association
Between Vitamin D
Status and Physical
Performance: In
CHIANTI Study

Lofti et al.
Hypovitaminosis D
in female patients
with chronic
low back pain

Multiple linear
regression analysis
N = 976
showed vitamin D
levels were
M:F–not specified
significantly
Measures:
associated with
sociodemographic, SPPB score in men
physical
(β coefficient [SE]:
performance battery 0.38[0.18], p =
(SPPB) test,
0.04)
handgrip strength,
Men and women
behavioral
with VD levels <
characteristics,
25 nmol/L had
BMI, cognition,
significantly lower
health conditions,
SPPB scores
creatinine,
whereas those with
hemoglobin, and
VD <50 nmol/L
albumin
also had
VD method: RIA
significantly lower
handgrip strength
(p<0.05).
Stepwise multiple
regression with
N=60
adjustment with
Ages 20-50 years of confounders,
patients with LBP
age
had significantly
Control
lower VD levels
(p<0.05) and
N=20
significantly higher
PTH (p<0.05) and
Measures:
ALP (p<.001) than
Physical exam
controls.
Pain assessment (110)
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Risk factors for
VDD questionnaire
Ca, phosphate,
ALP, PTH
VD method:
RIA by Diasorin
Gerdhem et al.

2005

Prospective
longitudinal
study eval.
any assocs
between VD
status and
fallassociated
variables and
fracture in
ambulatory
elderly
women

Sweden

2003

Crosssectional
study to
evaluate
prevalence of
VDD in
patients with
complaints of
persistent,
nonspecific
MS pain.

U.S.

Association
between 25hydroxy vitamin D
levels, physical
activity,
muscle strength and
fractures in the
prospective
population-based
OPRA Study of
Elderly Women
Plotnikoff et al.
Prevalence of
severe hypovitaminosis D in
patients with
persistent,
nonspecific
musculoskeletal
pain

Using Spearman
rank’s test VD
N=986
status correlated
with gait speed(r =
Measures at
baseline and 3 year 0.17, P <.001),
Romberg balance
follow up:
test (r=0.14, P
Romberg test, gait
<0.001), selfspeed, muscle
estimated activity
strength, DEXA, X- level (r=0.15,
rays
P<0.001) and thigh
muscle strength
VD method: chemi(r=0.08. P=0.02)
luminescence

N=150
M:F–44:106
83 immigrant
67 nonimmigrant
Measures:
VD method:
RIA by Diasorin

Immigrant patients:
100% VDD with ≤
20 ng/ml; Severity
of deficiency was
disproportionate by
age for young
women (P<0.001),
and by race for
African American
patients (P=0.006);
Season was not a
significant factor in
determining
vitamin D serum
levels (P=0.06)
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Table 5

Vitamin D and Pelvic Floor Disorders
Authors/Title

Year

Design

Aydogmus et al.

2015

Cross-sectional
study in pregnant
women admitted to
hospital in their 3rd
trimester and
compared with
healthy nulliparous
women. Serum
samples collected
in 3rd trimester (36
weeks) and pelvic
floor muscle
strength measured
at 8-10 weeks
postpartum

Association of
antepartum vitamin
D levels with
postpartum pelvic
floor muscle
strength and
symptoms

Sample
characteristics
Turkish pregnant
women

Results

Using multivariate
linear regression,
women who were
Group I (vitamin D VDD had lower
<15 ng/ml; normal
PFMS in women
delivery)
who had a vaginal
delivery (p=0.001)
N = 42
and the relationship
Group II (vitamin D was not significant
< 15ng/ml;
in women with
cesarean delivery)
cesarean delivery
(p=0.258).
N = 24
Group III (vitamin
D ≥15 ng/ml;
normal delivery)
N = 48
Group IV (vitamin
D ≥15 ng/ml;
cesarean delivery)
N = 34
Total sample = 148
Measures:
Urinary Distress
Inventory SF (UDI6)
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Incontinence
impact
questionnaire (IIQ7)
Birth statistics
Digital
perineometer to test
PFMS
Vitamin D
methodology:
ELISA

Parker-Autry et al.
Vitamin D
deficiency is
associated with
increased fecal
incontinence
symptoms

2014

Retrospective chart
review of casecontrol study to
assess if women
being seen at
gynecology clinic
for fecal
incontinence
symptoms and
those presenting for
other gynecologic
complaints and
comparing their
vitamin D levels.

U.S.
Case
N=44
Control group
N = 103
Measures:
Fecal Incontinence
Severity Index
Manchester Health
Questionnaire
(MMHQ)
VD method: liquid
chromatography

Case group vitamin
D levels were
significantly lower
than those in the
control group
(p=0.04) with the
odds of vitamin D
deficiency almost
threefold higher
(OR2.77, 95%
CI(1.08-7.09) in
women with fecal
incontinence when
compared to
controls.
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Parker-Autry et al.
Vitamin D status in
women with pelvic
floor disorder
symptoms

2012

Retrospective chart
review of women
who visited a
urogynecology
clinic to assess
associations
between vitamin D
status and pelvic
floor symptom
distress (PFD) and
quality of life

U.S.
N=268 (PFD
group)
225–Non-Hispanic
White
40–African
American
N = 126 (No PFD)
Measures:
CRADI-8
(Colorectal Anal
Distress Inventory)
Incontiencen
Impact
Questionnaire (IIQ7)
VD method: liquid
chromotography

Mean vitamin D
levels were higher in
women with no PFD
(P<0.0001).
CRADI-8 and IIQ-7
scores were higher
among women with
vitamin D
insufficiency
(defined as 15 ng/ml
to 29 ng/ml); Higher
IIQ-7 scores were
independently
associated with
vitamin D
insufficiency
(p<0.0001).
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Vaughn et al.

2011

Vitamin D and
Lower Urinary
Tract Symptoms
Among US Men:
Results from the
2005-2006
National
Health and
Nutrition
Examination
Survey

Cross-sectional
survey of US
noninstitutionalized
population from
NHANES 20052006 to evaluate
the association of
vitamin D level and
lower urinary tract
symptoms (LUTS)
among US men

N = 2837

Multivariable
logistic regression
Men ≥ 20 years of
analysis after
age
adjusting for age and
race norms, vitamin
Measures:
D deficiency was
LUTS (nocturia,
associated with the
incomplete
presence of
emptying, hesitancy moderate-serve UI
and urinary
(OR 1.8, 95% CI
incontinence)
1.1, 3.0) and at least
1 LUTS (OR 1.4,
Age
95% CI 1.0-2.0)
Race/ethnicity
Education
BMI
Chronic diseases
Self-reported health
status
Prior diagnosis of
benign prostatic
enlargement or
prostate cancer
Vitamin D
methodology:
Diasorin (RIA)

Badalian et al.
Vitamin D and
pelvic floor
disorders in
women: Results

2010

Cross-sectional
survey of
nonpregnant
women based on
NHANES data
from 2005-2006 to

N = 1881
U.S. women ≥ 20
years of age
Measures:

Adjusted logistic
regression models,
decreased risk of
pelvic floor
disorders with
increasing vitamin D

230
from the national
health and nutrition
examination survey

estimate prevalence
of vitamin D
deficiency in
women with pelvic
floor disorders

Incontinence
severity index of
both urinary and
fecal incontinence

levels in all women
(OR 0.94, 95% CI,
0.88-0.99); In
women >50 yrs and
older (OR 0.92; 95%
CI 0.85-0.99)
Likelihood of
urinary incontinence
was significantly
reduced in women >
50yrs with vitamin
D levels >30 ng/ml
(OR 0.55; 95% CI
0.34-0.91)

APPENDIX F
PSYCHOMETRICS OF SF-12
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